


**Appendix 1.2 :**  
**Statistical Analysis Report**



Pharmacologie médicale



Bordeaux PharmacoeEpi CIC  
Bordeaux CIC1401

---

## SALT-II

### Study of Acute Liver Transplant

**Prolongation & continuation of the SALT-I study**

“A study of drug-exposed acute liver failure in European transplant centres”

---

### Statistical Analysis Report

Version 1.0

5<sup>th</sup> July 2016

**COORDINATING CENTRE**

Bordeaux PharmacoeEpi

Service de Pharmacologie, Pharmacoe-épidémiologie CIC Bordeaux CIC1401


INSERM - Université de BORDEAUX – CHU de Bordeaux – Adera

Bâtiment Le Tondu – Case 41

146 rue Léo Saignat – 33076 Bordeaux Cedex

## **SALT-II Study**

### **Results of analyses for the six-years period (2008-2013)**



**SALT-II - Figure 1: Identification and selection of ALFT cases for data analysis for the period 2008 to 2013**

SALT-II - Table 1: Characteristics of ALFT cases according to drug exposure in the 30 days prior to index date for the year 2008 to 2013

	Acute drug overdose n = 132	Exposed to drugs n = 82	Not exposed to drugs n = 32	Total n = 246
<b>Gender, n (%)</b>				
Male	36 (27.3)	37 (45.1)	13 (40.6)	86 (35.0)
Female	96 (72.7)	45 (54.9)	19 (59.4)	160 (65.0)
<b>Age at registration in transplant list (in years)</b>				
Size (missing)	132 (0)	82 (0)	32 (0)	246 (0)
Mean ( $\pm$ SD)	36.9 (12.6)	43.8 (12.9)	42.2 (15.0)	39.9 (13.4)
Median	35.5	43.5	38.0	38.5
[p25% - p75%]	[27.0;47.0]	[34.0;54.0]	[33.0;55.0]	[29.0;50.0]
[Min - Max]	[18.0;66.0]	[18.0;69.0]	[21.0;76.0]	[18.0;76.0]
<b>Age at registration in transplant list (in categories), n (%)</b>				
[18 - 30[ years	47 (35.6)	12 (14.6)	6 (18.8)	65 (26.4)
[30 - 40[ years	33 (25.0)	21 (25.6)	12 (37.5)	66 (26.8)
[40 - 50[ years	29 (22.0)	19 (23.2)	4 (12.5)	52 (21.1)
[50 - 60[ years	17 (12.9)	21 (25.6)	5 (15.6)	43 (17.5)
$\geq 60$ years	6 (4.5)	9 (11.0)	5 (15.6)	20 (8.1)
<b>Transplanted, n (%)</b>	78 (59.1)	63 (76.8)	28 (87.5)	169 (68.7)
<b>Year of registration in transplant list, n (%)</b>				
2008	15 (11.4)	11 (13.4)	6 (18.8)	32 (13.0)
2009	16 (12.1)	14 (17.1)	3 (9.4)	33 (13.4)
2010	25 (18.9)	21 (25.6)	7 (21.9)	53 (21.5)
2011	17 (12.9)	13 (15.9)	7 (21.9)	37 (15.0)
2012	27 (20.5)	7 (8.5)	2 (6.3)	36 (14.6)
2013	32 (24.2)	16 (19.5)	7 (21.9)	55 (22.4)

**SALT-II - Table 2: Characteristics of ALFT cases according to drug exposure in the 90 days prior to index date for the year 2008 to 2013**

	Acute drug overdose n = 132	Exposed to drugs n = 91	Not exposed to drugs n = 23	Total n = 246
<b>Gender, n (%)</b>				
Male	36 (27.3)	41 (45.1)	9 (39.1)	86 (35.0)
Female	96 (72.7)	50 (54.9)	14 (60.9)	160 (65.0)
<b>Age at registration in transplant list (in years)</b>				
Size (missing)	132 (0)	91 (0)	23 (0)	246 (0)
Mean ( $\pm$ SD)	36.9 (12.6)	44.5 (13.6)	39.1 (12.6)	39.9 (13.4)
Median	35.5	44.0	35.0	38.5
[p25% - p75%]	[27.0;47.0]	[34.0;55.0]	[31.0;54.0]	[29.0;50.0]
[Min - Max]	[18.0;66.0]	[18.0;76.0]	[21.0;61.0]	[18.0;76.0]
<b>Age at registration in transplant list (in categories), n (%)</b>				
[18 - 30[ years	47 (35.6)	13 (14.3)	5 (21.7)	65 (26.4)
[30 - 40[ years	33 (25.0)	24 (26.4)	9 (39.1)	66 (26.8)
[40 - 50[ years	29 (22.0)	20 (22.0)	3 (13.0)	52 (21.1)
[50 - 60[ years	17 (12.9)	22 (24.2)	4 (17.4)	43 (17.5)
$\geq 60$ years	6 (4.5)	12 (13.2)	2 (8.7)	20 (8.1)
<b>Transplanted, n (%)</b>	78 (59.1)	71 (78.0)	20 (87.0)	169 (68.7)
<b>Year of registration in transplant list, n (%)</b>				
2008	15 (11.4)	12 (13.2)	5 (21.7)	32 (13.0)
2009	16 (12.1)	16 (17.6)	1 (4.3)	33 (13.4)
2010	25 (18.9)	24 (26.4)	4 (17.4)	53 (21.5)
2011	17 (12.9)	15 (16.5)	5 (21.7)	37 (15.0)
2012	27 (20.5)	7 (7.7)	2 (8.7)	36 (14.6)
2013	32 (24.2)	17 (18.7)	6 (26.1)	55 (22.4)

SALT-II - Table 3: Characteristics of ALFT cases according to drug exposure in the 15 days prior to index date for the year 2008 to 2013

	Acute drug overdose n = 132	Exposed to drugs n = 75	Not exposed to drugs n = 39	Total n = 246
<b>Gender, n (%)</b>				
Male	36 (27.3)	33 (44.0)	17 (43.6)	86 (35.0)
Female	96 (72.7)	42 (56.0)	22 (56.4)	160 (65.0)
<b>Age at registration in transplant list (in years)</b>				
Size (missing)	132 (0)	75 (0)	39 (0)	246 (0)
Mean ( $\pm$ SD)	36.9 (12.6)	43.3 (12.7)	43.6 (15.0)	39.9 (13.4)
Median	35.5	43.0	39.0	38.5
[p25% - p75%]	[27.0;47.0]	[34.0;54.0]	[33.0;56.0]	[29.0;50.0]
[Min - Max]	[18.0;66.0]	[18.0;68.0]	[21.0;76.0]	[18.0;76.0]
<b>Age at registration in transplant list (in categories), n (%)</b>				
[18 - 30[ years	47 (35.6)	11 (14.7)	7 (17.9)	65 (26.4)
[30 - 40[ years	33 (25.0)	20 (26.7)	13 (33.3)	66 (26.8)
[40 - 50[ years	29 (22.0)	18 (24.0)	5 (12.8)	52 (21.1)
[50 - 60[ years	17 (12.9)	18 (24.0)	8 (20.5)	43 (17.5)
$\geq 60$ years	6 (4.5)	8 (10.7)	6 (15.4)	20 (8.1)
<b>Transplanted, n (%)</b>	78 (59.1)	58 (77.3)	33 (84.6)	169 (68.7)
<b>Year of registration in transplant list, n (%)</b>				
2008	15 (11.4)	11 (14.7)	6 (15.4)	32 (13.0)
2009	16 (12.1)	11 (14.7)	6 (15.4)	33 (13.4)
2010	25 (18.9)	20 (26.7)	8 (20.5)	53 (21.5)
2011	17 (12.9)	12 (16.0)	8 (20.5)	37 (15.0)
2012	27 (20.5)	6 (8.0)	3 (7.7)	36 (14.6)
2013	32 (24.2)	15 (20.0)	8 (20.5)	55 (22.4)

**SALT-II - Table 4: Characteristics of ALFT cases according to drug exposure in the 7 days prior to index date for the year 2008 to 2013**

	Acute drug overdose n = 132	Exposed to drugs n = 69	Not exposed to drugs n = 45	Total n = 246
<b>Gender, n (%)</b>				
Male	36 (27.3)	32 (46.4)	18 (40.0)	86 (35.0)
Female	96 (72.7)	37 (53.6)	27 (60.0)	160 (65.0)
<b>Age at registration in transplant list (in years)</b>				
Size (missing)	132 (0)	69 (0)	45 (0)	246 (0)
Mean ( $\pm$ SD)	36.9 (12.6)	44.0 (12.3)	42.4 (15.2)	39.9 (13.4)
Median	35.5	43.0	39.0	38.5
[p25% - p75%]	[27.0;47.0]	[34.0;54.0]	[33.0;54.0]	[29.0;50.0]
[Min - Max]	[18.0;66.0]	[18.0;68.0]	[19.0;76.0]	[18.0;76.0]
<b>Age at registration in transplant list (in categories), n (%)</b>				
[18 - 30[ years	47 (35.6)	8 (11.6)	10 (22.2)	65 (26.4)
[30 - 40[ years	33 (25.0)	20 (29.0)	13 (28.9)	66 (26.8)
[40 - 50[ years	29 (22.0)	16 (23.2)	7 (15.6)	52 (21.1)
[50 - 60[ years	17 (12.9)	17 (24.6)	9 (20.0)	43 (17.5)
$\geq 60$ years	6 (4.5)	8 (11.6)	6 (13.3)	20 (8.1)
<b>Transplanted, n (%)</b>	78 (59.1)	52 (75.4)	39 (86.7)	169 (68.7)
<b>Year of registration in transplant list, n (%)</b>				
2008	15 (11.4)	10 (14.5)	7 (15.6)	32 (13.0)
2009	16 (12.1)	10 (14.5)	7 (15.6)	33 (13.4)
2010	25 (18.9)	20 (29.0)	8 (17.8)	53 (21.5)
2011	17 (12.9)	11 (15.9)	9 (20.0)	37 (15.0)
2012	27 (20.5)	5 (7.2)	4 (8.9)	36 (14.6)
2013	32 (24.2)	13 (18.8)	10 (22.2)	55 (22.4)



SALT-II - Table 5: Drug exposure of ALFT cases according to drug exposure in the 30 days prior to index date for the years 2008 to 2013

	Acute drug overdose n = 132	Exposed to drugs n = 82	Not exposed to drugs n = 32	Total n = 246
<b>At least one exposure at the following ATC codes in the 30 days prior to index date, n (%)</b>	<b>132 (100.0)</b>	<b>82 (100.0)</b>	<b>0 (0.0)</b>	<b>214 (87.0)</b>
<b>Nervous system (N)</b>	<b>131 (99.2)</b>	<b>50 (61.0)</b>		<b>181 (73.6)</b>
Other analgesics and antipyretics (N02B)	127 (96.2)	37 (45.1)		164 (66.7)
Paracetamol (N02BE01)	109 (82.6)	32 (39.0)		141 (57.3)
Paracetamol, combinations excl. psycholeptics (N02BE51)	22 (16.7)	4 (4.9)		26 (10.6)
Acetylsalicylic acid (N02BA01)	0 (0.0)	5 (6.1)		5 (2.0)
Paracetamol, combinations with psycholeptics (N02BE71)	2 (1.5)	2 (2.4)		4 (1.6)
Nefopam (N02BG06)	0 (0.0)	2 (2.4)		2 (0.8)
Anxiolytics (N05B)	43 (32.6)	11 (13.4)		54 (22.0)
Oxazepam (N05BA04)	9 (6.8)	3 (3.7)		12 (4.9)
Alprazolam (N05BA12)	11 (8.3)	1 (1.2)		12 (4.9)
Bromazepam (N05BA08)	9 (6.8)	2 (2.4)		11 (4.5)
Hydroxyzine (N05BB01)	4 (3.0)	2 (2.4)		6 (2.4)
Diazepam (N05BA01)	2 (1.5)	1 (1.2)		3 (1.2)
Prazepam (N05BA11)	3 (2.3)	0 (0.0)		3 (1.2)
Etifoxine (N05BX03)	3 (2.3)	0 (0.0)		3 (1.2)
Potassium clorazepate (N05BA05)	1 (0.8)	1 (1.2)		2 (0.8)
Lorazepam (N05BA06)	1 (0.8)	1 (1.2)		2 (0.8)
Clobazam (N05BA09)	2 (1.5)	0 (0.0)		2 (0.8)
Meprobamate (N05BC01)	0 (0.0)	1 (1.2)		1 (0.4)
Meprobamate, combinations (N05BC51)	0 (0.0)	1 (1.2)		1 (0.4)
Antidepressants (N06A)	29 (22.0)	13 (15.9)		42 (17.1)
Escitalopram (N06AB10)	8 (6.1)	1 (1.2)		9 (3.7)
Venlafaxine (N06AX16)	2 (1.5)	4 (4.9)		6 (2.4)
Amitriptyline (N06AA09)	3 (2.3)	2 (2.4)		5 (2.0)
Paroxetine (N06AB05)	4 (3.0)	0 (0.0)		4 (1.6)
Fluoxetine (N06AB03)	3 (2.3)	0 (0.0)		3 (1.2)
Mianserin (N06AX03)	1 (0.8)	2 (2.4)		3 (1.2)
Citalopram (N06AB04)	1 (0.8)	1 (1.2)		2 (0.8)
Sertraline (N06AB06)	2 (1.5)	0 (0.0)		2 (0.8)
Iproniazide (N06AF05)	0 (0.0)	2 (2.4)		2 (0.8)
Clomipramine (N06AA04)	1 (0.8)	0 (0.0)		1 (0.4)
Trimipramine (N06AA06)	1 (0.8)	0 (0.0)		1 (0.4)
Moclobemide (N06AG02)	0 (0.0)	1 (1.2)		1 (0.4)
Tianeptine (N06AX14)	1 (0.8)	0 (0.0)		1 (0.4)
Duloxetine (N06AX21)	1 (0.8)	0 (0.0)		1 (0.4)
Agomelatine (N06AX22)	1 (0.8)	0 (0.0)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 82	Not exposed to drugs n = 32	Total n = 246
Antiepileptics (N03A)	14 (10.6)	11 (13.4)		25 (10.2)
Carbamazepine (N03AF01)	3 (2.3)	4 (4.9)		7 (2.8)
Valproic acid (N03AG01)	4 (3.0)	3 (3.7)		7 (2.8)
Clonazepam (N03AE01)	4 (3.0)	2 (2.4)		6 (2.4)
Levetiracetam (N03AX14)	3 (2.3)	2 (2.4)		5 (2.0)
Lamotrigine (N03AX09)	1 (0.8)	3 (3.7)		4 (1.6)
Pregabalin (N03AX16)	1 (0.8)	1 (1.2)		2 (0.8)
Phenobarbital (N03AA02)	0 (0.0)	1 (1.2)		1 (0.4)
Topiramate (N03AX11)	1 (0.8)	0 (0.0)		1 (0.4)
Gabapentin (N03AX12)	0 (0.0)	1 (1.2)		1 (0.4)
Hypnotics and sedatives (N05C)	20 (15.2)	3 (3.7)		23 (9.3)
Zolpidem (N05CF02)	11 (8.3)	1 (1.2)		12 (4.9)
Zopiclone (N05CF01)	6 (4.5)	1 (1.2)		7 (2.8)
Lormetazepam (N05CD06)	1 (0.8)	0 (0.0)		1 (0.4)
Opioids (N02A)	11 (8.3)	3 (3.7)		14 (5.7)
Tramadol, combinations (N02AX52)	6 (4.5)	0 (0.0)		6 (2.4)
Tramadol (N02AX02)	3 (2.3)	1 (1.2)		4 (1.6)
Morphine (N02AA01)	1 (0.8)	1 (1.2)		2 (0.8)
Oxycodone (N02AA05)	0 (0.0)	1 (1.2)		1 (0.4)
Dihydrocodeine (N02AA08)	0 (0.0)	1 (1.2)		1 (0.4)
Fentanyl (N02AB03)	0 (0.0)	1 (1.2)		1 (0.4)
Antipsychotics (N05A)	8 (6.1)	2 (2.4)		10 (4.1)
Risperidone (N05AX08)	3 (2.3)	1 (1.2)		4 (1.6)
Cyamemazine (N05AA06)	1 (0.8)	1 (1.2)		2 (0.8)
Tiapride (N05AL03)	2 (1.5)	0 (0.0)		2 (0.8)
Levomepromazine (N05AA02)	0 (0.0)	1 (1.2)		1 (0.4)
Periciazine (N05AC01)	1 (0.8)	0 (0.0)		1 (0.4)
Loxapine (N05AH01)	1 (0.8)	0 (0.0)		1 (0.4)
Olanzapine (N05AH03)	1 (0.8)	0 (0.0)		1 (0.4)
Drugs used in addictive disorders (N07B)	4 (3.0)	2 (2.4)		6 (2.4)
Disulfiram (N07BB01)	1 (0.8)	2 (2.4)		3 (1.2)
Buprenorphine (N07BC01)	2 (1.5)	0 (0.0)		2 (0.8)
Acamprosate (N07BB03)	1 (0.8)	0 (0.0)		1 (0.4)
Antimigraine preparations (N02C)	2 (1.5)	2 (2.4)		4 (1.6)
Dihydroergotamine (N02CA01)	0 (0.0)	1 (1.2)		1 (0.4)
Zolmitriptan (N02CC03)	1 (0.8)	0 (0.0)		1 (0.4)
Almotriptan (N02CC05)	1 (0.8)	0 (0.0)		1 (0.4)
Eletriptan (N02CC06)	1 (0.8)	0 (0.0)		1 (0.4)
Pizotifen (N02CX01)	0 (0.0)	1 (1.2)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 82	Not exposed to drugs n = 32	Total n = 246
Psychostimulants, agents used for adhd and nootropics (N06B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Amphetamine (N06BA01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Anesthetics, general (N01A)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Desflurane (N01AB07)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Thiopental (N01AF03)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Sufentanil (N01AH03)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Ketamine (N01AX03)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Anticholinergic agents (N04A)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Tropatepine (N04AA12)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Antivertigo preparations (N07C)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Acetyllicucine (N07CA04)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<b>Antiinfectives for systemic use (J)</b>	<b>5 (3.8)</b>	<b>34 (41.5)</b>		<b>39 (15.9)</b>
Drugs for treatment of tuberculosis (J04A)	0 (0.0)	16 (19.5)		16 (6.5)
<i>Rifampicin, pyrazinamide, ethambutol and isoniazid (J04AM06)</i>	0 (0.0)	10 (12.2)		10 (4.1)
<i>Rifampicin and isoniazid (J04AM02)</i>	0 (0.0)	6 (7.3)		6 (2.4)
<i>Ethambutol (J04AK02)</i>	0 (0.0)	2 (2.4)		2 (0.8)
<i>Rifampicin, pyrazinamide and isoniazid (J04AM05)</i>	0 (0.0)	2 (2.4)		2 (0.8)
<i>Rifampicin (J04AB02)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Rifabutin (J04AB04)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Isoniazid (J04AC01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Pyrazinamide (J04AK01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Direct acting antivirals (J05A)	1 (0.8)	12 (14.6)		13 (5.3)
<i>Tenofovir disoproxil and emtricitabine (J05AR03)</i>	0 (0.0)	4 (4.9)		4 (1.6)
<i>Ritonavir (J05AE03)</i>	0 (0.0)	3 (3.7)		3 (1.2)
<i>Efavirenz (J05AG03)</i>	0 (0.0)	3 (3.7)		3 (1.2)
<i>Emtricitabine, tenofovir disoproxil and efavirenz (J05AR06)</i>	0 (0.0)	3 (3.7)		3 (1.2)
<i>Valaciclovir (J05AB11)</i>	1 (0.8)	1 (1.2)		2 (0.8)
<i>Atazanavir (J05AE08)</i>	0 (0.0)	2 (2.4)		2 (0.8)
<i>Tenofovir disoproxil (J05AF07)</i>	0 (0.0)	2 (2.4)		2 (0.8)
<i>Aciclovir (J05AB01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Ribavirin (J05AB04)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Valganciclovir (J05AB14)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Emtricitabine (J05AF09)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Nucleoside and nucleotide reverse transcriptase inhibitors, combinations (J05AF30)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Nevirapine (J05AG01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Raltegravir (J05AX08)</i>	0 (0.0)	1 (1.2)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 82	Not exposed to drugs n = 32	Total n = 246
Beta-lactam antibacterials, penicillins (J01C)	3 (2.3)	7 (8.5)		10 (4.1)
<i>Amoxicillin (J01CA04)</i>	1 (0.8)	5 (6.1)		6 (2.4)
<i>Amoxicillin and enzyme inhibitor (J01CR02)</i>	1 (0.8)	1 (1.2)		2 (0.8)
<i>Cloxacillin (J01CF02)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Piperacillin and enzyme inhibitor (J01CR05)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Aminoglycoside antibacterials (J01G)	0 (0.0)	3 (3.7)		3 (1.2)
<i>Amikacin (J01GB06)</i>	0 (0.0)	2 (2.4)		2 (0.8)
<i>Gentamicin (J01GB03)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Antimycotics for systemic use (J02A)	0 (0.0)	3 (3.7)		3 (1.2)
<i>Fluconazole (J02AC01)</i>	0 (0.0)	2 (2.4)		2 (0.8)
<i>Caspofungin (J02AX04)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Other beta-lactam antibacterials (J01D)	1 (0.8)	2 (2.4)		3 (1.2)
<i>Ceftazidime (J01DD02)</i>	0 (0.0)	2 (2.4)		2 (0.8)
<i>Cefotaxime (J01DD01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Ceftriaxone (J01DD04)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Cefpodoxime (J01DD13)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Sulfonamides and trimethoprim (J01E)	0 (0.0)	3 (3.7)		3 (1.2)
<i>Sulfamethoxazole and trimethoprim (J01EE01)</i>	0 (0.0)	3 (3.7)		3 (1.2)
Macrolides, lincosamides and streptogramins (J01F)	0 (0.0)	2 (2.4)		2 (0.8)
<i>Azithromycin (J01FA10)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Telithromycin (J01FA15)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Other antibacterials (J01X)	0 (0.0)	2 (2.4)		2 (0.8)
<i>Vancomycin (J01XA01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Nitrofurantoin (J01XE01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Bacterial and viral vaccines, combined (J07C)	0 (0.0)	1 (1.2)		1 (0.4)
Quinolone antibacterials (J01M)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Ofloxacin (J01MA01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<b>Alimentary tract and metabolism (A)</b>	<b>16 (12.1)</b>	<b>17 (20.7)</b>		<b>33 (13.4)</b>
Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) (A02B)	6 (4.5)	3 (3.7)		9 (3.7)
<i>Lansoprazole (A02BC03)</i>	3 (2.3)	1 (1.2)		4 (1.6)
<i>Omeprazole (A02BC01)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Esomeprazole (A02BC05)</i>	1 (0.8)	1 (1.2)		2 (0.8)
<i>Pantoprazole (A02BC02)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Blood glucose lowering drugs, excl. insulins (A10B)	2 (1.5)	4 (4.9)		6 (2.4)
<i>Metformin (A10BA02)</i>	1 (0.8)	4 (4.9)		5 (2.0)
<i>Glibenclamide (A10BB01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Metformin and sitagliptin (A10BD07)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Sitagliptin (A10BH01)</i>	0 (0.0)	1 (1.2)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 82	Not exposed to drugs n = 32	Total n = 246
Drugs for functional bowel disorders (A03A)	3 (2.3)	3 (3.7)		6 (2.4)
<i>Phloroglucinol</i> (A03AX12)	3 (2.3)	1 (1.2)		4 (1.6)
<i>Trimebutine</i> (A03AA05)	0 (0.0)	2 (2.4)		2 (0.8)
<i>Alverine, combinations</i> (A03AX58)	0 (0.0)	1 (1.2)		1 (0.4)
Antipropulsives (A07D)	4 (3.0)	1 (1.2)		5 (2.0)
<i>Loperamide</i> (A07DA03)	4 (3.0)	1 (1.2)		5 (2.0)
Propulsives (A03F)	3 (2.3)	2 (2.4)		5 (2.0)
<i>Metoclopramide</i> (A03FA01)	2 (1.5)	2 (2.4)		4 (1.6)
<i>Domperidone</i> (A03FA03)	1 (0.8)	0 (0.0)		1 (0.4)
Antacids (A02A)	0 (0.0)	4 (4.9)		4 (1.6)
<i>Aluminium hydroxide</i> (A02AB01)	0 (0.0)	1 (1.2)		1 (0.4)
Laxatives (A06A)	0 (0.0)	4 (4.9)		4 (1.6)
<i>Liquid paraffin</i> (A06AA01)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Senna glycosides, combinations</i> (A06AB56)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Ispaghula, combinations</i> (A06AC51)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Lactulose</i> (A06AD11)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Macrogol</i> (A06AD15)	0 (0.0)	1 (1.2)		1 (0.4)
Antiemetics and antinauseants (A04A)	2 (1.5)	1 (1.2)		3 (1.2)
<i>Metopimazine</i> (A04AD05)	2 (1.5)	0 (0.0)		2 (0.8)
Insulins and analogues (A10A)	1 (0.8)	2 (2.4)		3 (1.2)
<i>Insulin (human)</i> (A10AB01)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Insulin glargine</i> (A10AE04)	1 (0.8)	0 (0.0)		1 (0.4)
Bile therapy (A05A)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Ursodeoxycholic acid</i> (A05AA02)	0 (0.0)	1 (1.2)		1 (0.4)
Multivitamins, combinations (A11A)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Multivitamins and other minerals, incl. combinations</i> (A11AA03)	0 (0.0)	1 (1.2)		1 (0.4)
Other drugs for acid related disorders (A02X)	1 (0.8)	0 (0.0)		1 (0.4)
Vitamin a and d, incl. combinations of the two (A11C)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Calcifediol</i> (A11CC06)	0 (0.0)	1 (1.2)		1 (0.4)
<b>Musculo-skeletal system (M)</b>	<b>19 (14.4)</b>	<b>13 (15.9)</b>		<b>32 (13.0)</b>
Antiinflammatory and antirheumatic products, non-steroids (M01A)	16 (12.1)	8 (9.8)		24 (9.8)
<i>Ibuprofen</i> (M01AE01)	6 (4.5)	4 (4.9)		10 (4.1)
<i>Diclofenac</i> (M01AB05)	2 (1.5)	0 (0.0)		2 (0.8)
<i>Ketoprofen</i> (M01AE03)	2 (1.5)	0 (0.0)		2 (0.8)
<i>Diclofenac, combinations</i> (M01AB55)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Piroxicam</i> (M01AC01)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Naproxen</i> (M01AE02)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Nimesulide</i> (M01AX17)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Celecoxib</i> (M01AH01)	0 (0.0)	1 (1.1)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 82	Not exposed to drugs n = 32	Total n = 246
Muscle relaxants, centrally acting agents (M03B)	4 (3.0)	1 (1.2)		5 (2.0)
<i>Tetrazepam (M03BX07)</i>	3 (2.3)	0 (0.0)		3 (1.2)
<i>Baclofen (M03BX01)</i>	1 (0.8)	1 (1.2)		2 (0.8)
Antigout preparations (M04A)	1 (0.8)	1 (1.2)		2 (0.8)
<i>Allopurinol (M04AA01)</i>	1 (0.8)	1 (1.2)		2 (0.8)
Muscle relaxants, peripherally acting agents (M03A)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Rocuronium bromide (M03AC09)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Muscle relaxants, directly acting agents (M03C)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Dantrolene (M03CA01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Other drugs for disorders of the musculo-skeletal system (M09A)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Chondrocytes, autologous (M09AX02)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<b>Cardiovascular system (C)</b>	<b>12 (9.1)</b>	<b>18 (22.0)</b>		<b>30 (12.2)</b>
Lipid modifying agents, plain (C10A)	3 (2.3)	8 (9.8)		11 (4.5)
<i>Atorvastatin (C10AA05)</i>	2 (1.5)	3 (3.7)		5 (2.0)
<i>Simvastatin (C10AA01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Pravastatin (C10AA03)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Rosuvastatin (C10AA07)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Fenofibrate (C10AB05)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Colestyramine (C10AC01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Beta blocking agents (C07A)	2 (1.5)	5 (6.1)		7 (2.8)
<i>Atenolol (C07AB03)</i>	1 (0.8)	3 (3.7)		4 (1.6)
<i>Propranolol (C07AA05)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Sotalol (C07AA07)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Nebivolol (C07AB12)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Selective calcium channel blockers with mainly vascular effects (C08C)	2 (1.5)	5 (6.1)		7 (2.8)
<i>Amlodipine (C08CA01)</i>	1 (0.8)	2 (2.4)		3 (1.2)
<i>Lercanidipine (C08CA13)</i>	1 (0.8)	2 (2.4)		3 (1.2)
<i>Manidipine (C08CA11)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Angiotensin ii antagonists, plain (C09C)	3 (2.3)	3 (3.7)		6 (2.4)
<i>Losartan (C09CA01)</i>	0 (0.0)	2 (2.4)		2 (0.8)
<i>Irbesartan (C09CA04)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Valsartan (C09CA03)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Candesartan (C09CA06)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Ace inhibitors, combinations (C09B)	1 (0.8)	2 (2.4)		3 (1.2)
<i>Perindopril and diuretics (C09BA04)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Ramipril and diuretics (C09BA05)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Trandolapril and verapamil (C09BB10)</i>	1 (0.8)	0 (0.0)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 82	Not exposed to drugs n = 32	Total n = 246
Ace inhibitors, plain (C09A)	1 (0.8)	2 (2.4)		3 (1.2)
<i>Perindopril (C09AA04)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Ramipril (C09AA05)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Angiotensin ii antagonists, combinations (C09D)	2 (1.5)	0 (0.0)		2 (0.8)
<i>Olmesartan medoxomil and diuretics (C09DA08)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Olmesartan medoxomil and amlodipine (C09DB02)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antiadrenergic agents, centrally acting (C02A)	1 (0.8)	1 (1.2)		2 (0.8)
<i>Moxonidine (C02AC05)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Rilmenidine (C02AC06)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Antiarrhythmics, class i and iii (C01B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Amiodarone (C01BD01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Vasodilators used in cardiac diseases (C01D)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Heptaminol (C01DX08)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Low-ceiling diuretics, excl. thiazides (C03B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Indapamide (C03BA11)</i>	1 (0.8)	0 (0.0)		1 (0.4)
High-ceiling diuretics (C03C)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Furosemide (C03CA01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Potassium-sparing agents (C03D)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Spironolactone (C03DA01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Peripheral vasodilators (C04A)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Naftidrofuryl (C04AX21)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Capillary stabilizing agents (C05C)	0 (0.0)	1 (1.2)		1 (0.4)
<b>Respiratory system (R)</b>	<b>12 (9.1)</b>	<b>6 (7.3)</b>		<b>18 (7.3)</b>
Antihistamines for systemic use (R06A)	6 (4.5)	2 (2.4)		8 (3.3)
<i>Alimemazine (R06AD01)</i>	5 (3.8)	0 (0.0)		5 (2.0)
<i>Dexchlorpheniramine (R06AB02)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Desloratadine (R06AX27)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Adrenergics, inhalants (R03A)	4 (3.0)	2 (2.4)		6 (2.4)
<i>Salbutamol (R03AC02)</i>	3 (2.3)	1 (1.2)		4 (1.6)
<i>Formoterol and budesonide (R03AK07)</i>	0 (0.0)	2 (2.4)		2 (0.8)
<i>Terbutaline (R03AC03)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Salmeterol and fluticasone (R03AK06)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Cough suppressants, excl. combinations with expectorants (R05D)	2 (1.5)	0 (0.0)		2 (0.8)
<i>Combinations (R05DA20)</i>	2 (1.5)	0 (0.0)		2 (0.8)
Other drugs for obstructive airway diseases, inhalants (R03B)	1 (0.8)	1 (1.2)		2 (0.8)
<i>Budesonide (R03BA02)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Ipratropium bromide (R03BB01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Tiotropium bromide (R03BB04)</i>	0 (0.0)	1 (1.2)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 82	Not exposed to drugs n = 32	Total n = 246
Other systemic drugs for obstructive airway diseases (R03D)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Fenspiride (R03DX03)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Other cold combination preparations (R05X)	0 (0.0)	1 (1.2)		1 (0.4)
<b>Genito urinary system and sex hormones (G)</b>	<b>5 (3.8)</b>	<b>7 (8.5)</b>		<b>12 (4.9)</b>
Hormonal contraceptives for systemic use (G03A)	3 (2.3)	2 (2.4)		5 (2.0)
<i>Gestodene and estrogen (G03AA10)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Progestogens (G03D)	1 (0.8)	3 (3.7)		4 (1.6)
<i>Progesterone (G03DA04)</i>	0 (0.0)	2 (2.4)		2 (0.8)
<i>Nomegestrol (G03DB04)</i>	1 (0.8)	1 (1.2)		2 (0.8)
Other urologicals, incl. antispasmodics (G04B)	1 (0.8)	1 (1.2)		2 (0.8)
<i>Solifenacin (G04BD08)</i>	1 (0.8)	1 (1.2)		2 (0.8)
Estrogens (G03C)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Estradiol (G03CA03)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Drugs used in benign prostatic hypertrophy (G04C)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Alfuzosin (G04CA01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Gonadotropins and other ovulation stimulants (G03G)	0 (0.0)	1 (1.2)		1 (0.4)
<b>Blood and blood forming organs (B)</b>	<b>3 (2.3)</b>	<b>8 (9.8)</b>		<b>11 (4.5)</b>
Antithrombotic agents (B01A)	2 (1.5)	8 (9.8)		10 (4.1)
<i>Acetylsalicylic acid (B01AC06)</i>	1 (0.8)	5 (6.1)		6 (2.4)
<i>Clopidogrel (B01AC04)</i>	1 (0.8)	3 (3.7)		4 (1.6)
<i>Fluindione (B01AA12)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Nadroparin (B01AB06)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Iron preparations (B03A)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Ferrous sulfate (B03AA07)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<b>Systemic hormonal preparations (excluded sex hormones and insulines) (H)</b>	<b>5 (3.8)</b>	<b>6 (7.3)</b>		<b>11 (4.5)</b>
Corticosteroids for systemic use, plain (H02A)	3 (2.3)	2 (2.4)		5 (2.0)
<i>Prednisone (H02AB07)</i>	2 (1.5)	1 (1.2)		3 (1.2)
<i>Methylprednisolone (H02AB04)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<i>Prednisolone (H02AB06)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Thyroid preparations (H03A)	2 (1.5)	3 (3.7)		5 (2.0)
<i>Levothyroxine sodium (H03AA01)</i>	2 (1.5)	3 (3.7)		5 (2.0)
Hypothalamic hormones (H01C)	0 (0.0)	1 (1.2)		1 (0.4)



	Acute drug overdose n = 132	Exposed to drugs n = 82	Not exposed to drugs n = 32	Total n = 246
<b>Drugs</b>	<b>7 (5.3)</b>	<b>0 (0.0)</b>		<b>7 (2.8)</b>
Cannabis	6 (4.5)	0 (0.0)		6 (2.4)
Ecstasy	2 (1.5)	0 (0.0)		2 (0.8)
Cocaine	1 (0.8)	0 (0.0)		1 (0.4)
LSA	1 (0.8)	0 (0.0)		1 (0.4)
Mushrooms	1 (0.8)	0 (0.0)		1 (0.4)
<b>Antineoplastic and immunomodulating agents (L)</b>	<b>1 (0.8)</b>	<b>3 (3.7)</b>		<b>4 (1.6)</b>
Immunosuppressants (L04A)	1 (0.8)	1 (1.2)		2 (0.8)
<i>Infliximab (L04AA12)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Tacrolimus (L04AD02)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Antimetabolites (L01B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Methotrexate (L01BA01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Other antineoplastic agents (L01X)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Imatinib (L01XE01)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Immunostimulants (L03A)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Glatiramer acetate (L03AX13)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<b>Dermatologicals (D)</b>	<b>1 (0.8)</b>	<b>1 (1.2)</b>		<b>2 (0.8)</b>
Antifungals for systemic use (D01B)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Terbinafine (D01BA02)</i>	0 (0.0)	1 (1.2)		1 (0.4)
Other dermatological preparations (D11A)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Minoxidil (D11AX01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<b>Food supplement</b>	<b>0 (0.0)</b>	<b>2 (2.4)</b>		<b>2 (0.8)</b>
Fortimel	0 (0.0)	1 (1.2)		1 (0.4)
Vitonic	0 (0.0)	1 (1.2)		1 (0.4)
<b>Homeopathy</b>	<b>1 (0.8)</b>	<b>1 (1.2)</b>		<b>2 (0.8)</b>
Organic silicon	0 (0.0)	1 (1.2)		1 (0.4)
Sedatif PC	1 (0.8)	0 (0.0)		1 (0.4)
<b>Antiparasitic products, insecticides and repellents (P)</b>	<b>1 (0.8)</b>	<b>0 (0.0)</b>		<b>1 (0.4)</b>
Antitrematodals (P02B)	1 (0.8)	0 (0.0)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 82	Not exposed to drugs n = 32	Total n = 246
<b>Various (V)</b>	0 (0.0)	1 (1.2)		1 (0.4)
All other therapeutic products (V03A)	0 (0.0)	1 (1.2)		1 (0.4)
<i>Calcium folinate (V03AF03)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<b>No ATC code</b>	<b>0 (0.0)</b>	<b>1 (1.2)</b>		<b>1 (0.4)</b>

**SALT-II - Table 5b: Paracetamol exposure of ALFT cases according to drug exposure in the 30 days prior to index date for the years 2008 to 2013**

	Acute drug overdose n = 132	Exposed to drugs n = 82	Not exposed to drugs n = 32	Total n = 246
<b>At least one exposure at paracetamol in the 30 days prior to index date, n (%)</b>				
<b>Paracetamol, plain and combinations</b>	<b>130 (98.5)</b>	<b>35 (42.7)</b>	<b>0 (0.0)</b>	<b>165 (67.1)</b>
Paracetamol (N02BE01)	109 (82.6)	32 (39.0)	0 (0.0)	141 (57.3)
Paracetamol, combinations excl. psycholeptics (N02BE51)	22 (16.7)	4 (4.9)	0 (0.0)	26 (10.6)
Paracetamol, combinations with psycholeptics (N02BE71)	2 (1.5)	2 (2.4)	0 (0.0)	4 (1.6)
Codeine, combinations excl. psycholeptics (N02AA59)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Tramadol, combinations (N02AX52)	6 (4.5)	0 (0.0)	0 (0.0)	6 (2.4)
<b>At least one overdose, n (%)</b>	<b>126 (95.5)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>126 (51.2)</b>
<b>At least one intentional overdose, n (%)</b>	<b>69 (52.3)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>69 (28.0)</b>
<b>At least one non-intentional overdose, n (%)</b>	<b>57 (43.2)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>57 (23.2)</b>

SALT-II - Table 6: Drug exposure of ALFT cases according to drug exposure in the 90 days prior to index date for the years 2008 to 2013

	Acute drug overdose n = 132	Exposed to drugs n = 91	Not exposed to drugs n = 23	Total n = 246
<b>At least one exposure at the following ATC codes in the 90 days prior to index date, n (%)</b>	<b>132 (100.0)</b>	<b>91 (100.0)</b>	<b>0 (0.0)</b>	<b>223 (90.7)</b>
<b>Nervous system (N)</b>	<b>131 (99.2)</b>	<b>54 (59.3)</b>		<b>185 (75.2)</b>
Other analgesics and antipyretics (N02B)	127 (96.2)	41 (45.1)		168 (68.3)
<i>Paracetamol (N02BE01)</i>	109 (82.6)	36 (39.6)		145 (58.9)
<i>Paracetamol, combinations excl. psycholeptics (N02BE51)</i>	23 (17.4)	4 (4.4)		27 (11.0)
<i>Acetylsalicylic acid (N02BA01)</i>	1 (0.8)	5 (5.5)		6 (2.4)
<i>Paracetamol, combinations with psycholeptics (N02BE71)</i>	2 (1.5)	2 (2.2)		4 (1.6)
<i>Nefopam (N02BG06)</i>	0 (0.0)	2 (2.2)		2 (0.8)
Anxiolytics (N05B)	47 (35.6)	13 (14.3)		60 (24.4)
<i>Bromazepam (N05BA08)</i>	10 (7.6)	3 (3.3)		13 (5.3)
<i>Oxazepam (N05BA04)</i>	9 (6.8)	3 (3.3)		12 (4.9)
<i>Alprazolam (N05BA12)</i>	11 (8.3)	1 (1.1)		12 (4.9)
<i>Hydroxyzine (N05BB01)</i>	5 (3.8)	2 (2.2)		7 (2.8)
<i>Diazepam (N05BA01)</i>	3 (2.3)	1 (1.1)		4 (1.6)
<i>Prazepam (N05BA11)</i>	4 (3.0)	0 (0.0)		4 (1.6)
<i>Lorazepam (N05BA06)</i>	1 (0.8)	2 (2.2)		3 (1.2)
<i>Etifoxine (N05BX03)</i>	3 (2.3)	0 (0.0)		3 (1.2)
<i>Potassium clorazepate (N05BA05)</i>	1 (0.8)	1 (1.1)		2 (0.8)
<i>Clobazam (N05BA09)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Meprobamate (N05BC01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Meprobamate, combinations (N05BC51)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Antidepressants (N06A)	30 (22.7)	13 (14.3)		43 (17.5)
<i>Escitalopram (N06AB10)</i>	8 (6.1)	1 (1.1)		9 (3.7)
<i>Venlafaxine (N06AX16)</i>	2 (1.5)	4 (4.4)		6 (2.4)
<i>Amitriptyline (N06AA09)</i>	3 (2.3)	2 (2.2)		5 (2.0)
<i>Paroxetine (N06AB05)</i>	5 (3.8)	0 (0.0)		5 (2.0)
<i>Fluoxetine (N06AB03)</i>	3 (2.3)	0 (0.0)		3 (1.2)
<i>Mianserin (N06AX03)</i>	1 (0.8)	2 (2.2)		3 (1.2)
<i>Citalopram (N06AB04)</i>	1 (0.8)	1 (1.1)		2 (0.8)
<i>Sertraline (N06AB06)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Iproniazide (N06AF05)</i>	0 (0.0)	2 (2.2)		2 (0.8)
<i>Clomipramine (N06AA04)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Trimipramine (N06AA06)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Moclobemide (N06AG02)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Tianeptine (N06AX14)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Duloxetine (N06AX21)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Agomelatine (N06AX22)</i>	1 (0.8)	0 (0.0)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 91	Not exposed to drugs n = 23	Total n = 246
Antiepileptics (N03A)	15 (11.4)	12 (13.2)		27 (11.0)
<i>Valproic acid (N03AG01)</i>	5 (3.8)	3 (3.3)		8 (3.3)
<i>Carbamazepine (N03AF01)</i>	3 (2.3)	4 (4.4)		7 (2.8)
<i>Clonazepam (N03AE01)</i>	4 (3.0)	2 (2.2)		6 (2.4)
<i>Levetiracetam (N03AX14)</i>	3 (2.3)	2 (2.2)		5 (2.0)
<i>Lamotrigine (N03AX09)</i>	1 (0.8)	3 (3.3)		4 (1.6)
<i>Pregabalin (N03AX16)</i>	1 (0.8)	2 (2.2)		3 (1.2)
<i>Phenobarbital (N03AA02)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Topiramate (N03AX11)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Gabapentin (N03AX12)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Hypnotics and sedatives (N05C)	23 (17.4)	4 (4.4)		27 (11.0)
<i>Zolpidem (N05CF02)</i>	13 (9.8)	1 (1.1)		14 (5.7)
<i>Zopiclone (N05CF01)</i>	7 (5.3)	1 (1.1)		8 (3.3)
<i>Lormetazepam (N05CD06)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Opioids (N02A)	13 (9.8)	4 (4.4)		17 (6.9)
<i>Tramadol, combinations (N02AX52)</i>	7 (5.3)	0 (0.0)		7 (2.8)
<i>Tramadol (N02AX02)</i>	3 (2.3)	2 (2.2)		5 (2.0)
<i>Morphine (N02AA01)</i>	2 (1.5)	1 (1.1)		3 (1.2)
<i>Oxycodone (N02AA05)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Dihydrocodeine (N02AA08)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Fentanyl (N02AB03)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Antipsychotics (N05A)	9 (6.8)	2 (2.2)		11 (4.5)
<i>Risperidone (N05AX08)</i>	3 (2.3)	1 (1.1)		4 (1.6)
<i>Cyamemazine (N05AA06)</i>	1 (0.8)	1 (1.1)		2 (0.8)
<i>Tiapride (N05AL03)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Levomepromazine (N05AA02)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Periciazine (N05AC01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Loxapine (N05AH01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Olanzapine (N05AH03)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Amisulpride (N05AL05)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Drugs used in addictive disorders (N07B)	4 (3.0)	2 (2.2)		6 (2.4)
<i>Disulfiram (N07BB01)</i>	1 (0.8)	2 (2.2)		3 (1.2)
<i>Buprenorphine (N07BC01)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Acamprosate (N07BB03)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antimigraine preparations (N02C)	3 (2.3)	2 (2.2)		5 (2.0)
<i>Eletriptan (N02CC06)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Dihydroergotamine (N02CA01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Zolmitriptan (N02CC03)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Almotriptan (N02CC05)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Pizotifen (N02CX01)</i>	0 (0.0)	1 (1.1)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 91	Not exposed to drugs n = 23	Total n = 246
Anesthetics, general (N01A)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Desflurane (N01AB07)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Ketamine (N01AX03)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Sufentanil (N01AH03)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Thiopental (N01AF03)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Anticholinergic agents (N04A)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Tropatepine (N04AA12)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Psychostimulants, agents used for adhd and nootropics (N06B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Amphetamine (N06BA01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antivertigo preparations (N07C)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Acetylleucine (N07CA04)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<b>Antiinfectives for systemic use (J)</b>	<b>5 (3.8)</b>	<b>34 (37.4)</b>		<b>39 (15.9)</b>
Drugs for treatment of tuberculosis (J04A)	0 (0.0)	16 (17.6)		16 (6.5)
<i>Rifampicin, pyrazinamide, ethambutol and isoniazid (J04AM06)</i>	0 (0.0)	10 (11.0)		10 (4.1)
<i>Rifampicin and isoniazid (J04AM02)</i>	0 (0.0)	6 (6.6)		6 (2.4)
<i>Ethambutol (J04AK02)</i>	0 (0.0)	2 (2.2)		2 (0.8)
<i>Rifampicin, pyrazinamide and isoniazid (J04AM05)</i>	0 (0.0)	2 (2.2)		2 (0.8)
<i>Rifampicin (J04AB02)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Rifabutin (J04AB04)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Isoniazid (J04AC01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Pyrazinamide (J04AK01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Direct acting antivirals (J05A)	1 (0.8)	12 (13.2)		13 (5.3)
<i>Tenofovir disoproxil and emtricitabine (J05AR03)</i>	0 (0.0)	5 (5.5)		5 (2.0)
<i>Efavirenz (J05AG03)</i>	0 (0.0)	4 (4.4)		4 (1.6)
<i>Ritonavir (J05AE03)</i>	0 (0.0)	3 (3.3)		3 (1.2)
<i>Emtricitabine, tenofovir disoproxil and efavirenz (J05AR06)</i>	0 (0.0)	3 (3.3)		3 (1.2)
<i>Valaciclovir (J05AB11)</i>	1 (0.8)	1 (1.1)		2 (0.8)
<i>Atazanavir (J05AE08)</i>	0 (0.0)	2 (2.2)		2 (0.8)
<i>Tenofovir disoproxil (J05AF07)</i>	0 (0.0)	2 (2.2)		2 (0.8)
<i>Nucleoside and nucleotide reverse transcriptase inhibitors, combinations (J05AF30)</i>	0 (0.0)	2 (2.2)		2 (0.8)
<i>Aciclovir (J05AB01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Ribavirin (J05AB04)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Valganciclovir (J05AB14)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Didanosine (J05AF02)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Emtricitabine (J05AF09)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Nevirapine (J05AG01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Raltegravir (J05AX08)</i>	0 (0.0)	1 (1.1)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 91	Not exposed to drugs n = 23	Total n = 246
Beta-lactam antibacterials, penicillins (J01C)	3 (2.3)	7 (7.7)		10 (4.1)
<i>Amoxicillin (J01CA04)</i>	1 (0.8)	5 (5.5)		6 (2.4)
<i>Amoxicillin and enzyme inhibitor (J01CR02)</i>	1 (0.8)	1 (1.1)		2 (0.8)
<i>Cloxacillin (J01CF02)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Piperacillin and enzyme inhibitor (J01CR05)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Aminoglycoside antibacterials (J01G)	0 (0.0)	3 (3.3)		3 (1.2)
<i>Amikacin (J01GB06)</i>	0 (0.0)	2 (2.2)		2 (0.8)
<i>Gentamicin (J01GB03)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Antimycotics for systemic use (J02A)	0 (0.0)	3 (3.3)		3 (1.2)
<i>Fluconazole (J02AC01)</i>	0 (0.0)	2 (2.2)		2 (0.8)
<i>Caspofungin (J02AX04)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Other beta-lactam antibacterials (J01D)	1 (0.8)	2 (2.2)		3 (1.2)
<i>Ceftazidime (J01DD02)</i>	0 (0.0)	2 (2.2)		2 (0.8)
<i>Cefotaxime (J01DD01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Ceftriaxone (J01DD04)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Cefpodoxime (J01DD13)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Sulfonamides and trimethoprim (J01E)	0 (0.0)	3 (3.3)		3 (1.2)
<i>Sulfamethoxazole and trimethoprim (J01EE01)</i>	0 (0.0)	3 (3.3)		3 (1.2)
Macrolides, lincosamides and streptogramins (J01F)	0 (0.0)	2 (2.2)		2 (0.8)
<i>Azithromycin (J01FA10)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Telithromycin (J01FA15)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Other antibacterials (J01X)	0 (0.0)	2 (2.2)		2 (0.8)
<i>Vancomycin (J01XA01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Nitrofurantoin (J01XE01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Bacterial and viral vaccines, combined (J07C)	0 (0.0)	1 (1.1)		1 (0.4)
Quinolone antibacterials (J01M)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Ofloxacin (J01MA01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<b>Alimentary tract and metabolism (A)</b>	<b>18 (13.6)</b>	<b>20 (22.0)</b>		<b>38 (15.4)</b>
Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) (A02B)	9 (6.8)	5 (5.5)		14 (5.7)
<i>Lansoprazole (A02BC03)</i>	4 (3.0)	1 (1.1)		5 (2.0)
<i>Omeprazole (A02BC01)</i>	3 (2.3)	1 (1.1)		4 (1.6)
<i>Esomeprazole (A02BC05)</i>	2 (1.5)	1 (1.1)		3 (1.2)
<i>Pantoprazole (A02BC02)</i>	0 (0.0)	2 (2.2)		2 (0.8)
Blood glucose lowering drugs, excl. insulins (A10B)	2 (1.5)	4 (4.4)		6 (2.4)
<i>Metformin (A10BA02)</i>	1 (0.8)	4 (4.4)		5 (2.0)
<i>Glibenclamide (A10BB01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Metformin and sitagliptin (A10BD07)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Sitagliptin (A10BH01)</i>	0 (0.0)	1 (1.1)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 91	Not exposed to drugs n = 23	Total n = 246
Drugs for functional bowel disorders (A03A)	3 (2.3)	3 (3.3)		6 (2.4)
<i>Phloroglucinol (A03AX12)</i>	3 (2.3)	1 (1.1)		4 (1.6)
<i>Trimebutine (A03AA05)</i>	0 (0.0)	2 (2.2)		2 (0.8)
<i>Alverine, combinations (A03AX58)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Propulsives (A03F)	3 (2.3)	3 (3.3)		6 (2.4)
<i>Metoclopramide (A03FA01)</i>	2 (1.5)	2 (2.2)		4 (1.6)
<i>Domperidone (A03FA03)</i>	1 (0.8)	1 (1.1)		2 (0.8)
Antacids (A02A)	0 (0.0)	5 (5.5)		5 (2.0)
<i>Aluminium hydroxide (A02AB01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Laxatives (A06A)	1 (0.8)	4 (4.4)		5 (2.0)
<i>Liquid paraffin (A06AA01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Bisacodyl (A06AB02)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Senna glycosides, combinations (A06AB56)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Ispaghula, combinations (A06AC51)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Lactulose (A06AD11)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Macrogol (A06AD15)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Antipropulsives (A07D)	4 (3.0)	1 (1.1)		5 (2.0)
<i>Loperamide (A07DA03)</i>	4 (3.0)	1 (1.1)		5 (2.0)
Antiemetics and antinauseants (A04A)	2 (1.5)	1 (1.1)		3 (1.2)
<i>Metopimazine (A04AD05)</i>	2 (1.5)	0 (0.0)		2 (0.8)
Insulins and analogues (A10A)	1 (0.8)	2 (2.2)		3 (1.2)
<i>Insulin (human) (A10AB01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Insulin glargine (A10AE04)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Other drugs for acid related disorders (A02X)	1 (0.8)	0 (0.0)		1 (0.4)
Bile therapy (A05A)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Ursodeoxycholic acid (A05AA02)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Multivitamins, combinations (A11A)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Multivitamins and other minerals, incl. combinations (A11AA03)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Vitamin a and d, incl. combinations of the two (A11C)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Calcifediol (A11CC06)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<b>Cardiovascular system (C)</b>	<b>13 (9.8)</b>	<b>19 (20.9)</b>		<b>32 (13.0)</b>
Lipid modifying agents, plain (C10A)	4 (3.0)	8 (8.8)		12 (4.9)
<i>Atorvastatin (C10AA05)</i>	2 (1.5)	3 (3.3)		5 (2.0)
<i>Rosuvastatin (C10AA07)</i>	1 (0.8)	1 (1.1)		2 (0.8)
<i>Simvastatin (C10AA01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Pravastatin (C10AA03)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Fenofibrate (C10AB05)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Colestyramine (C10AC01)</i>	0 (0.0)	1 (1.1)		1 (0.4)



	Acute drug overdose n = 132	Exposed to drugs n = 91	Not exposed to drugs n = 23	Total n = 246
Beta blocking agents (C07A)	3 (2.3)	6 (6.6)		9 (3.7)
<i>Atenolol (C07AB03)</i>	1 (0.8)	3 (3.3)		4 (1.6)
<i>Propranolol (C07AA05)</i>	1 (0.8)	1 (1.1)		2 (0.8)
<i>Nebivolol (C07AB12)</i>	1 (0.8)	1 (1.1)		2 (0.8)
<i>Sotalol (C07AA07)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Selective calcium channel blockers with mainly vascular effects (C08C)	2 (1.5)	5 (5.5)		7 (2.8)
<i>Amlodipine (C08CA01)</i>	1 (0.8)	2 (2.2)		3 (1.2)
<i>Lercanidipine (C08CA13)</i>	1 (0.8)	2 (2.2)		3 (1.2)
<i>Manidipine (C08CA11)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Angiotensin ii antagonists, plain (C09C)	3 (2.3)	3 (3.3)		6 (2.4)
<i>Losartan (C09CA01)</i>	0 (0.0)	2 (2.2)		2 (0.8)
<i>Irbesartan (C09CA04)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Valsartan (C09CA03)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Candesartan (C09CA06)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Ace inhibitors, plain (C09A)	1 (0.8)	3 (3.3)		4 (1.6)
<i>Lisinopril (C09AA03)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Perindopril (C09AA04)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Ramipril (C09AA05)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Ace inhibitors, combinations (C09B)	1 (0.8)	2 (2.2)		3 (1.2)
<i>Perindopril and diuretics (C09BA04)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Ramipril and diuretics (C09BA05)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Trandolapril and verapamil (C09BB10)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Angiotensin ii antagonists, combinations (C09D)	2 (1.5)	1 (1.1)		3 (1.2)
<i>Valsartan and diuretics (C09DA03)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Olmesartan medoxomil and diuretics (C09DA08)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Olmesartan medoxomil and amlodipine (C09DB02)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Vasodilators used in cardiac diseases (C01D)	1 (0.8)	1 (1.1)		2 (0.8)
<i>Glyceryl trinitrate (C01DA02)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Heptaminol (C01DX08)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antiadrenergic agents, centrally acting (C02A)	1 (0.8)	1 (1.1)		2 (0.8)
<i>Moxonidine (C02AC05)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Rilmenidine (C02AC06)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Capillary stabilizing agents (C05C)	1 (0.8)	1 (1.1)		2 (0.8)
Antiarrhythmics, class i and iii (C01B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Amiodarone (C01BD01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Low-ceiling diuretics, excl. thiazides (C03B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Indapamide (C03BA11)</i>	1 (0.8)	0 (0.0)		1 (0.4)
High-ceiling diuretics (C03C)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Furosemide (C03CA01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Potassium-sparing agents (C03D)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Spironolactone (C03DA01)</i>	0 (0.0)	1 (1.1)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 91	Not exposed to drugs n = 23	Total n = 246
Peripheral vasodilators (C04A)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Naftidrofuryl (C04AX21)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<b>Musculo-skeletal system (M)</b>	<b>19 (14.4)</b>	<b>13 (14.3)</b>		<b>32 (13.0)</b>
Antiinflammatory and antirheumatic products, non-steroids (M01A)	16 (12.1)	8 (8.8)		24 (9.8)
<i>Ibuprofen (M01AE01)</i>	6 (4.5)	4 (4.4)		10 (4.1)
<i>Diclofenac (M01AB05)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Ketoprofen (M01AE03)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Diclofenac, combinations (M01AB55)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Piroxicam (M01AC01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Naproxen (M01AE02)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Nimesulide (M01AX17)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Celecoxib (M01AH01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Muscle relaxants, centrally acting agents (M03B)	4 (3.0)	1 (1.1)		5 (2.0)
<i>Tetrazepam (M03BX07)</i>	3 (2.3)	0 (0.0)		3 (1.2)
<i>Baclofen (M03BX01)</i>	1 (0.8)	1 (1.1)		2 (0.8)
Antigout preparations (M04A)	1 (0.8)	1 (1.1)		2 (0.8)
<i>Allopurinol (M04AA01)</i>	1 (0.8)	1 (1.1)		2 (0.8)
Muscle relaxants, peripherally acting agents (M03A)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Rocuronium bromide (M03AC09)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Muscle relaxants, directly acting agents (M03C)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Dantrolene (M03CA01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Other drugs for disorders of the musculo-skeletal system (M09A)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Chondrocytes, autologous (M09AX02)</i>	0 (0.0)	1 (1.2)		1 (0.4)
<b>Respiratory system (R)</b>	<b>12 (9.1)</b>	<b>9 (9.9)</b>		<b>21 (8.5)</b>
Antihistamines for systemic use (R06A)	6 (4.5)	5 (5.5)		11 (4.5)
<i>Alimemazine (R06AD01)</i>	5 (3.8)	0 (0.0)		5 (2.0)
<i>Desloratadine (R06AX27)</i>	0 (0.0)	2 (2.2)		2 (0.8)
<i>Dexchlorpheniramine (R06AB02)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Levocetirizine (R06AE09)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Adrenergics, inhalants (R03A)	5 (3.8)	2 (2.2)		7 (2.8)
<i>Salbutamol (R03AC02)</i>	4 (3.0)	1 (1.1)		5 (2.0)
<i>Formoterol and budesonide (R03AK07)</i>	0 (0.0)	2 (2.2)		2 (0.8)
<i>Terbutaline (R03AC03)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Salmeterol and fluticasone (R03AK06)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Other drugs for obstructive airway diseases, inhalants (R03B)	1 (0.8)	1 (1.1)		2 (0.8)
<i>Budesonide (R03BA02)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Ipratropium bromide (R03BB01)</i>	1 (0.8)	0 (0.0)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 91	Not exposed to drugs n = 23	Total n = 246
<i>Tiotropium bromide (R03BB04)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Cough suppressants, excl. combinations with expectorants (R05D)	2 (1.5)	0 (0.0)		2 (0.8)
<i>Combinations (R05DA20)</i>	2 (1.5)	0 (0.0)		2 (0.8)
Other systemic drugs for obstructive airway diseases (R03D)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Fenspiride (R03DX03)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Other cold combination preparations (R05X)	0 (0.0)	1 (1.1)		1 (0.4)
<b>Blood and blood forming organs (B)</b>	<b>3 (2.3)</b>	<b>10 (11.0)</b>		<b>13 (5.3)</b>
Antithrombotic agents (B01A)	2 (1.5)	10 (11.0)		12 (4.9)
<i>Acetylsalicylic acid (B01AC06)</i>	1 (0.8)	6 (6.6)		7 (2.8)
<i>Clopidogrel (B01AC04)</i>	1 (0.8)	4 (4.4)		5 (2.0)
<i>Fluindione (B01AA12)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<i>Nadroparin (B01AB06)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Iron preparations (B03A)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Ferrous sulfate (B03AA07)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<b>Genito urinary system and sex hormones (G)</b>	<b>6 (4.5)</b>	<b>7 (7.7)</b>		<b>13 (5.3)</b>
Hormonal contraceptives for systemic use (G03A)	3 (2.3)	2 (2.2)		5 (2.0)
<i>Gestodene and estrogen (G03AA10)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Progestogens (G03D)	1 (0.8)	3 (3.3)		4 (1.6)
<i>Nomegestrol (G03DB04)</i>	1 (0.8)	1 (1.1)		2 (0.8)
<i>Progesterone (G03DA04)</i>	0 (0.0)	2 (2.2)		2 (0.8)
Estrogens (G03C)	0 (0.0)	2 (2.2)		2 (0.8)
<i>Estradiol (G03CA03)</i>	0 (0.0)	2 (2.2)		2 (0.8)
Other urologicals, incl. antispasmodics (G04B)	1 (0.8)	1 (1.1)		2 (0.8)
<i>Solifenacin (G04BD08)</i>	1 (0.8)	1 (1.1)		2 (0.8)
Gonadotropins and other ovulation stimulants (G03G)	0 (0.0)	1 (1.1)		1 (0.4)
Other sex hormones and modulators of the genital system (G03X)	1 (0.8)	0 (0.0)		1 (0.4)
Drugs used in benign prostatic hypertrophy (G04C)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Alfuzosin (G04CA01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<b>Systemic hormonal preparations (excluded sex hormones and insulines) (H)</b>	<b>5 (3.8)</b>	<b>7 (7.7)</b>		<b>12 (4.9)</b>
Corticosteroids for systemic use, plain (H02A)	3 (2.3)	3 (3.3)		6 (2.4)
<i>Prednisone (H02AB07)</i>	2 (1.5)	1 (1.1)		3 (1.2)
<i>Methylprednisolone (H02AB04)</i>	0 (0.0)	2 (2.2)		2 (0.8)
<i>Prednisolone (H02AB06)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Thyroid preparations (H03A)	2 (1.5)	3 (3.3)		5 (2.0)
<i>Levothyroxine sodium (H03AA01)</i>	2 (1.5)	3 (3.3)		5 (2.0)

	Acute drug overdose n = 132	Exposed to drugs n = 91	Not exposed to drugs n = 23	Total n = 246
Hypothalamic hormones (H01C)	0 (0.0)	1 (1.1)		1 (0.4)
<b>Drugs</b>	<b>9 (6.8)</b>	<b>0 (0.0)</b>		<b>9 (3.7)</b>
Cannabis	8 (6.1)	0 (0.0)		8 (3.3)
Ecstasy	2 (1.5)	0 (0.0)		2 (0.8)
Cocaine	1 (0.8)	0 (0.0)		1 (0.4)
LSA	1 (0.8)	0 (0.0)		1 (0.4)
Mushrooms	1 (0.8)	0 (0.0)		1 (0.4)
<b>Antineoplastic and immunomodulating agents (L)</b>	<b>1 (0.8)</b>	<b>4 (4.4)</b>		<b>5 (2.0)</b>
Immunosuppressants (L04A)	1 (0.8)	2 (2.2)		3 (1.2)
<i>Infliximab (L04AA12)</i>	1 (0.8)	1 (1.1)		2 (0.8)
<i>Tacrolimus (L04AD02)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Antimetabolites (L01B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Methotrexate (L01BA01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Other antineoplastic agents (L01X)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Imatinib (L01XE01)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Immunostimulants (L03A)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Glatiramer acetate (L03AX13)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<b>Homeopathy</b>	<b>1 (0.8)</b>	<b>2 (2.2)</b>		<b>3 (1.2)</b>
Homeopathy	0 (0.0)	1 (1.1)		1 (0.4)
Organic silicon	0 (0.0)	1 (1.1)		1 (0.4)
Sedatif PC	1 (0.8)	0 (0.0)		1 (0.4)
<b>Dermatologicals (D)</b>	<b>1 (0.8)</b>	<b>1 (1.1)</b>		<b>2 (0.8)</b>
Antifungals for systemic use (D01B)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Terbinafine (D01BA02)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Other dermatological preparations (D11A)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Minoxidil (D11AX01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<b>Antiparasitic products, insecticides and repellents (P)</b>	<b>1 (0.8)</b>	<b>1 (1.1)</b>		<b>2 (0.8)</b>
Antimalarials (P01B)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Proguanil, combinations (P01BB51)</i>	0 (0.0)	1 (1.1)		1 (0.4)
Antitrematodals (P02B)	1 (0.8)	0 (0.0)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 91	Not exposed to drugs n = 23	Total n = 246
<b>Food supplement</b>	<b>0 (0.0)</b>	<b>2 (2.2)</b>		<b>2 (0.8)</b>
Fortimel	0 (0.0)	1 (1.1)		1 (0.4)
Vitonic	0 (0.0)	1 (1.1)		1 (0.4)
<b>Various (V)</b>	<b>0 (0.0)</b>	<b>1 (1.1)</b>		<b>1 (0.4)</b>
All other therapeutic products (V03A)	0 (0.0)	1 (1.1)		1 (0.4)
<i>Calcium folinate (V03AF03)</i>	0 (0.0)	1 (1.1)		1 (0.4)
<b>No ATC code</b>	<b>0 (0.0)</b>	<b>1 (1.1)</b>		<b>1 (0.4)</b>

**SALT-II - Table 6b: Paracetamol exposure of ALFT cases according to drug exposure in the 90 days prior to index date for the years 2008 to 2013**

	Acute drug overdose n = 132	Exposed to drugs n = 91	Not exposed to drugs n = 23	Total n = 246
<b>At least one exposure at paracetamol in the 90 days prior to index date, n (%)</b>				
<b>Paracetamol, plain and combinations</b>	<b>130 (98.5)</b>	<b>39 (42.9)</b>	<b>0 (0.0)</b>	<b>169 (68.7)</b>
Paracetamol (N02BE01)	109 (82.6)	36 (39.6)	0 (0.0)	145 (58.9)
Paracetamol, combinations excl. psycholeptics (N02BE51)	23 (17.4)	4 (4.4)	0 (0.0)	27 (11.0)
Paracetamol, combinations with psycholeptics (N02BE71)	2 (1.5)	2 (2.2)	0 (0.0)	4 (1.6)
Codeine, combinations excl. psycholeptics (N02AA59)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Tramadol, combinations (N02AX52)	7 (5.3)	0 (0.0)	0 (0.0)	7 (2.8)
<b>At least one overdose, n (%)</b>	<b>126 (95.5)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>126 (51.2)</b>
<b>At least one intentional overdose, n (%)</b>	<b>69 (52.3)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>69 (28.0)</b>
<b>At least one non-intentional overdose, n (%)</b>	<b>57 (43.2)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>57 (23.2)</b>

SALT-II - Table 7: Drug exposure of ALFT cases according to drug exposure in the 15 days prior to index date for the years 2008 to 2013

	Acute drug overdose n = 132	Exposed to drugs n = 75	Not exposed to drugs n = 39	Total n = 246
<b>At least one exposure at the following ATC codes in the 15 days prior to index date, n (%)</b>	<b>132 (100.0)</b>	<b>75 (100.0)</b>	<b>0 (0.0)</b>	<b>207 (84.1)</b>
<b>Nervous system (N)</b>	<b>131 (99.2)</b>	<b>47 (62.7)</b>		<b>178 (72.4)</b>
Other analgesics and antipyretics (N02B)	127 (96.2)	36 (48.0)		163 (66.3)
<i>Paracetamol (N02BE01)</i>	109 (82.6)	32 (42.7)		141 (57.3)
<i>Paracetamol, combinations excl. psycholeptics (N02BE51)</i>	22 (16.7)	4 (5.3)		26 (10.6)
<i>Paracetamol, combinations with psycholeptics (N02BE71)</i>	2 (1.5)	2 (2.7)		4 (1.6)
<i>Acetylsalicylic acid (N02BA01)</i>	0 (0.0)	3 (4.0)		3 (1.2)
<i>Nefopam (N02BG06)</i>	0 (0.0)	2 (2.7)		2 (0.8)
Anxiolytics (N05B)	42 (31.8)	10 (13.3)		52 (21.1)
<i>Oxazepam (N05BA04)</i>	9 (6.8)	3 (4.0)		12 (4.9)
<i>Alprazolam (N05BA12)</i>	11 (8.3)	1 (1.3)		12 (4.9)
<i>Bromazepam (N05BA08)</i>	8 (6.1)	2 (2.7)		10 (4.1)
<i>Hydroxyzine (N05BB01)</i>	4 (3.0)	1 (1.3)		5 (2.0)
<i>Diazepam (N05BA01)</i>	2 (1.5)	1 (1.3)		3 (1.2)
<i>Przepam (N05BA11)</i>	3 (2.3)	0 (0.0)		3 (1.2)
<i>Etifoxine (N05BX03)</i>	3 (2.3)	0 (0.0)		3 (1.2)
<i>Potassium clorazepate (N05BA05)</i>	1 (0.8)	1 (1.3)		2 (0.8)
<i>Lorazepam (N05BA06)</i>	1 (0.8)	1 (1.3)		2 (0.8)
<i>Clobazam (N05BA09)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Meprobamate (N05BC01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Meprobamate, combinations (N05BC51)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Antidepressants (N06A)	29 (22.0)	12 (16.0)		41 (16.7)
<i>Escitalopram (N06AB10)</i>	8 (6.1)	1 (1.3)		9 (3.7)
<i>Venlafaxine (N06AX16)</i>	2 (1.5)	4 (5.3)		6 (2.4)
<i>Amitriptyline (N06AA09)</i>	3 (2.3)	1 (1.3)		4 (1.6)
<i>Paroxetine (N06AB05)</i>	4 (3.0)	0 (0.0)		4 (1.6)
<i>Fluoxetine (N06AB03)</i>	3 (2.3)	0 (0.0)		3 (1.2)
<i>Mianserin (N06AX03)</i>	1 (0.8)	2 (2.7)		3 (1.2)
<i>Citalopram (N06AB04)</i>	1 (0.8)	1 (1.3)		2 (0.8)
<i>Sertraline (N06AB06)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Iproniazide (N06AF05)</i>	0 (0.0)	2 (2.7)		2 (0.8)
<i>Clomipramine (N06AA04)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Trimipramine (N06AA06)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Moclobemide (N06AG02)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Tianeptine (N06AX14)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Duloxetine (N06AX21)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Agomelatine (N06AX22)</i>	1 (0.8)	0 (0.0)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 75	Not exposed to drugs n = 39	Total n = 246
Antiepileptics (N03A)	14 (10.6)	9 (12.0)		23 (9.3)
<i>Valproic acid (N03AG01)</i>	4 (3.0)	3 (4.0)		7 (2.8)
<i>Clonazepam (N03AE01)</i>	4 (3.0)	2 (2.7)		6 (2.4)
<i>Carbamazepine (N03AF01)</i>	3 (2.3)	3 (4.0)		6 (2.4)
<i>Levetiracetam (N03AX14)</i>	3 (2.3)	2 (2.7)		5 (2.0)
<i>Lamotrigine (N03AX09)</i>	1 (0.8)	3 (4.0)		4 (1.6)
<i>Topiramate (N03AX11)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Gabapentin (N03AX12)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Pregabalin (N03AX16)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Hypnotics and sedatives (N05C)	20 (15.2)	3 (4.0)		23 (9.3)
<i>Zolpidem (N05CF02)</i>	10 (7.6)	1 (1.3)		11 (4.5)
<i>Zopiclone (N05CF01)</i>	6 (4.5)	1 (1.3)		7 (2.8)
<i>Lormetazepam (N05CD06)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Opioids (N02A)	11 (8.3)	3 (4.0)		14 (5.7)
<i>Tramadol, combinations (N02AX52)</i>	6 (4.5)	0 (0.0)		6 (2.4)
<i>Tramadol (N02AX02)</i>	3 (2.3)	1 (1.3)		4 (1.6)
<i>Morphine (N02AA01)</i>	1 (0.8)	1 (1.3)		2 (0.8)
<i>Fentanyl (N02AB03)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Oxycodone (N02AA05)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Dihydrocodeine (N02AA08)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Antipsychotics (N05A)	7 (5.3)	2 (2.7)		9 (3.7)
<i>Risperidone (N05AX08)</i>	3 (2.3)	1 (1.3)		4 (1.6)
<i>Cyamemazine (N05AA06)</i>	1 (0.8)	1 (1.3)		2 (0.8)
<i>Tiapride (N05AL03)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Levomepromazine (N05AA02)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Periciazine (N05AC01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Olanzapine (N05AH03)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Drugs used in addictive disorders (N07B)	3 (2.3)	2 (2.7)		5 (2.0)
<i>Disulfiram (N07BB01)</i>	1 (0.8)	2 (2.7)		3 (1.2)
<i>Buprenorphine (N07BC01)</i>	2 (1.5)	0 (0.0)		2 (0.8)
Antimigraine preparations (N02C)	1 (0.8)	2 (2.7)		3 (1.2)
<i>Dihydroergotamine (N02CA01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Zolmitriptan (N02CC03)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Pizotifen (N02CX01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Anesthetics, general (N01A)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Desflurane (N01AB07)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Thiopental (N01AF03)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Sufentanil (N01AH03)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Ketamine (N01AX03)</i>	0 (0.0)	1 (1.3)		1 (0.4)



	Acute drug overdose n = 132	Exposed to drugs n = 75	Not exposed to drugs n = 39	Total n = 246
Anticholinergic agents (N04A)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Tropatepine (N04AA12)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Psychostimulants, agents used for adhd and nootropics (N06B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Amphetamine (N06BA01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antivertigo preparations (N07C)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Acetyllecine (N07CA04)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<b>Antiinfectives for systemic use (J)</b>	<b>4 (3.0)</b>	<b>31 (41.3)</b>		<b>35 (14.2)</b>
Drugs for treatment of tuberculosis (J04A)	0 (0.0)	16 (21.3)		16 (6.5)
<i>Rifampicin, pyrazinamide, ethambutol and isoniazid (J04AM06)</i>	0 (0.0)	9 (12.0)		9 (3.7)
<i>Rifampicin and isoniazid (J04AM02)</i>	0 (0.0)	6 (8.0)		6 (2.4)
<i>Ethambutol (J04AK02)</i>	0 (0.0)	2 (2.7)		2 (0.8)
<i>Rifampicin, pyrazinamide and isoniazid (J04AM05)</i>	0 (0.0)	2 (2.7)		2 (0.8)
<i>Rifampicin (J04AB02)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Rifabutin (J04AB04)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Isoniazid (J04AC01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Pyrazinamide (J04AK01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Direct acting antivirals (J05A)	1 (0.8)	12 (16.0)		13 (5.3)
<i>Tenofovir disoproxil and emtricitabine (J05AR03)</i>	0 (0.0)	3 (4.0)		3 (1.2)
<i>Emtricitabine, tenofovir disoproxil and efavirenz (J05AR06)</i>	0 (0.0)	3 (4.0)		3 (1.2)
<i>Valaciclovir (J05AB11)</i>	1 (0.8)	1 (1.3)		2 (0.8)
<i>Ritonavir (J05AE03)</i>	0 (0.0)	2 (2.7)		2 (0.8)
<i>Tenofovir disoproxil (J05AF07)</i>	0 (0.0)	2 (2.7)		2 (0.8)
<i>Efavirenz (J05AG03)</i>	0 (0.0)	2 (2.7)		2 (0.8)
<i>Aciclovir (J05AB01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Ribavirin (J05AB04)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Valganciclovir (J05AB14)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Atazanavir (J05AE08)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Emtricitabine (J05AF09)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Nucleoside and nucleotide reverse transcriptase inhibitors, combinations (J05AF30)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Nevirapine (J05AG01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Raltegravir (J05AX08)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Beta-lactam antibacterials, penicillins (J01C)	3 (2.3)	5 (6.7)		8 (3.3)
<i>Amoxicillin (J01CA04)</i>	1 (0.8)	4 (5.3)		5 (2.0)
<i>Amoxicillin and enzyme inhibitor (J01CR02)</i>	1 (0.8)	1 (1.3)		2 (0.8)
<i>Cloxacillin (J01CF02)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Other beta-lactam antibacterials (J01D)	1 (0.8)	1 (1.3)		2 (0.8)
<i>Ceftazidime (J01DD02)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Ceftriaxone (J01DD04)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Cefpodoxime (J01DD13)</i>	1 (0.8)	0 (0.0)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 75	Not exposed to drugs n = 39	Total n = 246
Sulfonamides and trimethoprim (J01E)	0 (0.0)	2 (2.7)		2 (0.8)
<i>Sulfamethoxazole and trimethoprim (J01EE01)</i>	0 (0.0)	2 (2.7)		2 (0.8)
Macrolides, lincosamides and streptogramins (J01F)	0 (0.0)	2 (2.7)		2 (0.8)
<i>Azithromycin (J01FA10)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Telithromycin (J01FA15)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Aminoglycoside antibacterials (J01G)	0 (0.0)	2 (2.7)		2 (0.8)
<i>Amikacin (J01GB06)</i>	0 (0.0)	2 (2.7)		2 (0.8)
Antimycotics for systemic use (J02A)	0 (0.0)	2 (2.7)		2 (0.8)
<i>Fluconazole (J02AC01)</i>	0 (0.0)	2 (2.7)		2 (0.8)
Quinolone antibacterials (J01M)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Ofloxacin (J01MA01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Other antibacterials (J01X)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Nitrofurantoin (J01XE01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<b>Alimentary tract and metabolism (A)</b>	<b>15 (11.4)</b>	<b>15 (20.0)</b>		<b>30 (12.2)</b>
Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) (A02B)	6 (4.5)	1 (1.3)		7 (2.8)
<i>Lansoprazole (A02BC03)</i>	3 (2.3)	1 (1.3)		4 (1.6)
<i>Omeprazole (A02BC01)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Esomeprazole (A02BC05)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Blood glucose lowering drugs, excl. insulins (A10B)	2 (1.5)	4 (5.3)		6 (2.4)
<i>Metformin (A10BA02)</i>	1 (0.8)	4 (5.3)		5 (2.0)
<i>Glibenclamide (A10BB01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Metformin and sitagliptin (A10BD07)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Sitagliptin (A10BH01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Drugs for functional bowel disorders (A03A)	3 (2.3)	2 (2.7)		5 (2.0)
<i>Phloroglucinol (A03AX12)</i>	3 (2.3)	1 (1.3)		4 (1.6)
<i>Trimebutine (A03AA05)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Alverine, combinations (A03AX58)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Antipropulsives (A07D)	4 (3.0)	1 (1.3)		5 (2.0)
<i>Loperamide (A07DA03)</i>	4 (3.0)	1 (1.3)		5 (2.0)
Propulsives (A03F)	2 (1.5)	2 (2.7)		4 (1.6)
<i>Metoclopramide (A03FA01)</i>	1 (0.8)	2 (2.7)		3 (1.2)
<i>Domperidone (A03FA03)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antiemetics and antinauseants (A04A)	2 (1.5)	1 (1.3)		3 (1.2)
<i>Metopimazine (A04AD05)</i>	2 (1.5)	0 (0.0)		2 (0.8)
Insulins and analogues (A10A)	1 (0.8)	2 (2.7)		3 (1.2)
<i>Insulin (human) (A10AB01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Insulin glargine (A10AE04)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antacids (A02A)	0 (0.0)	2 (2.7)		2 (0.8)
<i>Aluminium hydroxide (A02AB01)</i>	0 (0.0)	1 (1.3)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 75	Not exposed to drugs n = 39	Total n = 246
Other drugs for acid related disorders (A02X)	1 (0.8)	0 (0.0)		1 (0.4)
Bile therapy (A05A)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Ursodeoxycholic acid (A05AA02)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Laxatives (A06A)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Liquid paraffin (A06AA01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Multivitamins, combinations (A11A)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Multivitamins and other minerals, incl. combinations (A11AA03)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Vitamin a and d, incl. combinations of the two (A11C)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Calcifediol (A11CC06)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<b>Musculo-skeletal system (M)</b>	<b>19 (14.4)</b>	<b>11 (14.7)</b>		<b>30 (12.2)</b>
Antiinflammatory and antirheumatic products, non-steroids (M01A)	16 (12.1)	6 (8.0)		22 (8.9)
<i>Ibuprofen (M01AE01)</i>	6 (4.5)	3 (4.0)		9 (3.7)
<i>Diclofenac (M01AB05)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Ketoprofen (M01AE03)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Diclofenac, combinations (M01AB55)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Piroxicam (M01AC01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Naproxen (M01AE02)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Nimesulide (M01AX17)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Muscle relaxants, centrally acting agents (M03B)	4 (3.0)	1 (1.3)		5 (2.0)
<i>Tetrazepam (M03BX07)</i>	3 (2.3)	0 (0.0)		3 (1.2)
<i>Baclofen (M03BX01)</i>	1 (0.8)	1 (1.3)		2 (0.8)
Antigout preparations (M04A)	1 (0.8)	1 (1.3)		2 (0.8)
<i>Allopurinol (M04AA01)</i>	1 (0.8)	1 (1.3)		2 (0.8)
Muscle relaxants, peripherally acting agents (M03A)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Rocuronium bromide (M03AC09)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Muscle relaxants, directly acting agents (M03C)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Dantrolene (M03CA01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Other drugs for disorders of the musculo-skeletal system (M09A)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Chondrocytes, autologous (M09AX02)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<b>Cardiovascular system (C)</b>	<b>11 (8.3)</b>	<b>17 (22.7)</b>		<b>28 (11.4)</b>
Lipid modifying agents, plain (C10A)	3 (2.3)	8 (10.7)		11 (4.5)
<i>Atorvastatin (C10AA05)</i>	2 (1.5)	3 (4.0)		5 (2.0)
<i>Simvastatin (C10AA01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Pravastatin (C10AA03)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Rosuvastatin (C10AA07)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Fenofibrate (C10AB05)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Colestyramine (C10AC01)</i>	0 (0.0)	1 (1.3)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 75	Not exposed to drugs n = 39	Total n = 246
Selective calcium channel blockers with mainly vascular effects (C08C)	2 (1.5)	5 (6.7)		7 (2.8)
<i>Amlodipine (C08CA01)</i>	1 (0.8)	2 (2.7)		3 (1.2)
<i>Lercanidipine (C08CA13)</i>	1 (0.8)	2 (2.7)		3 (1.2)
<i>Manidipine (C08CA11)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Angiotensin ii antagonists, plain (C09C)	3 (2.3)	3 (4.0)		6 (2.4)
<i>Losartan (C09CA01)</i>	0 (0.0)	2 (2.7)		2 (0.8)
<i>Irbesartan (C09CA04)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Valsartan (C09CA03)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Candesartan (C09CA06)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Beta blocking agents (C07A)	1 (0.8)	4 (5.3)		5 (2.0)
<i>Atenolol (C07AB03)</i>	0 (0.0)	3 (4.0)		3 (1.2)
<i>Propranolol (C07AA05)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Nebivolol (C07AB12)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Ace inhibitors, plain (C09A)	1 (0.8)	2 (2.7)		3 (1.2)
<i>Perindopril (C09AA04)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Ramipril (C09AA05)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Ace inhibitors, combinations (C09B)	1 (0.8)	2 (2.7)		3 (1.2)
<i>Perindopril and diuretics (C09BA04)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Ramipril and diuretics (C09BA05)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Trandolapril and verapamil (C09BB10)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antiadrenergic agents, centrally acting (C02A)	1 (0.8)	1 (1.3)		2 (0.8)
<i>Moxonidine (C02AC05)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Rilmenidine (C02AC06)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Angiotensin ii antagonists, combinations (C09D)	2 (1.5)	0 (0.0)		2 (0.8)
<i>Olmesartan medoxomil and diuretics (C09DA08)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Olmesartan medoxomil and amlodipine (C09DB02)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antiarrhythmics, class i and iii (C01B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Amiodarone (C01BD01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Vasodilators used in cardiac diseases (C01D)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Heptaminol (C01DX08)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Low-ceiling diuretics, excl. thiazides (C03B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Indapamide (C03BA11)</i>	1 (0.8)	0 (0.0)		1 (0.4)
High-ceiling diuretics (C03C)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Furosemide (C03CA01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Potassium-sparing agents (C03D)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Spironolactone (C03DA01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Peripheral vasodilators (C04A)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Naftidrofuryl (C04AX21)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Capillary stabilizing agents (C05C)	0 (0.0)	1 (1.3)		1 (0.4)

	Acute drug overdose n = 132		Exposed to drugs n = 75		Not exposed to drugs n = 39	Total n = 246	
<b>Respiratory system (R)</b>	<b>12</b>	<b>(9.1)</b>	<b>6</b>	<b>(8.0)</b>		<b>18</b>	<b>(7.3)</b>
Antihistamines for systemic use (R06A)	6	(4.5)	2	(2.7)		8	(3.3)
<i>Alimemazine (R06AD01)</i>	5	(3.8)	0	(0.0)		5	(2.0)
<i>Dexchlorpheniramine (R06AB02)</i>	0	(0.0)	1	(1.3)		1	(0.4)
<i>Desloratadine (R06AX27)</i>	0	(0.0)	1	(1.3)		1	(0.4)
Adrenergics, inhalants (R03A)	4	(3.0)	2	(2.7)		6	(2.4)
<i>Salbutamol (R03AC02)</i>	3	(2.3)	1	(1.3)		4	(1.6)
<i>Formoterol and budesonide (R03AK07)</i>	0	(0.0)	2	(2.7)		2	(0.8)
<i>Terbutaline (R03AC03)</i>	1	(0.8)	0	(0.0)		1	(0.4)
<i>Salmeterol and fluticasone (R03AK06)</i>	1	(0.8)	0	(0.0)		1	(0.4)
Other drugs for obstructive airway diseases, inhalants (R03B)	1	(0.8)	1	(1.3)		2	(0.8)
<i>Budesonide (R03BA02)</i>	1	(0.8)	0	(0.0)		1	(0.4)
<i>Ipratropium bromide (R03BB01)</i>	1	(0.8)	0	(0.0)		1	(0.4)
<i>Tiotropium bromide (R03BB04)</i>	0	(0.0)	1	(1.3)		1	(0.4)
Other systemic drugs for obstructive airway diseases (R03D)	0	(0.0)	1	(1.3)		1	(0.4)
<i>Fenspiride (R03DX03)</i>	0	(0.0)	1	(1.3)		1	(0.4)
Cough suppressants, excl. combinations with expectorants (R05D)	1	(0.8)	0	(0.0)		1	(0.4)
<i>Combinations (R05DA20)</i>	1	(0.8)	0	(0.0)		1	(0.4)
Other cold combination preparations (R05X)	0	(0.0)	1	(1.3)		1	(0.4)
<b>Genito urinary system and sex hormones (G)</b>	<b>5</b>	<b>(3.8)</b>	<b>7</b>	<b>(9.3)</b>		<b>12</b>	<b>(4.9)</b>
Hormonal contraceptives for systemic use (G03A)	3	(2.3)	2	(2.7)		5	(2.0)
<i>Gestodene and estrogen (G03AA10)</i>	0	(0.0)	1	(1.3)		1	(0.4)
Progestogens (G03D)	1	(0.8)	2	(2.7)		3	(1.2)
<i>Nomegestrol (G03DB04)</i>	1	(0.8)	1	(1.3)		2	(0.8)
<i>Progesterone (G03DA04)</i>	0	(0.0)	1	(1.3)		1	(0.4)
Other urologicals, incl. antispasmodics (G04B)	1	(0.8)	1	(1.3)		2	(0.8)
<i>Solifenacin (G04BD08)</i>	1	(0.8)	1	(1.3)		2	(0.8)
Estrogens (G03C)	0	(0.0)	1	(1.3)		1	(0.4)
<i>Estradiol (G03CA03)</i>	0	(0.0)	1	(1.3)		1	(0.4)
Gonadotropins and other ovulation stimulants (G03G)	0	(0.0)	1	(1.3)		1	(0.4)
Drugs used in benign prostatic hypertrophy (G04C)	0	(0.0)	1	(1.3)		1	(0.4)
<i>Alfuzosin (G04CA01)</i>	0	(0.0)	1	(1.3)		1	(0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 75	Not exposed to drugs n = 39	Total n = 246
<b>Blood and blood forming organs (B)</b>	<b>3 (2.3)</b>	<b>8 (10.7)</b>		<b>11 (4.5)</b>
Antithrombotic agents (B01A)	2 (1.5)	8 (10.7)		10 (4.1)
<i>Acetylsalicylic acid (B01AC06)</i>	1 (0.8)	5 (6.7)		6 (2.4)
<i>Clopidogrel (B01AC04)</i>	1 (0.8)	3 (4.0)		4 (1.6)
<i>Fluindione (B01AA12)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Nadroparin (B01AB06)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Iron preparations (B03A)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Ferrous sulfate (B03AA07)</i>	1 (0.8)	0 (0.0)		1 (0.4)
 <b>Systemic hormonal preparations (excluded sex hormones and insulines) (H)</b>	 <b>5 (3.8)</b>	 <b>5 (6.7)</b>		 <b>10 (4.1)</b>
Corticosteroids for systemic use, plain (H02A)	3 (2.3)	2 (2.7)		5 (2.0)
<i>Prednisone (H02AB07)</i>	2 (1.5)	1 (1.3)		3 (1.2)
<i>Methylprednisolone (H02AB04)</i>	0 (0.0)	1 (1.3)		1 (0.4)
<i>Prednisolone (H02AB06)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Thyroid preparations (H03A)	2 (1.5)	3 (4.0)		5 (2.0)
<i>Levothyroxine sodium (H03AA01)</i>	2 (1.5)	3 (4.0)		5 (2.0)
 <b>Drugs</b>	 <b>7 (5.3)</b>	 <b>0 (0.0)</b>		 <b>7 (2.8)</b>
Cannabis	6 (4.5)	0 (0.0)		6 (2.4)
Ecstasy	2 (1.5)	0 (0.0)		2 (0.8)
Cocaine	1 (0.8)	0 (0.0)		1 (0.4)
LSA	1 (0.8)	0 (0.0)		1 (0.4)
Mushrooms	1 (0.8)	0 (0.0)		1 (0.4)
 <b>Antineoplastic and immunomodulating agents (L)</b>	 <b>1 (0.8)</b>	 <b>3 (4.0)</b>		 <b>4 (1.6)</b>
Antimetabolites (L01B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Methotrexate (L01BA01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Other antineoplastic agents (L01X)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Imatinib (L01XE01)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Immunostimulants (L03A)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Glatiramer acetate (L03AX13)</i>	0 (0.0)	1 (1.3)		1 (0.4)
Immunosuppressants (L04A)	0 (0.0)	1 (1.3)		1 (0.4)
<i>Tacrolimus (L04AD02)</i>	0 (0.0)	1 (1.3)		1 (0.4)
 <b>Homeopathy</b>	 <b>1 (0.8)</b>	 <b>1 (1.3)</b>		 <b>2 (0.8)</b>
Organic silicon	0 (0.0)	1 (1.3)		1 (0.4)
Sedatif PC	1 (0.8)	0 (0.0)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 75	Not exposed to drugs n = 39	Total n = 246
<b>Antiparasitic products, insecticides and repellents (P)</b>	<b>1 (0.8)</b>	<b>0 (0.0)</b>		<b>1 (0.4)</b>
Antitrematodals (P02B)	1 (0.8)	0 (0.0)		1 (0.4)
<b>Dermatologicals (D)</b>	<b>0 (0.0)</b>	<b>1 (1.3)</b>		<b>1 (0.4)</b>
Antifungals for systemic use (D01B)	0 (0.0)	1 (1.3)		1 (0.4)
Terbinafine (D01BA02)	0 (0.0)	1 (1.3)		1 (0.4)
<b>Various (V)</b>	<b>0 (0.0)</b>	<b>1 (1.3)</b>		<b>1 (0.4)</b>
All other therapeutic products (V03A)	0 (0.0)	1 (1.3)		1 (0.4)
Calcium folinate (V03AF03)	0 (0.0)	1 (1.3)		1 (0.4)
<b>Food supplement</b>	<b>0 (0.0)</b>	<b>1 (1.3)</b>		<b>1 (0.4)</b>
Fortimel	0 (0.0)	1 (1.3)		1 (0.4)
<b>No ATC code</b>	<b>0 (0.0)</b>	<b>1 (1.3)</b>		<b>1 (0.4)</b>

**SALT-II - Table 7b: Paracetamol exposure of ALFT cases according to drug exposure in the 15 days prior to index date for the years 2008 to 2013**

	Acute drug overdose n = 132	Exposed to drugs n = 75	Not exposed to drugs n = 39	Total n = 246
<b>At least one exposure at paracetamol in the 15 days prior to index date, n (%)</b>				
<b>Paracetamol, plain and combinations</b>	<b>130 (98.5)</b>	<b>35 (46.7)</b>	<b>0 (0.0)</b>	<b>165 (67.1)</b>
Paracetamol (N02BE01)	109 (82.6)	32 (42.7)	0 (0.0)	141 (57.3)
Paracetamol, combinations excl. psycholeptics (N02BE51)	22 (16.7)	4 (5.3)	0 (0.0)	26 (10.6)
Paracetamol, combinations with psycholeptics (N02BE71)	2 (1.5)	2 (2.7)	0 (0.0)	4 (1.6)
Codeine, combinations excl. psycholeptics (N02AA59)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Tramadol, combinations (N02AX52)	6 (4.5)	0 (0.0)	0 (0.0)	6 (2.4)
<b>At least one overdose, n (%)</b>	<b>126 (95.5)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>126 (51.2)</b>
<b>At least one intentional overdose, n (%)</b>	<b>69 (52.3)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>69 (28.0)</b>
<b>At least one non-intentional overdose, n (%)</b>	<b>57 (43.2)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>57 (23.2)</b>



SALT-II - Table 8: Drug exposure of ALFT cases according to drug exposure in the 7 days prior to index date for the years 2008 to 2013

	Acute drug overdose n = 132	Exposed to drugs n = 69	Not exposed to drugs n = 45	Total n = 246
<b>At least one exposure at the following ATC codes in the 7 days prior to index date, n (%)</b>	<b>132 (100.0)</b>	<b>69 (100.0)</b>	<b>0 (0.0)</b>	<b>201 (81.7)</b>
<b>Nervous system (N)</b>	<b>130 (98.5)</b>	<b>43 (62.3)</b>		<b>173 (70.3)</b>
Other analgesics and antipyretics (N02B)	126 (95.5)	32 (46.4)		158 (64.2)
<i>Paracetamol (N02BE01)</i>	108 (81.8)	28 (40.6)		136 (55.3)
<i>Paracetamol, combinations excl. psycholeptics (N02BE51)</i>	22 (16.7)	3 (4.3)		25 (10.2)
<i>Paracetamol, combinations with psycholeptics (N02BE71)</i>	2 (1.5)	2 (2.9)		4 (1.6)
<i>Acetylsalicylic acid (N02BA01)</i>	0 (0.0)	2 (2.9)		2 (0.8)
<i>Nefopam (N02BG06)</i>	0 (0.0)	2 (2.9)		2 (0.8)
Anxiolytics (N05B)	42 (31.8)	10 (14.5)		52 (21.1)
<i>Oxazepam (N05BA04)</i>	9 (6.8)	3 (4.3)		12 (4.9)
<i>Alprazolam (N05BA12)</i>	11 (8.3)	1 (1.4)		12 (4.9)
<i>Bromazepam (N05BA08)</i>	8 (6.1)	2 (2.9)		10 (4.1)
<i>Hydroxyzine (N05BB01)</i>	4 (3.0)	1 (1.4)		5 (2.0)
<i>Diazepam (N05BA01)</i>	2 (1.5)	1 (1.4)		3 (1.2)
<i>Przepam (N05BA11)</i>	3 (2.3)	0 (0.0)		3 (1.2)
<i>Etifoxine (N05BX03)</i>	3 (2.3)	0 (0.0)		3 (1.2)
<i>Lorazepam (N05BA06)</i>	1 (0.8)	1 (1.4)		2 (0.8)
<i>Clobazam (N05BA09)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Potassium clorazepate (N05BA05)</i>	1 (0.8)	1 (1.4)		2 (0.8)
<i>Meprobamate (N05BC01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Meprobamate, combinations (N05BC51)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Antidepressants (N06A)	29 (22.0)	12 (17.4)		41 (16.7)
<i>Escitalopram (N06AB10)</i>	8 (6.1)	1 (1.4)		9 (3.7)
<i>Venlafaxine (N06AX16)</i>	2 (1.5)	4 (5.8)		6 (2.4)
<i>Amitriptyline (N06AA09)</i>	3 (2.3)	1 (1.4)		4 (1.6)
<i>Paroxetine (N06AB05)</i>	4 (3.0)	0 (0.0)		4 (1.6)
<i>Fluoxetine (N06AB03)</i>	3 (2.3)	0 (0.0)		3 (1.2)
<i>Mianserin (N06AX03)</i>	1 (0.8)	2 (2.9)		3 (1.2)
<i>Citalopram (N06AB04)</i>	1 (0.8)	1 (1.4)		2 (0.8)
<i>Sertraline (N06AB06)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Iproniazide (N06AF05)</i>	0 (0.0)	2 (2.9)		2 (0.8)
<i>Clomipramine (N06AA04)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Trimipramine (N06AA06)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Moclobemide (N06AG02)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Tianeptine (N06AX14)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Duloxetine (N06AX21)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Agomelatine (N06AX22)</i>	1 (0.8)	0 (0.0)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 69	Not exposed to drugs n = 45	Total n = 246
Hypnotics and sedatives (N05C)	20 (15.2)	3 (4.3)		23 (9.3)
<i>Zolpidem (N05CF02)</i>	10 (7.6)	1 (1.4)		11 (4.5)
<i>Zopiclone (N05CF01)</i>	6 (4.5)	1 (1.4)		7 (2.8)
<i>Lormetazepam (N05CD06)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antiepileptics (N03A)	14 (10.6)	7 (10.1)		21 (8.5)
<i>Valproic acid (N03AG01)</i>	4 (3.0)	3 (4.3)		7 (2.8)
<i>Clonazepam (N03AE01)</i>	4 (3.0)	1 (1.4)		5 (2.0)
<i>Carbamazepine (N03AF01)</i>	3 (2.3)	2 (2.9)		5 (2.0)
<i>Levetiracetam (N03AX14)</i>	3 (2.3)	2 (2.9)		5 (2.0)
<i>Lamotrigine (N03AX09)</i>	1 (0.8)	2 (2.9)		3 (1.2)
<i>Topiramate (N03AX11)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Gabapentin (N03AX12)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Pregabalin (N03AX16)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Opioids (N02A)	11 (8.3)	3 (4.3)		14 (5.7)
<i>Tramadol, combinations (N02AX52)</i>	6 (4.5)	0 (0.0)		6 (2.4)
<i>Tramadol (N02AX02)</i>	3 (2.3)	1 (1.4)		4 (1.6)
<i>Morphine (N02AA01)</i>	1 (0.8)	1 (1.4)		2 (0.8)
<i>Dihydrocodeine (N02AA08)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Fentanyl (N02AB03)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Antipsychotics (N05A)	7 (5.3)	2 (2.9)		9 (3.7)
<i>Risperidone (N05AX08)</i>	3 (2.3)	1 (1.4)		4 (1.6)
<i>Cyamemazine (N05AA06)</i>	1 (0.8)	1 (1.4)		2 (0.8)
<i>Tiapride (N05AL03)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Levomepromazine (N05AA02)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Periciazine (N05AC01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Olanzapine (N05AH03)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Drugs used in addictive disorders (N07B)	3 (2.3)	2 (2.9)		5 (2.0)
<i>Disulfiram (N07BB01)</i>	1 (0.8)	2 (2.9)		3 (1.2)
<i>Buprenorphine (N07BC01)</i>	2 (1.5)	0 (0.0)		2 (0.8)
Antimigraine preparations (N02C)	1 (0.8)	2 (2.9)		3 (1.2)
<i>Dihydroergotamine (N02CA01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Zolmitriptan (N02CC03)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Pizotifen (N02CX01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Anesthetics, general (N01A)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Desflurane (N01AB07)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Thiopental (N01AF03)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Sufentanil (N01AH03)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Ketamine (N01AX03)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Anticholinergic agents (N04A)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Tropatepine (N04AA12)</i>	0 (0.0)	1 (1.4)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 69	Not exposed to drugs n = 45	Total n = 246
Psychostimulants, agents used for adhd and nootropics (N06B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Amphetamine (N06BA01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antivertigo preparations (N07C)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Acetylleucine (N07CA04)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<b>Antiinfectives for systemic use (J)</b>	<b>4 (3.0)</b>	<b>28 (40.6)</b>		<b>32 (13.0)</b>
Drugs for treatment of tuberculosis (J04A)	0 (0.0)	14 (20.3)		14 (5.7)
<i>Rifampicin, pyrazinamide, ethambutol and isoniazid (J04AM06)</i>	0 (0.0)	7 (10.1)		7 (2.8)
<i>Rifampicin and isoniazid (J04AM02)</i>	0 (0.0)	5 (7.2)		5 (2.0)
<i>Rifampicin, pyrazinamide and isoniazid (J04AM05)</i>	0 (0.0)	2 (2.9)		2 (0.8)
<i>Rifabutin (J04AB04)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Isoniazid (J04AC01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Pyrazinamide (J04AK01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Ethambutol (J04AK02)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Direct acting antivirals (J05A)	1 (0.8)	12 (17.4)		13 (5.3)
<i>Tenofovir disoproxil and emtricitabine (J05AR03)</i>	0 (0.0)	3 (4.3)		3 (1.2)
<i>Emtricitabine, tenofovir disoproxil and efavirenz (J05AR06)</i>	0 (0.0)	3 (4.3)		3 (1.2)
<i>Valaciclovir (J05AB11)</i>	1 (0.8)	1 (1.4)		2 (0.8)
<i>Ritonavir (J05AE03)</i>	0 (0.0)	2 (2.9)		2 (0.8)
<i>Tenofovir disoproxil (J05AF07)</i>	0 (0.0)	2 (2.9)		2 (0.8)
<i>Efavirenz (J05AG03)</i>	0 (0.0)	2 (2.9)		2 (0.8)
<i>Aciclovir (J05AB01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Ribavirin (J05AB04)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Valganciclovir (J05AB14)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Atazanavir (J05AE08)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Emtricitabine (J05AF09)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Nucleoside and nucleotide reverse transcriptase inhibitors, combinations (J05AF30)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Nevirapine (J05AG01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Raltegravir (J05AX08)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Beta-lactam antibacterials, penicillins (J01C)	3 (2.3)	3 (4.3)		6 (2.4)
<i>Amoxicillin (J01CA04)</i>	1 (0.8)	2 (2.9)		3 (1.2)
<i>Amoxicillin and enzyme inhibitor (J01CR02)</i>	1 (0.8)	1 (1.4)		2 (0.8)
<i>Cloxacillin (J01CF02)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antimycotics for systemic use (J02A)	0 (0.0)	2 (2.9)		2 (0.8)
<i>Fluconazole (J02AC01)</i>	0 (0.0)	2 (2.9)		2 (0.8)
Other beta-lactam antibacterials (J01D)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Cefpodoxime (J01DD13)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Sulfonamides and trimethoprim (J01E)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Sulfamethoxazole and trimethoprim (J01EE01)</i>	0 (0.0)	1 (1.4)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 69	Not exposed to drugs n = 45	Total n = 246
Macrolides, lincosamides and streptogramins (J01F)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Telithromycin (J01FA15)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Quinolone antibacterials (J01M)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Ofloxacin (J01MA01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Other antibacterials (J01X)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Nitrofurantoin (J01XE01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<b>Alimentary tract and metabolism (A)</b>	<b>15 (11.4)</b>	<b>15 (21.7)</b>		<b>30 (12.2)</b>
Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) (A02B)	6 (4.5)	1 (1.4)		7 (2.8)
<i>Lansoprazole (A02BC03)</i>	3 (2.3)	1 (1.4)		4 (1.6)
<i>Omeprazole (A02BC01)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Esomeprazole (A02BC05)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Blood glucose lowering drugs, excl. insulins (A10B)	2 (1.5)	4 (5.8)		6 (2.4)
<i>Metformin (A10BA02)</i>	1 (0.8)	4 (5.8)		5 (2.0)
<i>Glibenclamide (A10BB01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Metformin and sitagliptin (A10BD07)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Sitagliptin (A10BH01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Drugs for functional bowel disorders (A03A)	3 (2.3)	2 (2.9)		5 (2.0)
<i>Phloroglucinol (A03AX12)</i>	3 (2.3)	1 (1.4)		4 (1.6)
<i>Trimebutine (A03AA05)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Alverine, combinations (A03AX58)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Propulsives (A03F)	2 (1.5)	2 (2.9)		4 (1.6)
<i>Metoclopramide (A03FA01)</i>	1 (0.8)	2 (2.9)		3 (1.2)
<i>Domperidone (A03FA03)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antipropulsives (A07D)	4 (3.0)	0 (0.0)		4 (1.6)
<i>Loperamide (A07DA03)</i>	4 (3.0)	0 (0.0)		4 (1.6)
Antiemetics and antinauseants (A04A)	2 (1.5)	1 (1.4)		3 (1.2)
<i>Metopimazine (A04AD05)</i>	2 (1.5)	0 (0.0)		2 (0.8)
Insulins and analogues (A10A)	1 (0.8)	2 (2.9)		3 (1.2)
<i>Insulin (human) (A10AB01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Insulin glargine (A10AE04)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antacids (A02A)	0 (0.0)	2 (2.9)		2 (0.8)
<i>Aluminium hydroxide (A02AB01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Other drugs for acid related disorders (A02X)	1 (0.8)	0 (0.0)		1 (0.4)
Bile therapy (A05A)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Ursodeoxycholic acid (A05AA02)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Laxatives (A06A)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Liquid paraffin (A06AA01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Multivitamins, combinations (A11A)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Multivitamins and other minerals, incl. combinations (A11AA03)</i>	0 (0.0)	1 (1.4)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 69	Not exposed to drugs n = 45	Total n = 246
Vitamin a and d, incl. combinations of the two (A11C)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Calcifediol (A11CC06)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<b>Musculo-skeletal system (M)</b>	<b>19 (14.4)</b>	<b>10 (14.5)</b>		<b>29 (11.8)</b>
Antiinflammatory and antirheumatic products, non-steroids (M01A)	16 (12.1)	5 (7.2)		21 (8.5)
<i>Ibuprofen (M01AE01)</i>	6 (4.5)	2 (2.9)		8 (3.3)
<i>Diclofenac (M01AB05)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Ketoprofen (M01AE03)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Diclofenac, combinations (M01AB55)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Piroxicam (M01AC01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Naproxen (M01AE02)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Nimesulide (M01AX17)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Muscle relaxants, centrally acting agents (M03B)	4 (3.0)	1 (1.4)		5 (2.0)
<i>Tetrazepam (M03BX07)</i>	3 (2.3)	0 (0.0)		3 (1.2)
<i>Baclofen (M03BX01)</i>	1 (0.8)	1 (1.4)		2 (0.8)
Antigout preparations (M04A)	1 (0.8)	1 (1.4)		2 (0.8)
<i>Allopurinol (M04AA01)</i>	1 (0.8)	1 (1.4)		2 (0.8)
Muscle relaxants, peripherally acting agents (M03A)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Rocuronium bromide (M03AC09)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Muscle relaxants, directly acting agents (M03C)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Dantrolene (M03CA01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Other drugs for disorders of the musculo-skeletal system (M09A)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Chondrocytes, autologous (M09AX02)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<b>Cardiovascular system (C)</b>	<b>11 (8.3)</b>	<b>16 (23.2)</b>		<b>27 (11.0)</b>
Lipid modifying agents, plain (C10A)	3 (2.3)	7 (10.1)		10 (4.1)
<i>Atorvastatin (C10AA05)</i>	2 (1.5)	3 (4.3)		5 (2.0)
<i>Simvastatin (C10AA01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Pravastatin (C10AA03)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Fenofibrate (C10AB05)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Colestyramine (C10AC01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Selective calcium channel blockers with mainly vascular effects (C08C)	2 (1.5)	4 (5.8)		6 (2.4)
<i>Amlodipine (C08CA01)</i>	1 (0.8)	2 (2.9)		3 (1.2)
<i>Lercanidipine (C08CA13)</i>	1 (0.8)	2 (2.9)		3 (1.2)
Angiotensin ii antagonists, plain (C09C)	3 (2.3)	3 (4.3)		6 (2.4)
<i>Losartan (C09CA01)</i>	0 (0.0)	2 (2.9)		2 (0.8)
<i>Irbesartan (C09CA04)</i>	2 (1.5)	0 (0.0)		2 (0.8)
<i>Valsartan (C09CA03)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Candesartan (C09CA06)</i>	1 (0.8)	0 (0.0)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 69	Not exposed to drugs n = 45	Total n = 246
Beta blocking agents (C07A)	1 (0.8)	4 (5.8)		5 (2.0)
<i>Atenolol (C07AB03)</i>	0 (0.0)	3 (4.3)		3 (1.2)
<i>Propranolol (C07AA05)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Nebivolol (C07AB12)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Ace inhibitors, plain (C09A)	1 (0.8)	2 (2.9)		3 (1.2)
<i>Perindopril (C09AA04)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Ramipril (C09AA05)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Ace inhibitors, combinations (C09B)	1 (0.8)	2 (2.9)		3 (1.2)
<i>Perindopril and diuretics (C09BA04)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Ramipril and diuretics (C09BA05)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Trandolapril and verapamil (C09BB10)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antiadrenergic agents, centrally acting (C02A)	1 (0.8)	1 (1.4)		2 (0.8)
<i>Moxonidine (C02AC05)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Rilmenidine (C02AC06)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Angiotensin ii antagonists, combinations (C09D)	2 (1.5)	0 (0.0)		2 (0.8)
<i>Olmesartan medoxomil and diuretics (C09DA08)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Olmesartan medoxomil and amlodipine (C09DB02)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Vasodilators used in cardiac diseases (C01D)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Heptaminol (C01DX08)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Antiarrhythmics, class i and iii (C01B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Amiodarone (C01BD01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Low-ceiling diuretics, excl. thiazides (C03B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Indapamide (C03BA11)</i>	1 (0.8)	0 (0.0)		1 (0.4)
High-ceiling diuretics (C03C)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Furosemide (C03CA01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Potassium-sparing agents (C03D)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Spironolactone (C03DA01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Peripheral vasodilators (C04A)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Naftidrofuryl (C04AX21)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<b>Respiratory system (R)</b>	<b>12 (9.1)</b>	<b>5 (7.2)</b>		<b>17 (6.9)</b>
Antihistamines for systemic use (R06A)	6 (4.5)	1 (1.4)		7 (2.8)
<i>Alimemazine (R06AD01)</i>	5 (3.8)	0 (0.0)		5 (2.0)
<i>Dexchlorpheniramine (R06AB02)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Adrenergics, inhalants (R03A)	4 (3.0)	2 (2.9)		6 (2.4)
<i>Salbutamol (R03AC02)</i>	3 (2.3)	1 (1.4)		4 (1.6)
<i>Formoterol and budesonide (R03AK07)</i>	0 (0.0)	2 (2.9)		2 (0.8)
<i>Terbutaline (R03AC03)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Salmeterol and fluticasone (R03AK06)</i>	1 (0.8)	0 (0.0)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 69	Not exposed to drugs n = 45	Total n = 246
Other drugs for obstructive airway diseases, inhalants (R03B)	1 (0.8)	1 (1.4)		2 (0.8)
<i>Budesonide (R03BA02)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Ipratropium bromide (R03BB01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<i>Tiotropium bromide (R03BB04)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Other systemic drugs for obstructive airway diseases (R03D)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Fenspiride (R03DX03)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Cough suppressants, excl. combinations with expectorants (R05D)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Combinations (R05DA20)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Other cold combination preparations (R05X)	0 (0.0)	1 (1.4)		1 (0.4)
<b>Blood and blood forming organs (B)</b>	<b>3 (2.3)</b>	<b>8 (11.6)</b>		<b>11 (4.5)</b>
Antithrombotic agents (B01A)	2 (1.5)	8 (11.6)		10 (4.1)
<i>Acetylsalicylic acid (B01AC06)</i>	1 (0.8)	5 (7.2)		6 (2.4)
<i>Clopidogrel (B01AC04)</i>	1 (0.8)	3 (4.3)		4 (1.6)
<i>Fluindione (B01AA12)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<i>Nadroparin (B01AB06)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Iron preparations (B03A)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Ferrous sulfate (B03AA07)</i>	1 (0.8)	0 (0.0)		1 (0.4)
<b>Genito urinary system and sex hormones (G)</b>	<b>5 (3.8)</b>	<b>6 (8.7)</b>		<b>11 (4.5)</b>
Hormonal contraceptives for systemic use (G03A)	3 (2.3)	2 (2.9)		5 (2.0)
<i>Gestodene and estrogen (G03AA10)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Progestogens (G03D)	1 (0.8)	2 (2.9)		3 (1.2)
<i>Nomegestrol (G03DB04)</i>	1 (0.8)	1 (1.4)		2 (0.8)
<i>Progesterone (G03DA04)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Other urologicals, incl. antispasmodics (G04B)	1 (0.8)	1 (1.4)		2 (0.8)
<i>Solifenacin (G04BD08)</i>	1 (0.8)	1 (1.4)		2 (0.8)
Estrogens (G03C)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Estradiol (G03CA03)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Drugs used in benign prostatic hypertrophy (G04C)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Alfuzosin (G04CA01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<b>Systemic hormonal preparations (excluded sex hormones and insulines) (H)</b>	<b>5 (3.8)</b>	<b>4 (5.8)</b>		<b>9 (3.7)</b>
Thyroid preparations (H03A)	2 (1.5)	3 (4.3)		5 (2.0)
<i>Levothyroxine sodium (H03AA01)</i>	2 (1.5)	3 (4.3)		5 (2.0)
Corticosteroids for systemic use, plain (H02A)	3 (2.3)	1 (1.4)		4 (1.6)
<i>Prednisone (H02AB07)</i>	2 (1.5)	1 (1.4)		3 (1.2)
<i>Prednisolone (H02AB06)</i>	1 (0.8)	0 (0.0)		1 (0.4)

	Acute drug overdose n = 132	Exposed to drugs n = 69	Not exposed to drugs n = 45	Total n = 246
<b>Drugs</b>	<b>7 (5.3)</b>	<b>0 (0.0)</b>		<b>7 (2.8)</b>
Cannabis	6 (4.5)	0 (0.0)		6 (2.4)
Ecstasy	2 (1.5)	0 (0.0)		2 (0.8)
Cocaine	1 (0.8)	0 (0.0)		1 (0.4)
LSA	1 (0.8)	0 (0.0)		1 (0.4)
Mushrooms	1 (0.8)	0 (0.0)		1 (0.4)
<b>Antineoplastic and immunomodulating agents (L)</b>	<b>1 (0.8)</b>	<b>3 (4.3)</b>		<b>4 (1.6)</b>
Antimetabolites (L01B)	1 (0.8)	0 (0.0)		1 (0.4)
<i>Methotrexate (L01BA01)</i>	1 (0.8)	0 (0.0)		1 (0.4)
Other antineoplastic agents (L01X)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Imatinib (L01XE01)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Immunostimulants (L03A)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Glatiramer acetate (L03AX13)</i>	0 (0.0)	1 (1.4)		1 (0.4)
Immunosuppressants (L04A)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Tacrolimus (L04AD02)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<b>Homeopathy</b>	<b>1 (0.8)</b>	<b>1 (1.4)</b>		<b>2 (0.8)</b>
Organic silicon	0 (0.0)	1 (1.4)		1 (0.4)
Sedatif PC	1 (0.8)	0 (0.0)		1 (0.4)
<b>Antiparasitic products, insecticides and repellents (P)</b>	<b>1 (0.8)</b>	<b>0 (0.0)</b>		<b>1 (0.4)</b>
Antitrepatodals (P02B)	1 (0.8)	0 (0.0)		1 (0.4)
<b>Various (V)</b>	<b>0 (0.0)</b>	<b>1 (1.4)</b>		<b>1 (0.4)</b>
All other therapeutic products (V03A)	0 (0.0)	1 (1.4)		1 (0.4)
<i>Calcium folinate (V03AF03)</i>	0 (0.0)	1 (1.4)		1 (0.4)
<b>Food supplement</b>	<b>0 (0.0)</b>	<b>1 (1.4)</b>		<b>1 (0.4)</b>
Fortimel	0 (0.0)	1 (1.4)		1 (0.4)
<b>No ATC code</b>	<b>0 (0.0)</b>	<b>1 (1.4)</b>		<b>1 (0.4)</b>



**SALT-II - Table 8b: Paracetamol exposure of ALFT cases according to drug exposure in the 7 days prior to index date for the years 2008 to 2013**

	Acute drug overdose n = 132	Exposed to drugs n = 69	Not exposed to drugs n = 45	Total n = 246
<b>At least one exposure at paracetamol in the 7 days prior to index date, n (%)</b>				
<b>Paracetamol, plain and combinations</b>	<b>129 (97.7)</b>	<b>31 (44.9)</b>	<b>0 (0.0)</b>	<b>160 (65.0)</b>
Paracetamol (N02BE01)	108 (81.8)	28 (40.6)	0 (0.0)	136 (55.3)
Paracetamol, combinations excl. psycholeptics (N02BE51)	22 (16.7)	3 (4.3)	0 (0.0)	25 (10.2)
Paracetamol, combinations with psycholeptics (N02BE71)	2 (1.5)	2 (2.9)	0 (0.0)	4 (1.6)
Codeine, combinations excl. psycholeptics (N02AA59)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Tramadol, combinations (N02AX52)	6 (4.5)	0 (0.0)	0 (0.0)	6 (2.4)
<b>At least one overdose, n (%)</b>	<b>126 (95.5)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>126 (51.2)</b>
<b>At least one intentional overdose, n (%)</b>	<b>69 (52.3)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>69 (28.0)</b>
<b>At least one non-intentional overdose, n (%)</b>	<b>57 (43.2)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>57 (23.2)</b>

Table 9: Drug exposure of ALFT cases according to time window for the years 2008 to 2013

Drug	n cases exposed to drugs in the 90 days prior to index date	n cases exposed to drugs in the 30 days prior to index date	n cases exposed to drugs in the 15 days prior to index date	n cases exposed to drugs in the 7 days prior to index date
<b>Paracetamol *</b>	39	35	35	31
<b>Paracetamol *</b> (with non-intentional overdoses)	96	92	92	88
<b>Paracetamol *</b> (with intentional or non-intentional overdoses)	165	161	161	157
<b>Treatment for tuberculosis (J04A)</b>	16	16	16	14
<b>Antidepressants (N06A)</b>	13	13	12	12
<b>Anxiolytics (N05B)</b>	13	11	10	10
<b>Direct acting antivirals (J05A)</b>	12	12	12	12
<b>Antiepileptics (N03A)</b>	12	11	9	7
<b>Antithrombotic agents (B01A)</b>	10	8	8	8
<b>Lipid modifying agents, plain (C10A)</b>	8	8	8	7
<b>NSAID (M01A)</b>	8	8	6	5
<b>Beta-lactam antibacterials, penicillins (J01C)</b>	7	7	5	3
<b>Beta blocking agents (C07A)</b>	6	5	4	4
<b>Acetylsalicylic acid (B01AC06)</b>	6	5	5	5
<b>Acetylsalicylic acid (N02BA01)</b>	5	5	3	2
<b>Selective calcium channel blockers (C08C)</b>	5	5	5	4
<b>Antacids (A02A)</b>	5	4	2	2

<b>Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)</b>	5	3	1	1
<b>Antihistamines (R06A)</b>	5	2	2	1

---

\* Plain and combinations (N02BE01 + N02BE51 + N02BE71 + N02AA59 + N02AX52)

**SALT-II - Table 10: Selection of the reference population in the EGB for the years 2008 to 2013**

	2008 n = 491 925 *		2009 n = 500 559 *		2010 n = 515 611 *		2011 n = 514 877 *		2012 n = 521 210 *		2013 n = 527 073 *		Total n = 587 723 *	
<b>Gender, n (%)</b>														
Male	237866	(48.4)	241979	(48.3)	249238	(48.3)	248286	(48.2)	251252	(48.2)	254092	(48.2)	285998	(48.7)
Female	254059	(51.6)	258580	(51.7)	266373	(51.7)	266591	(51.8)	269958	(51.8)	272981	(51.8)	301725	(51.3)
<b>Age at the 1st January of the considered year (in years)</b>														
Size (missing)	491925	(0)	500559	(0)	515611	(0)	514877	(0)	521210	(0)	527073	(0)	587723	(0)
Mean (± SD)	39.3	(23.1)	39.4	(23.2)	39.3	(23.3)	39.6	(23.4)	39.7	(23.5)	39.9	(23.6)	36.1	(23.7)
Median	39.0		39.0		39.0		39.0		39.0		39.0		35.0	
[p25% - p75%]	[20.0;56.0]		[20.0;57.0]		[20.0;57.0]		[20.0;57.0]		[20.0;57.0]		[21.0;58.0]		[16.0;54.0]	
[Min - Max]	[0.0;111.0]		[0.0;112.0]		[0.0;111.0]		[0.0;112.0]		[0.0;113.0]		[0.0;112.0]		[0.0;111.0]	
<b>Patients with age &lt; 18 years at the 1st January of the considered year, n (%)</b>	<b>108486</b>	<b>(22.1)</b>	<b>110691</b>	<b>(22.1)</b>	<b>113670</b>	<b>(22.0)</b>	<b>113589</b>	<b>(22.1)</b>	<b>114678</b>	<b>(22.0)</b>	<b>115941</b>	<b>(22.0)</b>	<b>124582</b>	<b>(21.2)</b>
<b>Patients with age &gt; 70 years at the 1st January of the considered year, n (%)</b>	<b>54570</b>	<b>(11.1)</b>	<b>55733</b>	<b>(11.1)</b>	<b>56893</b>	<b>(11.0)</b>	<b>57597</b>	<b>(11.2)</b>	<b>58415</b>	<b>(11.2)</b>	<b>59609</b>	<b>(11.3)</b>	<b>55901</b>	<b>(9.5)</b>
<b>Patients with active cancer in the considered year, n (%)</b>	<b>17288</b>	<b>(3.5)</b>	<b>18196</b>	<b>(3.6)</b>	<b>19107</b>	<b>(3.7)</b>	<b>19742</b>	<b>(3.8)</b>	<b>19678</b>	<b>(3.8)</b>	<b>19501</b>	<b>(3.7)</b>	<b>13942</b>	<b>(2.4)</b>
Patients with at least one ALD cancer in the considered year	14765	(3.0)	15526	(3.1)	16451	(3.2)	17109	(3.3)	17004	(3.3)	16968	(3.2)	12854	(2.2)
Patients with at least one hospitalisation for cancer in the considered year	5400	(1.1)	5888	(1.2)	5953	(1.2)	6248	(1.2)	6211	(1.2)	6232	(1.2)	2264	(0.4)
Patients with at least 3 dispensations of anti-androgens drug in the considered year	1462	(0.3)	1424	(0.3)	1417	(0.3)	1312	(0.3)	1296	(0.2)	1210	(0.2)	510	(0.1)
<b>Patients with age ≥ 18 years and without active cancer (reference population), n (%)</b>	<b>366190</b>	<b>(74.4)</b>	<b>371707</b>	<b>(74.3)</b>	<b>382851</b>	<b>(74.3)</b>	<b>381556</b>	<b>(74.1)</b>	<b>386854</b>	<b>(74.2)</b>	<b>391631</b>	<b>(74.3)</b>	<b>449172</b>	<b>(76.4)</b>
<b>Patients with age ≥ 18 years and without active cancer (extrapolation), n</b>	<b>48 082 718</b>		<b>48 603 894</b>		<b>48 558 426</b>		<b>48 735 903</b>		<b>48 816 573</b>		<b>49 164 821</b>		<b>57 717 234</b>	

\* affiliate to CNAM-TS (general regimen)

SALT-II - Table 11: Dispensation and number of DDD of the extrapolated population for the years 2008 to 2013

	2008 n = 48 082 718	2009 n = 48 603 894	2010 n = 48 558 426	2011 n = 48 735 903	2012 n = 48 816 573	2013 n = 49 164 821	Total n = 57 717 234
<b>At least one dispensation of paracetamol *, n (%)</b>	<b>23717765 (49.3)</b>	<b>26224510 (54.0)</b>	<b>25880261 (53.3)</b>	<b>27366224 (56.2)</b>	<b>27456369 (56.2)</b>	<b>27613625 (56.2)</b>	<b>47051322 (81.5)</b>
<b>Number of DDD per patient of paracetamol **</b>							
Size (missing)	23717765 (0)	26224510 (0)	25880261 (0)	27366224 (0)	27456369 (0)	27613625 (0)	47051322 (0)
Mean (± SD)	31.0 (724.0)	32.5 (664.7)	35.5 (707.0)	38.3 (772.8)	39.7 (772.6)	41.1 (785.4)	123.2 (2941.1)
Median	10.7	12.0	13.3	13.3	14.0	16.0	38.0
[p25% - p75%]	[5.3;26.7]	[5.3;29.3]	[5.3;32.0]	[6.0;35.3]	[6.7;37.3]	[8.0;40.0]	[16.0;102.7]
[Min - Max]	[0.3;11266.0]	[0.3;2378.7]	[0.3;2548.0]	[0.3;7012.0]	[0.3;4033.0]	[0.3;4236.0]	[0.3;19217.0]
<b>Total number of DDD of paracetamol, n **</b>	<b>735037737</b>	<b>853113264</b>	<b>919907464</b>	<b>1048959478</b>	<b>1088961011</b>	<b>1136275494</b>	<b>5782254449</b>
<b>Patient-years exposed to paracetamol, n **</b>	<b>23650441</b>	<b>26083343</b>	<b>25734171</b>	<b>27215721</b>	<b>27370271</b>	<b>27450419</b>	<b>157504366</b>
<b>At least one dispensation of NSAID (M01A), n (%)</b>	<b>18355540 (38.2)</b>	<b>19102701 (39.3)</b>	<b>18706910 (38.5)</b>	<b>18796822 (38.6)</b>	<b>18681882 (38.3)</b>	<b>18337581 (37.3)</b>	<b>40744642 (70.6)</b>
<b>Number of DDD per patient of NSAID (M01A) **</b>							
Size (missing)	18355540 (0)	19102701 (0)	18706910 (0)	18796822 (0)	18681882 (0)	18337581 (0)	40744642 (0)
Mean (± SD)	44.8 (849.3)	44.8 (854.4)	45.1 (826.0)	42.8 (788.8)	43.5 (800.3)	43.0 (790.4)	120.9 (2893.4)
Median	20.0	20.0	20.0	20.0	20.0	20.0	48.3
[p25% - p75%]	[11.7;42.5]	[11.7;42.5]	[13.3;43.3]	[12.5;41.7]	[13.3;42.0]	[13.3;40.9]	[20.0;111.3]
[Min - Max]	[2.5;1755.0]	[2.5;2140.0]	[2.5;2625.8]	[2.5;1316.7]	[2.5;1441.5]	[2.5;1433.0]	[2.5;7430.7]
<b>Total number of DDD of NSAID (M01A), n **</b>	<b>822166724</b>	<b>856085661</b>	<b>842992267</b>	<b>803653948</b>	<b>813230764</b>	<b>789188927</b>	<b>4927318292</b>
<b>Patient-years exposed to NSAID (M01A), n **</b>	<b>18331725</b>	<b>19026661</b>	<b>18630989</b>	<b>18722561</b>	<b>18658340</b>	<b>18264117</b>	<b>111634392</b>
<b>At least one dispensation of beta-lactam antibacterials (J01C), n (%)</b>	<b>9892263 (20.6)</b>	<b>10652911 (21.9)</b>	<b>10559064 (21.7)</b>	<b>10854666 (22.3)</b>	<b>11197093 (22.9)</b>	<b>11494922 (23.4)</b>	<b>32674690 (56.6)</b>
<b>Number of DDD per patient of beta-lactam antibacterials (J01C) **</b>							
Size (missing)	9892263 (0)	10652911 (0)	10559064 (0)	10854666 (0)	11197093 (0)	11494922 (0)	32674690 (0)
Mean (± SD)	24.4 (245.0)	24.9 (249.2)	25.4 (257.3)	26.0 (261.8)	26.7 (264.0)	27.1 (277.7)	51.1 (698.1)
Median	18.0	18.0	18.0	18.0	20.0	22.5	36.0
[p25% - p75%]	[12.0;27.0]	[12.0;28.0]	[12.0;28.0]	[13.5;28.0]	[13.5;30.0]	[13.5;30.0]	[18.0;63.0]
[Min - Max]	[1.5;924.0]	[1.5;910.0]	[1.5;1662.5]	[1.5;1208.0]	[1.5;1078.0]	[1.5;1770.0]	[1.5;4750.0]
<b>Total number of DDD of beta-lactam antibacterials (J01C), n **</b>	<b>241607779</b>	<b>265328708</b>	<b>267805536</b>	<b>282444202</b>	<b>298589662</b>	<b>311960724</b>	<b>1667736610</b>
<b>Patient-years exposed to beta-lactam antibacterials (J01C), n **</b>	<b>9862687</b>	<b>10595432</b>	<b>10500488</b>	<b>10797976</b>	<b>11164079</b>	<b>11430077</b>	<b>64350739</b>

	2008 n = 48 082 718	2009 n = 48 603 894	2010 n = 48 558 426	2011 n = 48 735 903	2012 n = 48 816 573	2013 n = 49 164 821	Total n = 57 717 234
<b>At least one dispensation of drugs for peptic ulcer and gastro-oesophageal reflux disease (A02B), n (%)</b>	<b>11421184 (23.8)</b>	<b>12020141 (24.7)</b>	<b>12420558 (25.6)</b>	<b>12688628 (26.0)</b>	<b>13084552 (26.8)</b>	<b>13379714 (27.2)</b>	<b>29403303 (50.9)</b>
<b>Number of DDD per patient of GORD (A02B) **</b>							
Size (missing)	11421184 (0)	12020141 (0)	12420558 (0)	12688628 (0)	13084552 (0)	13379714 (0)	29403303 (0)
Mean (± SD)	89.4 (1379.0)	91.9 (1398.0)	95.9 (1424.1)	98.3 (1456.4)	100.2 (1469.9)	103.2 (1492.1)	247.1 (5581.2)
Median	29.0	32.7	35.0	35.5	37.3	37.3	49.0
[p25% - p75%]	[14.0;126.0]	[14.0;130.7]	[14.0;140.0]	[14.0;145.2]	[14.0;149.3]	[14.0;154.0]	[16.4;185.9]
[Min - Max]	[0.0;1484.0]	[0.0;1415.3]	[0.0;1456.0]	[0.0;1456.0]	[0.0;1549.3]	[0.0;1493.3]	[0.0;8362.7]
<b>Total number of DDD of GORD (A02B), n **</b>	<b>1021531043</b>	<b>1104737049</b>	<b>1190787053</b>	<b>1246662151</b>	<b>1311141604</b>	<b>1381275522</b>	<b>7256134423</b>
<b>Patient-years exposed to GORD (A02B), n **</b>	<b>11371564</b>	<b>11940811</b>	<b>12334114</b>	<b>12604076</b>	<b>13027333</b>	<b>13285690</b>	<b>74563589</b>
<b>At least one dispensation of antihistamines (R06A), n (%)</b>	<b>9195409 (19.1)</b>	<b>9906359 (20.4)</b>	<b>9480124 (19.5)</b>	<b>9486864 (19.5)</b>	<b>9319703 (19.1)</b>	<b>9278704 (18.9)</b>	<b>26567815 (46.0)</b>
<b>Number of DDD per patient of antihistamines (R06A) **</b>							
Size (missing)	9195409 (0)	9906359 (0)	9480124 (0)	9486864 (0)	9319703 (0)	9278704 (0)	26567815 (0)
Mean (± SD)	66.1 (1323.8)	66.4 (1297.7)	71.1 (1317.3)	73.5 (1346.6)	75.4 (1357.2)	75.4 (1326.0)	152.2 (4387.1)
Median	30.0	30.0	30.0	30.0	30.0	30.0	32.5
[p25% - p75%]	[14.0;60.0]	[14.0;60.0]	[15.0;64.6]	[15.0;75.0]	[15.0;80.0]	[15.0;76.7]	[15.0;106.2]
[Min - Max]	[1.3;4850.0]	[1.3;4115.0]	[1.3;4780.0]	[1.3;5000.0]	[1.7;3700.0]	[1.7;2850.0]	[1.3;18695.0]
<b>Total number of DDD of antihistamines (R06A), n **</b>	<b>608207964</b>	<b>658003826</b>	<b>674131264</b>	<b>696837127</b>	<b>702837403</b>	<b>699799306</b>	<b>4039816891</b>
<b>Patient-years exposed to antihistamines (R06A), n **</b>	<b>9175316</b>	<b>9862222</b>	<b>9435088</b>	<b>9443194</b>	<b>9299872</b>	<b>9236053</b>	<b>56451747</b>
<b>At least one dispensation of anxiolytics (N05B), n (%)</b>	<b>8336362 (17.3)</b>	<b>8435213 (17.4)</b>	<b>8447359 (17.4)</b>	<b>8316317 (17.1)</b>	<b>8001507 (16.4)</b>	<b>7953134 (16.2)</b>	<b>20331487 (35.2)</b>
<b>Number of DDD per patient of anxiolytics (N05B) **</b>							
Size (missing)	8336362 (0)	8435213 (0)	8447359 (0)	8316317 (0)	8001507 (0)	7953134 (0)	20331487 (0)
Mean (± SD)	121.6 (2479.0)	122.5 (2521.5)	123.4 (2508.9)	122.8 (2500.7)	121.6 (2486.5)	121.7 (2544.3)	297.7 (9099.6)
Median	42.0	43.5	44.7	40.5	40.0	40.0	47.5
[p25% - p75%]	[18.0;140.0]	[18.0;140.0]	[18.0;140.0]	[18.0;140.0]	[18.0;138.0]	[18.0;133.3]	[18.0;198.0]
[Min - Max]	[5.0;5218.0]	[3.3;5270.0]	[3.3;4416.0]	[3.3;4730.0]	[5.0;4801.0]	[5.0;7350.0]	[3.3;27070.0]
<b>Total number of DDD of anxiolytics (N05B), n **</b>	<b>1013918604</b>	<b>1033556327</b>	<b>1042231501</b>	<b>1021182807</b>	<b>973068903</b>	<b>968136421</b>	<b>6052094564</b>
<b>Patient-years exposed to anxiolytics (N05B), n **</b>	<b>8295849</b>	<b>8371613</b>	<b>8376818</b>	<b>8252609</b>	<b>7958611</b>	<b>7887766</b>	<b>49143265</b>

	2008 n = 48 082 718	2009 n = 48 603 894	2010 n = 48 558 426	2011 n = 48 735 903	2012 n = 48 816 573	2013 n = 49 164 821	Total n = 57 717 234
<b>At least one dispensation of antidepressants (N06A), n (%)</b>	<b>4976515 (10.3)</b>	<b>5039145 (10.4)</b>	<b>5096371 (10.5)</b>	<b>5001351 (10.3)</b>	<b>4943640 (10.1)</b>	<b>4828499 (9.8)</b>	<b>11350851 (19.7)</b>
<b>Number of DDD per patient of antidepressants (N06A) **</b>							
Size (missing)	4976515 (0)	5039145 (0)	5096371 (0)	5001351 (0)	4943640 (0)	4828499 (0)	11350851 (0)
Mean (± SD)	193.8 (2196.8)	194.2 (2193.7)	201.3 (2222.2)	205.4 (2235.6)	205.2 (2265.5)	207.4 (2290.8)	530.0 (9224.7)
Median	140.0	140.0	146.0	154.0	154.0	154.0	160.0
[p25% - p75%]	[43.0;294.0]	[42.0;298.0]	[45.0;308.0]	[50.0;308.0]	[48.3;308.0]	[50.0;311.5]	[34.0;694.5]
[Min - Max]	[3.0;2436.0]	[3.0;2171.5]	[3.0;2502.3]	[3.0;2135.0]	[3.0;4544.0]	[3.0;7573.3]	[3.0;15037.3]
<b>Total number of DDD of antidepressants (N06A), n **</b>	<b>964418816</b>	<b>978425341</b>	<b>1025803397</b>	<b>1027130033</b>	<b>1014567687</b>	<b>1001327226</b>	<b>6011672500</b>
<b>Patient-years exposed to antidepressants (N06A), n **</b>	<b>4944610</b>	<b>4994913</b>	<b>5046996</b>	<b>4957058</b>	<b>4906576</b>	<b>4779148</b>	<b>29629300</b>
<b>At least one dispensation of lipid modifying agents (C10A), n (%)</b>	<b>6543568 (13.6)</b>	<b>6907110 (14.2)</b>	<b>7059271 (14.5)</b>	<b>7115296 (14.6)</b>	<b>7126896 (14.6)</b>	<b>6943305 (14.1)</b>	<b>10607977 (18.4)</b>
<b>Number of DDD per patient of lipid modifying agents (C10A) **</b>							
Size (missing)	6543568 (0)	6907110 (0)	7059271 (0)	7115296 (0)	7126896 (0)	6943305 (0)	10607977 (0)
Mean (± SD)	248.5 (2325.7)	250.1 (2423.1)	260.1 (2525.1)	262.2 (2568.3)	266.7 (2647.5)	268.4 (2720.9)	1020.2 (12448.8)
Median	208.0	205.3	208.0	208.0	208.0	205.3	773.0
[p25% - p75%]	[130.7;312.0]	[128.0;314.0]	[135.0;330.0]	[135.0;330.0]	[135.0;336.0]	[135.0;336.0]	[252.0;1402.0]
[Min - Max]	[6.9;4592.0]	[2.6;4312.0]	[6.9;3480.0]	[6.9;3300.0]	[6.9;3858.0]	[6.9;3623.0]	[2.6;17824.0]
<b>Total number of DDD of lipid modifying agents (C10A), n **</b>	<b>1626376363</b>	<b>1727790668</b>	<b>1836158784</b>	<b>1865570548</b>	<b>1900494951</b>	<b>1863282331</b>	<b>10819673646</b>
<b>Patient-years exposed to lipid modifying agents (C10A), n **</b>	<b>6515583</b>	<b>6861463</b>	<b>7008801</b>	<b>7067204</b>	<b>7093364</b>	<b>6890451</b>	<b>41436867</b>
<b>At least one dispensation of antithrombotic agents (B01A), n (%)</b>	<b>4118320 (8.6)</b>	<b>4421083 (9.1)</b>	<b>4577288 (9.4)</b>	<b>4704412 (9.7)</b>	<b>4861420 (10.0)</b>	<b>5014202 (10.2)</b>	<b>7971368 (13.8)</b>
<b>Number of DDD per patient of antithrombotic agents (B01A) **</b>							
Size (missing)	4118320 (0)	4421083 (0)	4577288 (0)	4704412 (0)	4861420 (0)	5014202 (0)	7971368 (0)
Mean (± SD)	294.1 (1867.7)	291.2 (1898.1)	299.2 (1891.4)	298.0 (1844.6)	291.4 (1776.5)	289.3 (1708.0)	1022.0 (10480.5)
Median	328.0	330.0	330.0	330.0	330.0	330.0	810.0
[p25% - p75%]	[180.0;360.0]	[180.0;360.0]	[192.0;360.0]	[210.0;360.0]	[180.0;360.0]	[180.0;360.0]	[210.0;1738.0]
[Min - Max]	[4.0;2460.0]	[2.5;2580.0]	[2.5;2820.0]	[2.5;2670.0]	[2.5;1740.0]	[2.5;1290.0]	[2.5;13200.0]
<b>Total number of DDD of antithrombotic agents (B01A), n **</b>	<b>1211231119</b>	<b>1287343590</b>	<b>1369735876</b>	<b>1401951748</b>	<b>1416467428</b>	<b>1450490563</b>	<b>8137220323</b>
<b>Patient-years exposed to antithrombotic agents (B01A), n **</b>	<b>4066687</b>	<b>4359122</b>	<b>4508727</b>	<b>4641649</b>	<b>4801710</b>	<b>4941107</b>	<b>27319002</b>

	2008 n = 48 082 718	2009 n = 48 603 894	2010 n = 48 558 426	2011 n = 48 735 903	2012 n = 48 816 573	2013 n = 49 164 821	Total n = 57 717 234
<b>At least one dispensation of beta blocking agents (C07A), n (%)</b>	<b>3993088 (8.3)</b>	<b>4191642 (8.6)</b>	<b>4293228 (8.8)</b>	<b>4324610 (8.9)</b>	<b>4384576 (9.0)</b>	<b>4442773 (9.0)</b>	<b>7461855 (12.9)</b>
<b>Number of DDD per patient of beta blocking agents (C07A) **</b>							
Size (missing)	3993088 (0)	4191642 (0)	4293228 (0)	4324610 (0)	4384576 (0)	4442773 (0)	7461855 (0)
Mean (± SD)	229.1 (1857.1)	226.3 (1855.3)	227.8 (1829.7)	225.2 (1828.3)	221.9 (1813.7)	219.1 (1797.8)	772.4 (9746.7)
Median	205.3	196.0	200.0	195.0	195.0	182.5	451.3
[p25% - p75%]	[90.0;360.0]	[90.0;360.0]	[90.0;360.0]	[90.0;360.0]	[90.0;360.0]	[90.0;354.0]	[75.0;1230.0]
[Min - Max]	[3.8;1480.0]	[3.8;1656.0]	[3.8;1786.7]	[3.8;2016.0]	[3.8;1864.0]	[3.8;1920.0]	[3.8;10213.3]
<b>Total number of DDD of beta blocking agents (C07A), n **</b>	<b>914776454</b>	<b>948565855</b>	<b>978098278</b>	<b>973968639</b>	<b>972951271</b>	<b>973411743</b>	<b>5761772240</b>
<b>Patient-years exposed to beta blocking agents (C07A), n **</b>	<b>3967802</b>	<b>4154000</b>	<b>4248313</b>	<b>4284006</b>	<b>4350762</b>	<b>4391676</b>	<b>25396560</b>
<b>At least one dispensation of antiepileptics (N03A), n (%)</b>	<b>2146641 (4.5)</b>	<b>2225341 (4.6)</b>	<b>2314870 (4.8)</b>	<b>2243143 (4.6)</b>	<b>1880681 (3.9)</b>	<b>1829944 (3.7)</b>	<b>5577778 (9.7)</b>
<b>Number of DDD per patient of antiepileptics (N03A) **</b>							
Size (missing)	2146641 (0)	2225341 (0)	2314870 (0)	2243143 (0)	1880681 (0)	1829944 (0)	5577778 (0)
Mean (± SD)	126.3 (2261.7)	126.0 (2231.3)	127.6 (2244.3)	133.8 (2315.7)	153.8 (2423.8)	160.8 (2487.8)	310.5 (8783.7)
Median	43.8	43.8	43.8	50.0	70.0	80.0	35.0
[p25% - p75%]	[14.0;163.1]	[14.0;165.0]	[14.0;168.0]	[14.0;180.0]	[15.0;215.0]	[18.7;222.0]	[12.5;210.0]
[Min - Max]	[1.4;2965.7]	[0.5;2530.7]	[0.2;3319.0]	[0.5;3022.0]	[1.4;3326.0]	[0.2;3478.0]	[0.2;16750.3]
<b>Total number of DDD of antiepileptics (N03A), n **</b>	<b>271189075</b>	<b>280290016</b>	<b>295353627</b>	<b>300039243</b>	<b>289176061</b>	<b>294312408</b>	<b>1730360430</b>
<b>Patient-years exposed to antiepileptics (N03A) , n **</b>	<b>2133258</b>	<b>2205368</b>	<b>2292354</b>	<b>2221521</b>	<b>1866230</b>	<b>1809955</b>	<b>12528686</b>
<b>At least one dispensation of acetylsalicylic acid (B01AC06), n (%)</b>	<b>2621303 (5.5)</b>	<b>2854191 (5.9)</b>	<b>3001377 (6.2)</b>	<b>3122039 (6.4)</b>	<b>3210611 (6.6)</b>	<b>3333482 (6.8)</b>	<b>5808600 (10.1)</b>
<b>Number of DDD per patient of acetylsalicylic acid (B01AC06) **</b>							
Size (missing)	2621303 (0)	2854191 (0)	3001377 (0)	3122039 (0)	3210611 (0)	3333482 (0)	5808600 (0)
Mean (± SD)	254.4 (1438.0)	250.9 (1445.4)	258.5 (1402.3)	256.4 (1410.2)	254.0 (1414.2)	255.3 (1393.0)	797.4 (8419.5)
Median	300.0	300.0	300.0	300.0	300.0	300.0	570.0
[p25% - p75%]	[150.0;360.0]	[150.0;360.0]	[180.0;360.0]	[150.0;360.0]	[150.0;360.0]	[150.0;360.0]	[120.0;1380.0]
[Min - Max]	[28.0;720.0]	[28.0;750.0]	[28.0;720.0]	[28.0;1140.0]	[28.0;780.0]	[30.0;930.0]	[28.0;3630.0]
<b>Total number of DDD of acetylsalicylic acid (B01AC06), n **</b>	<b>666800706</b>	<b>716123752</b>	<b>775760098</b>	<b>800461043</b>	<b>815600986</b>	<b>851147571</b>	<b>4625894155</b>
<b>Patient-years exposed to acetylsalicylic acid (B01AC06), n **</b>	<b>2593159</b>	<b>2818080</b>	<b>2962464</b>	<b>3083505</b>	<b>3177022</b>	<b>3290749</b>	<b>17924978</b>



	2008 n = 48 082 718	2009 n = 48 603 894	2010 n = 48 558 426	2011 n = 48 735 903	2012 n = 48 816 573	2013 n = 49 164 821	Total n = 57 717 234
<b>At least one dispensation of direct acting antivirals (J05A), n (%)</b>	<b>1070713 (2.2)</b>	<b>1572978 (3.2)</b>	<b>1110138 (2.3)</b>	<b>1169876 (2.4)</b>	<b>1176809 (2.4)</b>	<b>1214652 (2.5)</b>	<b>4716428 (8.2)</b>
<b>Number of DDD per patient of direct acting antivirals (J05A) **</b>							
Size (missing)	1070713 (0)	1572978 (0)	1110138 (0)	1169876 (0)	1176809 (0)	1214652 (0)	4716428 (0)
Mean (± SD)	44.9 (1775.8)	35.2 (1528.2)	50.7 (1851.7)	51.7 (1893.5)	54.4 (1889.2)	53.8 (1855.2)	74.2 (5078.3)
Median	5.0	5.0	6.7	5.3	6.7	6.3	6.3
[p25% - p75%]	[2.5;10.0]	[3.3;7.0]	[2.5;11.7]	[2.5;10.3]	[2.5;12.0]	[3.3;11.7]	[3.3;10.0]
[Min - Max]	[0.0;1858.9]	[0.0;1448.3]	[0.0;1541.0]	[0.0;2146.7]	[0.0;1500.0]	[0.0;1520.0]	[0.0;8649.8]
<b>Total number of DDD of direct acting antivirals (J05A), n **</b>	<b>48105023</b>	<b>55400067</b>	<b>56232926</b>	<b>60537733</b>	<b>63969592</b>	<b>65368479</b>	<b>349613819</b>
<b>Patient-years exposed to direct acting antivirals (J05A) , n **</b>	<b>1068988</b>	<b>1566444</b>	<b>1105590</b>	<b>1164231</b>	<b>1174197</b>	<b>1208916</b>	<b>7288365</b>
<b>At least one dispensation of antacids (A02A), n (%)</b>	<b>1367880 (2.8)</b>	<b>1344167 (2.8)</b>	<b>1226730 (2.5)</b>	<b>1065352 (2.2)</b>	<b>995716 (2.0)</b>	<b>906993 (1.8)</b>	<b>4698635 (8.1)</b>
<b>Number of DDD per patient of antacids (A02A) **</b>							
Size (missing)	1367880 (0)	1344167 (0)	1226730 (0)	1065352 (0)	995716 (0)	906993 (0)	4698635 (0)
Mean (± SD)	37.3 (819.0)	37.9 (830.5)	37.3 (807.4)	36.2 (826.2)	35.3 (755.9)	35.4 (766.1)	53.8 (1958.6)
Median	16.0	17.3	16.0	16.0	16.0	16.0	20.0
[p25% - p75%]	[7.0;32.0]	[8.0;32.0]	[7.0;32.0]	[7.0;32.0]	[7.0;32.0]	[7.0;32.0]	[8.0;42.0]
[Min - Max]	[2.0;1512.0]	[2.0;1620.0]	[2.0;1560.0]	[2.0;1368.0]	[2.0;1153.0]	[2.0;1222.0]	[2.0;6666.0]
<b>Total number of DDD of antacids (A02A), n **</b>	<b>50966304</b>	<b>50882010</b>	<b>45746119</b>	<b>38584430</b>	<b>35115666</b>	<b>32097083</b>	<b>253391612</b>
<b>Patient-years exposed to antacids (A02A), n **</b>	<b>1364443</b>	<b>1338238</b>	<b>1220445</b>	<b>1059948</b>	<b>993489</b>	<b>902463</b>	<b>6879026</b>
<b>At least one dispensation of selective calcium channel blockers (C08C), n (%)</b>	<b>2218448 (4.6)</b>	<b>2347787 (4.8)</b>	<b>2342449 (4.8)</b>	<b>2332909 (4.8)</b>	<b>2372769 (4.9)</b>	<b>2420928 (4.9)</b>	<b>4854033 (8.4)</b>
<b>Number of DDD per patient of selective calcium channel blockers (C08C) **</b>							
Size (missing)	2218448 (0)	2347787 (0)	2342449 (0)	2332909 (0)	2372769 (0)	2420928 (0)	4854033 (0)
Mean (± SD)	346.6 (2661.4)	343.8 (2696.7)	355.0 (2827.9)	357.8 (2726.8)	359.3 (2709.6)	361.4 (2721.2)	1024.6 (13350.8)
Median	360.0	360.0	360.0	360.0	360.0	360.0	570.0
[p25% - p75%]	[166.7;420.0]	[150.0;433.3]	[180.0;450.0]	[180.0;453.3]	[180.0;480.0]	[180.0;480.0]	[90.0;1680.0]
[Min - Max]	[6.7;1560.0]	[6.7;1770.0]	[6.7;11100.0]	[6.7;3863.3]	[6.7;2040.0]	[6.7;2070.0]	[6.7;11100.0]
<b>Total number of DDD of selective calcium channel blockers (C08C), n **</b>	<b>768884744</b>	<b>807066810</b>	<b>831581397</b>	<b>834804679</b>	<b>852509028</b>	<b>874904982</b>	<b>4969751639</b>

	2008 n = 48 082 718	2009 n = 48 603 894	2010 n = 48 558 426	2011 n = 48 735 903	2012 n = 48 816 573	2013 n = 49 164 821	Total n = 57 717 234
<b>Patient-years exposed to selective calcium channel blockers (C08C), n **</b>	2201631	2325063	2316513	2310700	2353324	2394597	13901828
<b>At least one dispensation of acetylsalicylic acid (N02BA01), n (%)</b>	<b>1260462 (2.6)</b>	<b>1247758 (2.6)</b>	<b>861074 (1.8)</b>	<b>872382 (1.8)</b>	<b>830644 (1.7)</b>	<b>790025 (1.6)</b>	<b>4161871 (7.2)</b>
<b>Number of DDD per patient of acetylsalicylic acid (N02BA01) **</b>							
Size (missing)	1260462 (0)	1247758 (0)	861074 (0)	872382 (0)	830644 (0)	790025 (0)	4161871 (0)
Mean (± SD)	12.2 (202.5)	12.3 (207.6)	13.6 (218.1)	13.4 (272.2)	13.3 (226.2)	12.9 (223.3)	18.1 (523.3)
Median	6.7	6.7	6.7	6.7	6.7	6.7	6.7
[p25% - p75%]	[6.7;13.3]	[6.7;13.3]	[6.7;13.3]	[6.7;13.3]	[6.7;13.3]	[6.7;13.3]	[6.7;13.3]
[Min - Max]	[3.3;350.0]	[3.3;460.0]	[3.3;293.3]	[3.3;1300.0]	[3.3;520.0]	[3.3;453.3]	[3.3;1486.7]
<b>Total number of DDD of acetylsalicylic acid (N02BA01), n **</b>	15427421	15390983	11707658	11726933	11022408	10213274	75488678
<b>Patient-years exposed to acetylsalicylic acid (N02BA01), n **</b>	1258973	1242861	857430	868824	829323	786959	5844370
<b>At least one dispensation of treatment for tuberculosis (J04A), n (%)</b>	<b>44826 (0.1)</b>	<b>43671 (0.1)</b>	<b>38628 (0.1)</b>	<b>43008 (0.1)</b>	<b>43610 (0.1)</b>	<b>41244 (0.1)</b>	<b>213246 (0.4)</b>
<b>Number of DDD per patient of treatment for tuberculosis (J04A) **</b>							
Size (missing)	44826 (0)	43671 (0)	38628 (0)	43008 (0)	43610 (0)	41244 (0)	213246 (0)
Mean (± SD)	110.5 (1635.4)	120.4 (1658.4)	114.8 (1483.4)	116.5 (1578.7)	106.8 (1310.9)	88.1 (1063.1)	130.9 (2048.3)
Median	60.0	75.0	70.0	63.3	72.0	60.0	80.0
[p25% - p75%]	[30.0;135.0]	[30.0;150.0]	[30.0;150.0]	[30.0;135.0]	[30.0;134.3]	[30.0;105.0]	[30.0;150.0]
[Min - Max]	[4.0;1285.0]	[4.0;981.3]	[4.0;933.3]	[4.0;1300.3]	[4.0;780.0]	[4.0;923.3]	[4.0;2283.3]
<b>Total number of DDD of treatment for tuberculosis (J04A), n **</b>	4955308	5259567	4434006	5011786	4659196	3632755	27952617
<b>Patient-years exposed to treatment for tuberculosis (J04A), n **</b>	44701	43368	38314	42693	43079	41019	253175

\* Plain and combinations (N02BE01 + N02BE51 + N02BE71 + N02AA59 + N02AX52)

\*\* among those concerned

SALT-II - Table 12: ALFT incidence rates per billion in drug-exposed patients (cases exposed 30 days prior to index date) for the years 2008 to 2013

Drug	Number of cases exposed to drugs	Number of DDD of drug (extrapolation)	Number of patients exposed to drug (extrapolation)	Number of patient-years exposed to drugs (extrapolation)	Case per billion DDD (for 6 years) [95% CI] <sup>1</sup>	Case per billion patients (for 6 years) [95% CI] <sup>1</sup>	Case per billion patient-years [95% CI] <sup>1</sup>
<b>Paracetamol *</b>	35	5 782 254 449	47 051 322	157 504 366	6.05 [4.22 ; 8.42]	743.87 [518.16 ; 1034.61]	222.22 [154.79 ; 309.07]
<b>Paracetamol *</b> (with non-intentional overdoses)	92	5 782 254 449	47 051 322	157 504 366	15.91 [12.83 ; 19.51]	1955.31 [1576.15 ; 2398.02]	584.11 [470.84 ; 716.36]
<b>Paracetamol *</b> (with intentional or non-intentional overdoses)	161	5 782 254 449	47 051 322	157 504 366	27.84 [23.71 ; 32.50]	3421.80 [2913.64 ; 3993.66]	1022.19 [870.39 ; 1193.03]
<b>Treatment for tuberculosis (J04A)</b>	16	27 952 617	213 246	253 175	572.40 [327.34 - 929.43]	75030.72 [42908.19 - 121831.1]	63197.39 [36141.01 - 102616.8]
<b>Antidepressants (N06A)</b>	13	6 011 672 500	11 350 851	29 629 300	2.16 [1.15 - 3.70]	1145.29 [609.65 - 1958.44]	438.75 [233.55 - 750.27]
<b>Direct acting antivirals (J05A)</b>	12	349 613 819	4 716 428	7 288 365	34.32 [17.73 - 59.95]	2544.30 [1314.55 - 4444.04]	1646.46 [850.67 - 2875.82]
<b>Anxiolytics (N05B)</b>	11	6 052 094 564	20 331 487	49 143 265	1.82 [0.91 - 3.25]	541.03 [270.02 - 967.96]	223.84 [111.71 - 400.46]
<b>Antiepileptics (N03A)</b>	11	1 730 360 430	5 577 778	12 528 686	6.36 [3.17 - 11.37]	1972.11 [984.26 - 3528.29]	877.99 [438.19 - 1570.80]
<b>Antithrombotic agents (B01A)</b>	8	8 137 220 323	7 971 368	27 319 002	0.98 [0.42 - 1.94]	1003.59 [432.80 - 1977.08]	292.84 [126.29 - 576.89]

<b>Lipid modifying agents, plain (C10A)</b>	8	10 819 673 646	10 607 977	41 436 867	0.74 [0.32 - 1.46]	754.15 [325.23 - 1485.67]	193.06 [83.26 - 380.34]
<b>NSAID (M01A)</b>	8	4 927 318 292	40 744 642	111 634 392	1.62 [0.70 - 3.20]	196.34 [84.67 - 386.80]	71.66 [30.90 - 141.18]
<b>Beta-lactam antibiotics, penicillins (J01C)</b>	7	1 667 736 610	32 674 690	64 350 739	4.20 [1.68 - 8.65]	214.23 [86.00 - 441.32]	108.78 [43.67 - 224.08]
<b>Beta blocking agents (C07A)</b>	5	5 761 772 240	7 461 855	25 396 560	0.87 [0.28 - 2.03]	670.07 [217.10 - 1563.95]	196.88 [63.79 - 459.51]
<b>Acetylsalicylic acid (B01AC06)</b>	5	4 625 894 155	5 808 600	17 924 978	1.08 [0.35 - 2.52]	860.79 [278.90 - 2009.09]	278.94 [90.38 - 651.05]
<b>Acetylsalicylic acid (N02BA01)</b>	5	75 488 678	4 161 871	5 844 370	66.24 [21.46 - 154.59]	1201.38 [389.25 - 2804.03]	855.52 [277.19 - 1996.79]
<b>Selective calcium channel blockers (C08C)</b>	5	4 969 751 639	4 854 033	13 901 828	1.01 [0.33 - 2.35]	1030.07 [333.74 - 2404.19]	359.66 [116.53 - 839.46]

\* Plain and combinations (N02BE01 + N02BE51 + N02BE71 + N02AA59 + N02AX52)

<sup>1</sup> by the Poisson method

SALT-II - Table 13: ALFT incidence rates per billion in drug-exposed patients (cases exposed 90 days prior to index date) for the years 2008 to 2013

Drug	Number of cases exposed to drugs	Number of DDD of drug (extrapolation)	Number of patients exposed to drug (extrapolation)	Number of patient-years exposed to drugs (extrapolation)	Case per billion DDD (for 6 years) [95% CI] <sup>1</sup>	Case per billion patients (for 6 years) [95% CI] <sup>1</sup>	Case per billion patient-years [95% CI] <sup>1</sup>
<b>Paracetamol *</b>	39	5 782 254 449	47 051 322	157 504 366	6.74 [4.80 ; 9.22]	828.88 [589.36 ; 1133.02]	247.61 [176.06 ; 338.47]
<b>Paracetamol *</b> (with non-intentional overdoses)	96	5 782 254 449	47 051 322	157 504 366	16.60 [13.45 ; 20.27]	2040.33 [1652.66 ; 2491.53]	609.51 [493.70 ; 744.30]
<b>Paracetamol *</b> (with intentional or non-intentional overdoses)	165	5 782 254 449	47 051 322	157 504 366	28.54 [24.35 ; 33.24]	3506.81 [2992.13 ; 4085.18]	1047.59 [893.84 ; 1220.37]
<b>Treatment for tuberculosis (J04A)</b>	16	27 952 617	213 246	253 175	572.40 [327.34 - 929.43]	75030.72 [42908.19 - 121831.1]	63197.39 [36141.01 - 102616.8]
<b>Antidepressants (N06A)</b>	13	6 011 672 500	11 350 851	29 629 300	2.16 [1.15 - 3.70]	1145.29 [609.65 - 1958.44]	438.75 [233.55 - 750.27]
<b>Anxiolytics (N05B)</b>	13	6 052 094 564	20 331 487	49 143 265	2.15 [1.14 - 3.67]	639.40 [340.36 - 1093.38]	264.53 [140.81 - 452.35]
<b>Direct acting antivirals (J05A)</b>	12	349 613 819	4 716 428	7 288 365	34.32 [17.73 - 59.95]	2544.30 [1314.55 - 4444.04]	1646.46 [850.67 - 2875.82]
<b>Antiepileptics (N03A)</b>	12	1 730 360 430	5 577 778	12 528 686	6.93 [3.58 - 12.11]	2151.39 [1111.55 - 3757.77]	957.80 [494.86 - 1672.96]
<b>Antithrombotic agents (B01A)</b>	10	8 137 220 323	7 971 368	27 319 002	1.23 [0.59 - 2.26]	1254.49 [602.16 - 2307.01]	366.05 [175.70 - 673.16]

<b>Lipid modifying agents, plain (C10A)</b>	8	10 819 673 646	10 607 977	41 436 867	0.74 [0.32 - 1.46]	754.15 [325.23 - 1485.67]	193.06 [83.26 - 380.34]
<b>NSAID (M01A)</b>	8	4 927 318 292	40 744 642	111 634 392	1.62 [0.70 - 3.20]	196.34 [84.67 - 386.80]	71.66 [30.90 - 141.18]
<b>Beta-lactam antibacterials, penicillins (J01C)</b>	7	1 667 736 610	32 674 690	64 350 739	4.20 [1.68 - 8.65]	214.23 [86.00 - 441.32]	108.78 [43.67 - 224.08]
<b>Beta blocking agents (C07A)</b>	6	5 761 772 240	7 461 855	25 396 560	1.04 [0.38 - 2.27]	804.09 [294.83 - 1750.24]	236.25 [86.63 - 514.24]
<b>Acetylsalicylic acid (B01AC06)</b>	6	4 625 894 155	5 808 600	17 924 978	1.30 [0.48 - 2.82]	1032.95 [378.75 - 2248.39]	334.73 [122.73 - 728.59]
<b>Acetylsalicylic acid (N02BA01)</b>	5	75 488 678	4 161 871	5 844 370	66.24 [21.46 - 154.59]	1201.38 [389.25 - 2804.03]	855.52 [277.19 - 1996.79]
<b>Selective calcium channel blockers (C08C)</b>	5	4 969 751 639	4 854 033	13 901 828	1.01 [0.33 - 2.35]	1030.07 [333.74 - 2404.19]	359.66 [116.53 - 839.46]
<b>Antacids (A02A)</b>	5	253 391 612	4 698 635	6 879 026	19.73 [6.39 - 46.06]	1064.14 [344.78 - 2483.70]	726.85 [235.50 - 1696.46]
<b>Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)</b>	5	7 256 134 423	29 403 303	74 563 589	0.69 [0.22 - 1.61]	170.05 [55.10 - 396.89]	67.06 [21.73 - 156.51]
<b>Antihistamines (R06A)</b>	5	4 039 816 891	26 567 815	56 451 747	1.24 [0.40 - 2.89]	188.20 [60.98 - 439.25]	88.57 [28.70 - 206.73]

\* Plain and combinations (N02BE01 + N02BE51 + N02BE71 + N02AA59 + N02AX52)  
<sup>1</sup> by the Poisson method

SALT-II - Table 14: ALFT incidence rates per billion in drug-exposed patients (cases exposed 15 days prior to index date) for the years 2008 to 2013

Drug	Number of cases exposed to drugs	Number of DDD of drug (extrapolation)	Number of patients exposed to drug (extrapolation)	Number of patient-years exposed to drugs (extrapolation)	Case per billion DDD (for 6 years) [95% CI] <sup>1</sup>	Case per billion patients (for 6 years) [95% CI] <sup>1</sup>	Case per billion patient-years [95% CI] <sup>1</sup>
<b>Paracetamol *</b>	35	5 782 254 449	47 051 322	157 504 366	6.05 [4.22 ; 8.42]	743.87 [518.16 ; 1034.61]	222.22 [154.79 ; 309.07]
<b>Paracetamol *</b> (with non-intentional overdoses)	92	5 782 254 449	47 051 322	157 504 366	15.91 [12.83 ; 19.51]	1955.31 [1576.15 ; 2398.02]	584.11 [470.84 ; 716.36]
<b>Paracetamol *</b> (with intentional or non-intentional overdoses)	161	5 782 254 449	47 051 322	157 504 366	27.84 [23.71 ; 32.50]	3421.80 [2913.64 ; 3993.66]	1022.19 [870.39 ; 1193.03]
<b>Treatment for tuberculosis (J04A)</b>	16	27 952 617	213 246	253 175	572.40 [327.34 - 929.43]	75030.72 [42908.19 - 121831.1]	63197.39 [36141.01 - 102616.8]
<b>Antidepressants (N06A)</b>	12	6 011 672 500	11 350 851	29 629 300	2.00 [1.03 - 3.49]	1057.19 [546.21 - 1846.56]	405.00 [209.25 - 707.41]
<b>Direct acting antivirals (J05A)</b>	12	349 613 819	4 716 428	7 288 365	34.32 [17.73 - 59.95]	2544.30 [1314.55 - 4444.04]	1646.46 [850.67 - 2875.82]
<b>Anxiolytics (N05B)</b>	10	6 052 094 564	20 331 487	49 143 265	1.65 [0.79 - 3.04]	491.85 [236.09 - 904.51]	203.49 [97.67 - 374.21]
<b>Antiepileptics (N03A)</b>	9	1 730 360 430	5 577 778	12 528 686	5.20 [2.38 - 9.87]	1613.55 [738.65 - 3062.15]	718.35 [328.85 - 1363.27]
<b>Antithrombotic agents (B01A)</b>	8	8 137 220 323	7 971 368	27 319 002	0.98 [0.42 - 1.94]	1003.59 [432.80 - 1977.08]	292.84 [126.29 - 576.89]



<b>Lipid modifying agents, plain (C10A)</b>	8	10 819 673 646	10 607 977	41 436 867	0.74 [0.32 - 1.46]	754.15 [325.23 - 1485.67]	193.06 [83.26 - 380.34]
<b>NSAID (M01A)</b>	6	4 927 318 292	40 744 642	111 634 392	1.22 [0.45 - 2.65]	147.26 [53.99 - 320.53]	53.75 [19.71 - 116.99]
<b>Beta-lactam antibiotics, penicillins (J01C)</b>	5	1 667 736 610	32 674 690	64 350 739	3.00 [0.97 - 7.00]	153.02 [49.58 - 357.16]	77.70 [25.17 - 181.35]
<b>Acetylsalicylic acid (B01AC06)</b>	5	4 625 894 155	5 808 600	17 924 978	1.08 [0.35 - 2.52]	860.79 [278.90 - 2009.09]	278.94 [90.38 - 651.05]
<b>Selective calcium channel blockers (C08C)</b>	5	4 969 751 639	4 854 033	13 901 828	1.01 [0.33 - 2.35]	1030.07 [333.74 - 2404.19]	359.66 [116.53 - 839.46]

---

\* Plain and combinations (N02BE01 + N02BE51 + N02BE71 + N02AA59 + N02AX52)

<sup>1</sup> by the Poisson method

SALT-II - Table 15: ALFT incidence rates per billion in drug-exposed patients (cases exposed 7 days prior to index date) for the years 2008 to 2013

Drug	Number of cases exposed to drugs	Number of DDD of drug (extrapolation)	Number of patients exposed to drug (extrapolation)	Number of patient-years exposed to drugs (extrapolation)	Case per billion DDD (for 6 years) [95% CI] <sup>1</sup>	Case per billion patients (for 6 years) [95% CI] <sup>1</sup>	Case per billion patient-years [95% CI] <sup>1</sup>
<b>Paracetamol *</b>	31	5 782 254 449	47 051 322	157 504 366	5.36 [3.64 ; 7.61]	658.86 [447.60 ; 935.15]	196.82 [133.71 ; 279.36]
<b>Paracetamol *</b> (with non-intentional overdoses)	88	5 782 254 449	47 051 322	157 504 366	15.22 [12.21 ; 18.75]	1870.30 [1500.06 ; 2304.29]	558.71 [448.11 ; 688.36]
<b>Paracetamol *</b> (with intentional or non-intentional overdoses)	157	5 782 254 449	47 051 322	157 504 366	27.15 [23.07 ; 31.75]	3336.78 [2835.24 ; 3902.06]	996.80 [846.97 ; 1165.66]
<b>Treatment for tuberculosis (J04A)</b>	14	27 952 617	213 246	253 175	500.85 [273.68 - 840.35]	65651.88 [35874.06 - 110154.5]	55297.72 [30216.25 - 92781.67]
<b>Antidepressants (N06A)</b>	12	6 011 672 500	11 350 851	29 629 300	2.00 [1.03 - 3.49]	1057.19 [546.21 - 1846.56]	405.00 [209.25 - 707.41]
<b>Direct acting antivirals (J05A)</b>	12	349 613 819	4 716 428	7 288 365	34.32 [17.73 - 59.95]	2544.30 [1314.55 - 4444.04]	1646.46 [850.67 - 2875.82]
<b>Anxiolytics (N05B)</b>	10	6 052 094 564	20 331 487	49 143 265	1.65 [0.79 - 3.04]	491.85 [236.09 - 904.51]	203.49 [97.67 - 374.21]
<b>Antithrombotic agents (B01A)</b>	8	8 137 220 323	7 971 368	27 319 002	0.98 [0.42 - 1.94]	1003.59 [432.80 - 1977.08]	292.84 [126.29 - 576.89]
<b>Antiepileptics (N03A)</b>	7	1 730 360 430	5 577 778	12 528 686	4.05 [1.62 - 8.33]	1254.98 [503.78 - 2585.26]	558.72 [224.29 - 1150.96]

<b>Lipid modifying agents, plain (C10A)</b>	7	10 819 673 646	10 607 977	41 436 867	0.65 [0.26 - 1.33]	659.88 [264.89 - 1359.35]	168.93 [67.81 - 348.00]
<b>NSAID (M01A)</b>	5	4 927 318 292	40 744 642	111 634 392	1.01 [0.33 - 2.37]	122.72 [39.76 - 286.42]	44.79 [14.51 - 104.54]
<b>Acetylsalicylic acid (B01AC06)</b>	5	4 625 894 155	5 808 600	17 924 978	1.08 [0.35 - 2.52]	860.79 [278.90 - 2009.09]	278.94 [90.38 - 651.05]


---

\* Plain and combinations (N02BE01 + N02BE51 + N02BE71 + N02AA59 + N02AX52)

<sup>1</sup> by the Poisson method

## **SALT-II Study**

### **Results of pooled analyse of SALT-I / SALT-II for the nine-years period (2005-2013)**



**SALT-II - Figure 2: Identification and selection of ALFT cases for data analysis for the period 2005 to 2013**

SALT-II - Table 16: Characteristics of ALFT cases according to drug exposure in the 30 days prior to index date for the year 2005 to 2013

	Acute drug overdose n = 164	Exposed to drugs n = 147	Not exposed to drugs n = 36	Total n = 347
<b>Gender, n (%)</b>				
Male	47 (28.7)	61 (41.5)	13 (36.1)	121 (34.9)
Female	117 (71.3)	86 (58.5)	23 (63.9)	226 (65.1)
<b>Age at registration in transplant list (in years)</b>				
Size (missing)	164 (0)	147 (0)	36 (0)	347 (0)
Mean ( $\pm$ SD)	37.0 (12.3)	42.4 (13.0)	41.7 (14.5)	39.8 (13.1)
Median	36.0	42.0	38.0	39.0
[p25% - p75%]	[27.5;47.0]	[33.0;52.0]	[33.0;54.0]	[29.0;50.0]
[Min - Max]	[18.0;66.0]	[18.0;69.0]	[21.0;76.0]	[18.0;76.0]
<b>Age at registration in transplant list (in categories), n (%)</b>				
[18 - 30[ years	56 (34.1)	27 (18.4)	7 (19.4)	90 (25.9)
[30 - 40[ years	42 (25.6)	37 (25.2)	14 (38.9)	93 (26.8)
[40 - 50[ years	35 (21.3)	37 (25.2)	5 (13.9)	77 (22.2)
[50 - 60[ years	25 (15.2)	32 (21.8)	5 (13.9)	62 (17.9)
$\geq 60$ years	6 (3.7)	14 (9.5)	5 (13.9)	25 (7.2)
<b>Transplanted, n (%)</b>	97 (59.1)	109 (74.1)	32 (88.9)	238 (68.6)
<b>Year of registration in transplant list, n (%)</b>				
2005	7 (4.3)	18 (12.2)	2 (5.6)	27 (7.8)
2006	12 (7.3)	20 (13.6)	0 (0.0)	32 (9.2)
2007	13 (7.9)	27 (18.4)	2 (5.6)	42 (12.1)
2008	15 (9.1)	11 (7.5)	6 (16.7)	32 (9.2)
2009	16 (9.8)	14 (9.5)	3 (8.3)	33 (9.5)
2010	25 (15.2)	21 (14.3)	7 (19.4)	53 (15.3)
2011	17 (10.4)	13 (8.8)	7 (19.4)	37 (10.7)
2012	27 (16.5)	7 (4.8)	2 (5.6)	36 (10.4)
2013	32 (19.5)	16 (10.9)	7 (19.4)	55 (15.9)

**SALT-II - Table 17: Characteristics of ALFT cases according to drug exposure in the 90 days prior to index date for the year 2005 to 2013**

	Acute drug overdose n = 164	Exposed to drugs n = 157	Not exposed to drugs n = 26	Total n = 347
<b>Gender, n (%)</b>				
Male	47 (28.7)	65 (41.4)	9 (34.6)	121 (34.9)
Female	117 (71.3)	92 (58.6)	17 (65.4)	226 (65.1)
<b>Age at registration in transplant list (in years)</b>				
Size (missing)	164 (0)	157 (0)	26 (0)	347 (0)
Mean ( $\pm$ SD)	37.0 (12.3)	42.9 (13.4)	38.5 (12.1)	39.8 (13.1)
Median	36.0	43.0	35.0	39.0
[p25% - p75%]	[27.5;47.0]	[34.0;53.0]	[31.0;45.0]	[29.0;50.0]
[Min - Max]	[18.0;66.0]	[18.0;76.0]	[21.0;61.0]	[18.0;76.0]
<b>Age at registration in transplant list (in categories), n (%)</b>				
[18 - 30[ years	56 (34.1)	28 (17.8)	6 (23.1)	90 (25.9)
[30 - 40[ years	42 (25.6)	40 (25.5)	11 (42.3)	93 (26.8)
[40 - 50[ years	35 (21.3)	39 (24.8)	3 (11.5)	77 (22.2)
[50 - 60[ years	25 (15.2)	33 (21.0)	4 (15.4)	62 (17.9)
$\geq 60$ years	6 (3.7)	17 (10.8)	2 (7.7)	25 (7.2)
<b>Transplanted, n (%)</b>	97 (59.1)	118 (75.2)	23 (88.5)	238 (68.6)
<b>Year of registration in transplant list, n (%)</b>				
2005	7 (4.3)	18 (11.5)	2 (7.7)	27 (7.8)
2006	12 (7.3)	20 (12.7)	0 (0.0)	32 (9.2)
2007	13 (7.9)	28 (17.8)	1 (3.8)	42 (12.1)
2008	15 (9.1)	12 (7.6)	5 (19.2)	32 (9.2)
2009	16 (9.8)	16 (10.2)	1 (3.8)	33 (9.5)
2010	25 (15.2)	24 (15.3)	4 (15.4)	53 (15.3)
2011	17 (10.4)	15 (9.6)	5 (19.2)	37 (10.7)
2012	27 (16.5)	7 (4.5)	2 (7.7)	36 (10.4)
2013	32 (19.5)	17 (10.8)	6 (23.1)	55 (15.9)

SALT-II - Table 18: Characteristics of ALFT cases according to drug exposure in the 15 days prior to index date for the year 2005 to 2013

	Acute drug overdose n = 164	Exposed to drugs n = 139	Not exposed to drugs n = 44	Total n = 347
<b>Gender, n (%)</b>				
Male	47 (28.7)	56 (40.3)	18 (40.9)	121 (34.9)
Female	117 (71.3)	83 (59.7)	26 (59.1)	226 (65.1)
<b>Age at registration in transplant list (in years)</b>				
Size (missing)	164 (0)	139 (0)	44 (0)	347 (0)
Mean ( $\pm$ SD)	37.0 (12.3)	42.1 (12.9)	42.9 (14.5)	39.8 (13.1)
Median	36.0	42.0	38.5	39.0
[p25% - p75%]	[27.5;47.0]	[32.0;52.0]	[33.5;55.0]	[29.0;50.0]
[Min - Max]	[18.0;66.0]	[18.0;69.0]	[21.0;76.0]	[18.0;76.0]
<b>Age at registration in transplant list (in categories), n (%)</b>				
[18 - 30[ years	56 (34.1)	26 (18.7)	8 (18.2)	90 (25.9)
[30 - 40[ years	42 (25.6)	35 (25.2)	16 (36.4)	93 (26.8)
[40 - 50[ years	35 (21.3)	36 (25.9)	6 (13.6)	77 (22.2)
[50 - 60[ years	25 (15.2)	29 (20.9)	8 (18.2)	62 (17.9)
$\geq 60$ years	6 (3.7)	13 (9.4)	6 (13.6)	25 (7.2)
<b>Transplanted, n (%)</b>	97 (59.1)	103 (74.1)	38 (86.4)	238 (68.6)
<b>Year of registration in transplant list, n (%)</b>				
2005	7 (4.3)	18 (12.9)	2 (4.5)	27 (7.8)
2006	12 (7.3)	19 (13.7)	1 (2.3)	32 (9.2)
2007	13 (7.9)	27 (19.4)	2 (4.5)	42 (12.1)
2008	15 (9.1)	11 (7.9)	6 (13.6)	32 (9.2)
2009	16 (9.8)	11 (7.9)	6 (13.6)	33 (9.5)
2010	25 (15.2)	20 (14.4)	8 (18.2)	53 (15.3)
2011	17 (10.4)	12 (8.6)	8 (18.2)	37 (10.7)
2012	27 (16.5)	6 (4.3)	3 (6.8)	36 (10.4)
2013	32 (19.5)	15 (10.8)	8 (18.2)	55 (15.9)



**SALT-II - Table 19: Characteristics of ALFT cases according to drug exposure in the 7 days prior to index date for the year 2005 to 2013**

	Acute drug overdose n = 164	Exposed to drugs n = 132	Not exposed to drugs n = 51	Total n = 347
<b>Gender, n (%)</b>				
Male	47 (28.7)	55 (41.7)	19 (37.3)	121 (34.9)
Female	117 (71.3)	77 (58.3)	32 (62.7)	226 (65.1)
<b>Age at registration in transplant list (in years)</b>				
Size (missing)	164 (0)	132 (0)	51 (0)	347 (0)
Mean ( $\pm$ SD)	37.0 (12.3)	42.5 (12.7)	41.7 (14.6)	39.8 (13.1)
Median	36.0	42.0	38.0	39.0
[p25% - p75%]	[27.5;47.0]	[34.0;52.0]	[31.0;54.0]	[29.0;50.0]
[Min - Max]	[18.0;66.0]	[18.0;69.0]	[19.0;76.0]	[18.0;76.0]
<b>Age at registration in transplant list (in categories), n (%)</b>				
[18 - 30[ years	56 (34.1)	23 (17.4)	11 (21.6)	90 (25.9)
[30 - 40[ years	42 (25.6)	34 (25.8)	17 (33.3)	93 (26.8)
[40 - 50[ years	35 (21.3)	34 (25.8)	8 (15.7)	77 (22.2)
[50 - 60[ years	25 (15.2)	28 (21.2)	9 (17.6)	62 (17.9)
$\geq 60$ years	6 (3.7)	13 (9.8)	6 (11.8)	25 (7.2)
<b>Transplanted, n (%)</b>	97 (59.1)	96 (72.7)	45 (88.2)	238 (68.6)
<b>Year of registration in transplant list, n (%)</b>				
2005	7 (4.3)	17 (12.9)	3 (5.9)	27 (7.8)
2006	12 (7.3)	19 (14.4)	1 (2.0)	32 (9.2)
2007	13 (7.9)	27 (20.5)	2 (3.9)	42 (12.1)
2008	15 (9.1)	10 (7.6)	7 (13.7)	32 (9.2)
2009	16 (9.8)	10 (7.6)	7 (13.7)	33 (9.5)
2010	25 (15.2)	20 (15.2)	8 (15.7)	53 (15.3)
2011	17 (10.4)	11 (8.3)	9 (17.6)	37 (10.7)
2012	27 (16.5)	5 (3.8)	4 (7.8)	36 (10.4)
2013	32 (19.5)	13 (9.8)	10 (19.6)	55 (15.9)

**SALT-II - Table 20: Drug exposure of ALFT cases according to drug exposure in the 30 days prior to index date for the years 2005 to 2013**

	Acute drug overdose n = 164	Exposed to drugs n = 147	Not exposed to drugs n = 36	Total n = 347
<b>At least one exposure at the following ATC codes in the 30 days prior to index date, n (%)</b>	164 (100.0)	147 (100.0)	0 (0.0)	311 (89.6)
<b>Nervous system (N)</b>	<b>163 (99.4)</b>	<b>105 (71.4)</b>		<b>268 (77.2)</b>
Other analgesics and antipyretics (N02B)	158 (96.3)	86 (58.5)		244 (70.3)
Paracetamol (N02BE01)	138 (84.1)	73 (49.7)		211 (60.8)
Paracetamol, combinations excl. psycholeptics (N02BE51)	30 (18.3)	13 (8.8)		43 (12.4)
Acetylsalicylic acid (N02BA01)	1 (0.6)	11 (7.5)		12 (3.5)
Paracetamol, combinations with psycholeptics (N02BE71)	2 (1.2)	2 (1.4)		4 (1.2)
Nefopam (N02BG06)	0 (0.0)	2 (1.4)		2 (0.6)
Anxiolytics (N05B)	56 (34.1)	20 (13.6)		76 (21.9)
Oxazepam (N05BA04)	11 (6.7)	5 (3.4)		16 (4.6)
Bromazepam (N05BA08)	13 (7.9)	3 (2.0)		16 (4.6)
Alprazolam (N05BA12)	13 (7.9)	1 (0.7)		14 (4.0)
Hydroxyzine (N05BB01)	4 (2.4)	4 (2.7)		8 (2.3)
Prazepam (N05BA11)	3 (1.8)	3 (2.0)		6 (1.7)
Clobazam (N05BA09)	3 (1.8)	2 (1.4)		5 (1.4)
Diazepam (N05BA01)	3 (1.8)	1 (0.7)		4 (1.2)
Etifoxine (N05BX03)	3 (1.8)	1 (0.7)		4 (1.2)
Potassium clorazepate (N05BA05)	2 (1.2)	2 (1.4)		4 (1.2)
Meprobamate, combinations (N05BC51)	2 (1.2)	1 (0.7)		3 (0.9)
Lorazepam (N05BA06)	1 (0.6)	1 (0.7)		2 (0.6)
Meprobamate (N05BC01)	1 (0.6)	1 (0.7)		2 (0.6)
Antidepressants (N06A)	42 (25.6)	17 (11.6)		59 (17.0)
Escitalopram (N06AB10)	11 (6.7)	1 (0.7)		12 (3.5)
Paroxetine (N06AB05)	7 (4.3)	2 (1.4)		9 (2.6)
Venlafaxine (N06AX16)	4 (2.4)	5 (3.4)		9 (2.6)
Amitriptyline (N06AA09)	4 (2.4)	3 (2.0)		7 (2.0)
Fluoxetine (N06AB03)	4 (2.4)	0 (0.0)		4 (1.2)
Citalopram (N06AB04)	2 (1.2)	1 (0.7)		3 (0.9)
Mianserin (N06AX03)	1 (0.6)	2 (1.4)		3 (0.9)
Sertraline (N06AB06)	3 (1.8)	0 (0.0)		3 (0.9)
Iproniazide (N06AF05)	0 (0.0)	2 (1.4)		2 (0.6)
Mirtazapine (N06AX1)	2 (1.2)	0 (0.0)		2 (0.6)
Agomelatine (N06AX22)	1 (0.6)	0 (0.0)		1 (0.3)
Clomipramine (N06AA04)	1 (0.6)	0 (0.0)		1 (0.3)
Duloxetine (N06AX21)	1 (0.6)	0 (0.0)		1 (0.3)
Milnacipran (N06AX17)	1 (0.6)	0 (0.0)		1 (0.3)
Moclobemide (N06AG02)	0 (0.0)	1 (0.7)		1 (0.3)
Tianeptine (N06AX14)	1 (0.6)	0 (0.0)		1 (0.3)

	Acute drug overdose n = 164	Exposed to drugs n = 147	Not exposed to drugs n = 36	Total n = 347
<i>Trimipramine (N06AA06)</i>	1 (0.6)	0 (0.0)		1 (0.3)
Antiepileptics (N03A)	18 (11.0)	18 (12.2)		36 (10.4)
<i>Valproic acid (N03AG01)</i>	6 (3.7)	5 (3.4)		11 (3.2)
<i>Clonazepam (N03AE01)</i>	5 (3.0)	4 (2.7)		9 (2.6)
<i>Carbamazepine (N03AF01)</i>	3 (1.8)	5 (3.4)		8 (2.3)
<i>Levetiracetam (N03AX14)</i>	3 (1.8)	3 (2.0)		6 (1.7)
<i>Lamotrigine (N03AX09)</i>	1 (0.6)	3 (2.0)		4 (1.2)
<i>Pregabalin (N03AX16)</i>	2 (1.2)	2 (1.4)		4 (1.2)
<i>Gabapentin (N03AX12)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Phenobarbital (N03AA02)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Phenytoin (N03AB02)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Topiramate (N03AX11)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<i>Valpromide (N03AG02)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Hypnotics and sedatives (N05C)	25 (15.2)	5 (3.4)		30 (8.6)
<i>Zolpidem (N05CF02)</i>	14 (8.5)	1 (0.7)		15 (4.3)
<i>Zopiclone (N05CF01)</i>	6 (3.7)	3 (2.0)		9 (2.6)
<i>Lormetazepam (N05CD06)</i>	2 (1.2)	0 (0.0)		2 (0.6)
<i>Nitrazepam (N05CD02)</i>	1 (0.6)	0 (0.0)		1 (0.3)
Opioids (N02A)	16 (9.8)	4 (2.7)		20 (5.8)
<i>Tramadol, combinations (N02AX52)</i>	6 (3.7)	0 (0.0)		6 (1.7)
<i>Tramadol (N02AX02)</i>	4 (2.4)	1 (0.7)		5 (1.4)
<i>Morphine (N02AA01)</i>	2 (1.2)	1 (0.7)		3 (0.9)
<i>Dextropropoxyphene (N02AC04)</i>	2 (1.2)	0 (0.0)		2 (0.6)
<i>Dextropropoxyphene, comb. excl. psycholeptics (N02AC54)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Dihydrocodeine (N02AA08)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Fentanyl (N02AB03)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Oxycodone (N02AA05)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Antipsychotics (N05A)	9 (5.5)	5 (3.4)		14 (4.0)
<i>Cyamemazine (N05AA06)</i>	2 (1.2)	2 (1.4)		4 (1.2)
<i>Risperidone (N05AX08)</i>	3 (1.8)	1 (0.7)		4 (1.2)
<i>Olanzapine (N05AH03)</i>	1 (0.6)	1 (0.7)		2 (0.6)
<i>Tiapride (N05AL03)</i>	2 (1.2)	0 (0.0)		2 (0.6)
<i>Levomepromazine (N05AA02)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Loxapine (N05AH01)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<i>Periciazine (N05AC01)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<i>Zuclopenthixol (N05AF05)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Drugs used in addictive disorders (N07B)	6 (3.7)	2 (1.4)		8 (2.3)
<i>Disulfiram (N07BB01)</i>	2 (1.2)	2 (1.4)		4 (1.2)
<i>Acamprosate (N07BB03)</i>	3 (1.8)	0 (0.0)		3 (0.9)
<i>Buprenorphine (N07BC01)</i>	2 (1.2)	0 (0.0)		2 (0.6)
Antimigraine preparations (N02C)	2 (1.2)	3 (2.0)		5 (1.4)

	Acute drug overdose n = 164	Exposed to drugs n = 147	Not exposed to drugs n = 36	Total n = 347
<i>Eletriptan (N02CC06)</i>	1 (0.6)	1 (0.7)		2 (0.6)
<i>Almotriptan (N02CC05)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<i>Dihydroergotamine (N02CA01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Pizotifen (N02CX01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Zolmitriptan (N02CC03)</i>	1 (0.6)	0 (0.0)		1 (0.3)
Anticholinergic agents (N04A)	0 (0.0)	2 (1.4)		2 (0.6)
<i>Biperiden (N04AA02)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Tropatepine (N04AA12)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Anesthetics, general (N01A)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Desflurane (N01AB07)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Ketamine (N01AX03)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Sufentanil (N01AH03)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Thiopental (N01AF03)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Antivertigo preparations (N07C)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Acetylleucine (N07CA04)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Dopaminergic agents (N04B)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Levodopa (N04BA01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Pribedil (N04BC08)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Psychostimulants, agents used for adhd and nootropics (N06B)	1 (0.6)	0 (0.0)		1 (0.3)
<i>Amphetamine (N06BA01)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<b>Alimentary tract and metabolism (A)</b>	<b>19 (11.6)</b>	<b>38 (25.9)</b>		<b>57 (16.4)</b>
Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) (A02B)	7 (4.3)	10 (6.8)		17 (4.9)
<i>Lansoprazole (A02BC03)</i>	3 (1.8)	2 (1.4)		5 (1.4)
<i>Esomeprazole (A02BC05)</i>	2 (1.2)	2 (1.4)		4 (1.2)
<i>Omeprazole (A02BC01)</i>	2 (1.2)	2 (1.4)		4 (1.2)
<i>Pantoprazole (A02BC02)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Rabeprazole (A02BC04)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Blood glucose lowering drugs, excl. insulins (A10B)	2 (1.2)	8 (5.4)		10 (2.9)
<i>Metformin (A10BA02)</i>	1 (0.6)	5 (3.4)		6 (1.7)
<i>Acarbose (A10BF01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Glibenclamide (A10BB01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Gliclazide (A10BB09)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Glimepiride (A10BB12)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Metformin and sitagliptin (A10BD07)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<i>Repaglinide (A10BX02)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Sitagliptin (A10BH01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Drugs for functional bowel disorders (A03A)	4 (2.4)	6 (4.1)		10 (2.9)
<i>Phloroglucinol (A03AX12)</i>	3 (1.8)	4 (2.7)		7 (2.0)
<i>Trimebutine (A03AA05)</i>	1 (0.6)	2 (1.4)		3 (0.9)

	Acute drug overdose n = 164	Exposed to drugs n = 147	Not exposed to drugs n = 36	Total n = 347
<i>Alverine, combinations (A03AX58)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Propulsives (A03F)	3 (1.8)	7 (4.8)		10 (2.9)
<i>Domperidone (A03FA03)</i>	1 (0.6)	5 (3.4)		6 (1.7)
<i>Metoclopramide (A03FA01)</i>	2 (1.2)	3 (2.0)		5 (1.4)
Antipropulsives (A07D)	4 (2.4)	4 (2.7)		8 (2.3)
<i>Loperamide (A07DA03)</i>	4 (2.4)	4 (2.7)		8 (2.3)
Antacids (A02A)	0 (0.0)	6 (4.1)		6 (1.7)
<i>Aluminium hydroxide (A02AB01)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Ordinary salt combinations and antifatulents (A02AF02)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Laxatives (A06A)	0 (0.0)	4 (2.7)		4 (1.2)
<i>Ispaghula, combinations (A06AC51)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Lactulose (A06AD11)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Liquid paraffin (A06AA01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Macrogol (A06AD15)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Senna glycosides, combinations (A06AB56)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Antiemetics and antinauseants (A04A)	2 (1.2)	2 (1.4)		4 (1.2)
<i>Metopimazine (A04AD05)</i>	2 (1.2)	1 (0.7)		3 (0.9)
Insulins and analogues (A10A)	1 (0.6)	2 (1.4)		3 (0.9)
<i>Insulin (human) (A10AB01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Insulin glargine (A10AE04)</i>	1 (0.6)	0 (0.0)		1 (0.3)
Other drugs for acid related disorders (A02X)	1 (0.6)	2 (1.4)		3 (0.9)
Vitamin a and d, incl. combinations of the two (A11C)	0 (0.0)	2 (1.4)		2 (0.6)
<i>Calcifediol (A11CC06)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Colecalciferol (A11CC05)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Bile therapy (A05A)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Ursodeoxycholic acid (A05AA02)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Calcium (A12A)	0 (0.0)	1 (0.7)		1 (0.3)
Intestinal antiinfectives (A07A)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Nifuroxazide (A07AX03)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Intestinal anti-inflammatory agents (A07E)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Sulfasalazine (A07EC01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Multivitamins, combinations (A11A)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Multivitamins and other minerals, incl. combinations (A11AA03)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Other antidiarrheals (A07X)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Racecadotril (A07XA04)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Potassium (A12B)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Potassium chloride (A12BA01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Vitamin b1, plain and in combination with vitamin b6 and b12 (A11D)	1 (0.6)	0 (0.0)		1 (0.3)
<b>Antiinfectives for systemic use (J)</b>	<b>7 (4.3)</b>	<b>48 (32.7)</b>		<b>55 (15.9)</b>

	Acute drug overdose n = 164	Exposed to drugs n = 147	Not exposed to drugs n = 36	Total n = 347
Drugs for treatment of tuberculosis (J04A)	0 (0.0)	19 (12.9)		19 (5.5)
<i>Rifampicin, pyrazinamide, ethambutol and isoniazid (J04AM06)</i>	0 (0.0)	11 (7.5)		11 (3.2)
<i>Rifampicin and isoniazid (J04AM02)</i>	0 (0.0)	6 (4.1)		6 (1.7)
<i>Ethambutol (J04AK02)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Isoniazid (J04AC01)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Pyrazinamide (J04AK01)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Rifampicin (J04AB02)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Rifampicin, pyrazinamide and isoniazid (J04AM05)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Rifabutin (J04AB04)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Beta-lactam antibacterials, penicillins (J01C)	4 (2.4)	13 (8.8)		17 (4.9)
<i>Amoxicillin (J01CA04)</i>	2 (1.2)	7 (4.8)		9 (2.6)
<i>Amoxicillin and enzyme inhibitor (J01CR02)</i>	1 (0.6)	4 (2.7)		5 (1.4)
<i>Piperacillin and enzyme inhibitor (J01CR05)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Cloxacillin (J01CF02)</i>	1 (0.6)	0 (0.0)		1 (0.3)
Direct acting antivirals (J05A)	1 (0.6)	13 (8.8)		14 (4.0)
<i>Tenofovir disoproxil and emtricitabine (J05AR03)</i>	0 (0.0)	4 (2.7)		4 (1.2)
<i>Efavirenz (J05AG03)</i>	0 (0.0)	3 (2.0)		3 (0.9)
<i>Emtricitabine, tenofovir disoproxil and efavirenz (J05AR06)</i>	0 (0.0)	3 (2.0)		3 (0.9)
<i>Ritonavir (J05AE03)</i>	0 (0.0)	3 (2.0)		3 (0.9)
<i>Aciclovir (J05AB01)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Atazanavir (J05AE08)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Tenofovir disoproxil (J05AF07)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Valaciclovir (J05AB11)</i>	1 (0.6)	1 (0.7)		2 (0.6)
<i>Emtricitabine (J05AF09)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Nevirapine (J05AG01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Nucleoside and nucleotide reverse transcriptase inhibitors, combinations (J05AF30)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Raltegravir (J05AX08)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Ribavirin (J05AB04)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Valganciclovir (J05AB14)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Other beta-lactam antibacterials (J01D)	1 (0.6)	6 (4.1)		7 (2.0)
<i>Cefpodoxime (J01DD13)</i>	1 (0.6)	2 (1.4)		3 (0.9)
<i>Ceftazidime (J01DD02)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Cefixime (J01DD08)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Cefotaxime (J01DD01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Cefradine (J01DB09)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Ceftriaxone (J01DD04)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Macrolides, lincosamides and streptogramins (J01F)	0 (0.0)	4 (2.7)		4 (1.2)
<i>Azithromycin (J01FA10)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Erythromycin (J01FA01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Roxithromycin (J01FA06)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Telithromycin (J01FA15)</i>	0 (0.0)	1 (0.7)		1 (0.3)

	Acute drug overdose n = 164	Exposed to drugs n = 147	Not exposed to drugs n = 36	Total n = 347
Aminoglycoside antibacterials (J01G)	0 (0.0)	3 (2.0)		3 (0.9)
<i>Amikacin (J01GB06)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Gentamicin (J01GB03)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Antimycotics for systemic use (J02A)	0 (0.0)	3 (2.0)		3 (0.9)
<i>Fluconazole (J02AC01)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Caspofungin (J02AX04)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Other antibacterials (J01X)	1 (0.6)	2 (1.4)		3 (0.9)
<i>Metronidazole (J01XD01)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<i>Nitrofurantoin (J01XE01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Vancomycin (J01XA01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Sulfonamides and trimethoprim (J01E)	0 (0.0)	3 (2.0)		3 (0.9)
<i>Sulfamethoxazole and trimethoprim (J01EE01)</i>	0 (0.0)	3 (2.0)		3 (0.9)
Quinolone antibacterials (J01M)	0 (0.0)	2 (1.4)		2 (0.6)
<i>Ciprofloxacin (J01MA02)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Ofloxacin (J01MA01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Bacterial and viral vaccines, combined (J07C)	0 (0.0)	1 (0.7)		1 (0.3)
<b>Musculo-skeletal system (M)</b>	<b>25 (15.2)</b>	<b>25 (17.0)</b>		<b>50 (14.4)</b>
Antiinflammatory and antirheumatic products, non-steroids (M01A)	18 (11.0)	18 (12.2)		36 (10.4)
<i>Ibuprofen (M01AE01)</i>	7 (4.3)	8 (5.4)		15 (4.3)
<i>Ketoprofen (M01AE03)</i>	2 (1.2)	3 (2.0)		5 (1.4)
<i>Diclofenac (M01AB05)</i>	2 (1.2)	1 (0.7)		3 (0.9)
<i>Celecoxib (M01AH01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Diclofenac, combinations (M01AB55)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Meloxicam (M01AC06)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Naproxen (M01AE02)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<i>Niflumic acid (M01AX02)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Nimesulide (M01AX17)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Piascledine (M01AX26)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Piroxicam (M01AC01)</i>	1 (0.6)	0 (0.0)		1 (0.3)
Muscle relaxants, centrally acting agents (M03B)	7 (4.3)	3 (2.0)		10 (2.9)
<i>Tetrazepam (M03BX07)</i>	5 (3.0)	2 (1.4)		7 (2.0)
<i>Baclofen (M03BX01)</i>	1 (0.6)	1 (0.7)		2 (0.6)
<i>Thiocolchicoside (M03BX05)</i>	1 (0.6)	0 (0.0)		1 (0.3)
Antigout preparations (M04A)	7 (4.3)	3 (2.0)		10 (2.9)
<i>Allopurinol (M04AA01)</i>	5 (3.0)	2 (1.4)		7 (2.0)
Drugs affecting bone structure and mineralization (M05B)	0 (0.0)	2 (1.4)		2 (0.6)
<i>Risedronic acid (M05BA07)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Strontium ranelate (M05BX03)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Muscle relaxants, directly acting agents (M03C)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Dantrolene (M03CA01)</i>	0 (0.0)	1 (0.7)		1 (0.3)

	Acute drug overdose n = 164	Exposed to drugs n = 147	Not exposed to drugs n = 36	Total n = 347
Muscle relaxants, peripherally acting agents (M03A)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Rocuronium bromide (M03AC09)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Other drugs for disorders of the musculo-skeletal system (M09A)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Chondrocytes, autologous (M09AX02)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Specific antirheumatic (M01C)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Penicillamine (M01CC01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<b>Cardiovascular system (C)</b>	<b>16 (9.8)</b>	<b>24 (16.3)</b>		<b>40 (11.5)</b>
Lipid modifying agents, plain (C10A)	6 (3.7)	11 (7.5)		17 (4.9)
<i>Atorvastatin (C10AA05)</i>	3 (1.8)	6 (4.1)		9 (2.6)
<i>Fenofibrate (C10AB05)</i>	2 (1.2)	0 (0.0)		2 (0.6)
<i>Simvastatin (C10AA01)</i>	1 (0.6)	1 (0.7)		2 (0.6)
<i>Colestyramine (C10AC01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Pravastatin (C10AA03)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Rosuvastatin (C10AA07)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Selective calcium channel blockers with mainly vascular effects (C08C)	3 (1.8)	7 (4.8)		10 (2.9)
<i>Lercanidipine (C08CA13)</i>	1 (0.6)	3 (2.0)		4 (1.2)
<i>Amlodipine (C08CA01)</i>	1 (0.6)	2 (1.4)		3 (0.9)
<i>Nicardipine (C08CA04)</i>	1 (0.6)	1 (0.7)		2 (0.6)
<i>Manidipine (C08CA11)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Angiotensin ii antagonists, plain (C09C)	3 (1.8)	6 (4.1)		9 (2.6)
<i>Losartan (C09CA01)</i>	0 (0.0)	4 (2.7)		4 (1.2)
<i>Irbesartan (C09CA04)</i>	2 (1.2)	0 (0.0)		2 (0.6)
<i>Candesartan (C09CA06)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<i>Olmesartan medoxomil (C09CA08)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Valsartan (C09CA03)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Beta blocking agents (C07A)	3 (1.8)	5 (3.4)		8 (2.3)
<i>Atenolol (C07AB03)</i>	2 (1.2)	3 (2.0)		5 (1.4)
<i>Propranolol (C07AA05)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Sotalol (C07AA07)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<i>Nebivolol (C07AB12)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Ace inhibitors, plain (C09A)	2 (1.2)	2 (1.4)		4 (1.2)
<i>Moexipril (C09AA13)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<i>Perindopril (C09AA04)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Ramipril (C09AA05)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Ace inhibitors, combinations (C09B)	1 (0.6)	2 (1.4)		3 (0.9)
<i>Perindopril and diuretics (C09BA04)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Ramipril and diuretics (C09BA05)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Trandolapril and verapamil (C09BB10)</i>	1 (0.6)	0 (0.0)		1 (0.3)
Angiotensin ii antagonists, combinations (C09D)	2 (1.2)	0 (0.0)		2 (0.6)



	Acute drug overdose n = 164	Exposed to drugs n = 147	Not exposed to drugs n = 36	Total n = 347
<i>Olmesartan medoxomil and amlodipine (C09DB02)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<i>Olmesartan medoxomil and diuretics (C09DA08)</i>	1 (0.6)	0 (0.0)		1 (0.3)
Antiadrenergic agents, centrally acting (C02A)	1 (0.6)	1 (0.7)		2 (0.6)
<i>Moxonidine (C02AC05)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<i>Rilmenidine (C02AC06)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Antiarrhythmics, class i and iii (C01B)	1 (0.6)	1 (0.7)		2 (0.6)
<i>Amiodarone (C01BD01)</i>	1 (0.6)	1 (0.7)		2 (0.6)
Capillary stabilizing agents (C05C)	1 (0.6)	1 (0.7)		2 (0.6)
<i>Troxerutin, combinations (C05CA54)</i>	1 (0.6)	0 (0.0)		1 (0.3)
High-ceiling diuretics (C03C)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Furosemide (C03CA01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Low-ceiling diuretics, excl. thiazides (C03B)	1 (0.6)	0 (0.0)		1 (0.3)
<i>Indapamide (C03BA11)</i>	1 (0.6)	0 (0.0)		1 (0.3)
Peripheral vasodilators (C04A)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Naftidrofuryl (C04AX21)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Potassium-sparing agents (C03D)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Spironolactone (C03DA01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Vasodilators used in cardiac diseases (C01D)	1 (0.6)	0 (0.0)		1 (0.3)
<i>Heptaminol (C01DX08)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<b>Respiratory system (R)</b>	<b>13 (7.9)</b>	<b>19 (12.9)</b>		<b>32 (9.2)</b>
Antihistamines for systemic use (R06A)	6 (3.7)	8 (5.4)		14 (4.0)
<i>Alimemazine (R06AD01)</i>	5 (3.0)	1 (0.7)		6 (1.7)
<i>Desloratadine (R06AX27)</i>	0 (0.0)	3 (2.0)		3 (0.9)
<i>Oxmemazine (R06AD08)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Cetirizine (R06AE07)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Dexchlorpheniramine (R06AB02)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Loratadine (R06AX13)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Adrenergics, inhalants (R03A)	5 (3.0)	6 (4.1)		11 (3.2)
<i>Salbutamol (R03AC02)</i>	4 (2.4)	3 (2.0)		7 (2.0)
<i>Formoterol and budesonide (R03AK07)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Terbutaline (R03AC03)</i>	1 (0.6)	1 (0.7)		2 (0.6)
<i>Formoterol (R03AC13)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Salmeterol and fluticasone (R03AK06)</i>	1 (0.6)	0 (0.0)		1 (0.3)
Other drugs for obstructive airway diseases, inhalants (R03B)	1 (0.6)	3 (2.0)		4 (1.2)
<i>Budesonide (R03BA02)</i>	1 (0.6)	1 (0.7)		2 (0.6)
<i>Fluticasone (R03BA05)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Ipratropium bromide (R03BB01)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<i>Tiotropium bromide (R03BB04)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Other systemic drugs for obstructive airway diseases (R03D)	0 (0.0)	4 (2.7)		4 (1.2)

	Acute drug overdose n = 164	Exposed to drugs n = 147	Not exposed to drugs n = 36	Total n = 347
<i>Fenspiride (R03DX03)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Montelukast (R03DC03)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Theophylline (R03DA04)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Cough suppressants, excl. combinations with expectorants (R05D)	2 (1.2)	1 (0.7)		3 (0.9)
<i>Combinations (R05DA20)</i>	2 (1.2)	0 (0.0)		2 (0.6)
<i>Pholcodine (R05DA08)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Expectorants, excl. combinations with cough suppressants (R05C)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Acetylcysteine (R05CB01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Other cold combination preparations (R05X)	0 (0.0)	1 (0.7)		1 (0.3)
<b>Systemic hormonal preparations (excluded sex hormones and insulines) (H)</b>	<b>7 (4.3)</b>	<b>14 (9.5)</b>		<b>21 (6.1)</b>
Corticosteroids for systemic use, plain (H02A)	4 (2.4)	7 (4.8)		11 (3.2)
<i>Prednisolone (H02AB06)</i>	2 (1.2)	2 (1.4)		4 (1.2)
<i>Prednisone (H02AB07)</i>	2 (1.2)	2 (1.4)		4 (1.2)
<i>Methylprednisolone (H02AB04)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Betamethasone (H02AB01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Thyroid preparations (H03A)	3 (1.8)	6 (4.1)		9 (2.6)
<i>Levothyroxine sodium (H03AA01)</i>	3 (1.8)	6 (4.1)		9 (2.6)
Hypothalamic hormones (H01C)	0 (0.0)	1 (0.7)		1 (0.3)
<b>Blood and blood forming organs (B)</b>	<b>4 (2.4)</b>	<b>16 (10.9)</b>		<b>20 (5.8)</b>
Antithrombotic agents (B01A)	3 (1.8)	12 (8.2)		15 (4.3)
<i>Acetylsalicylic acid (B01AC06)</i>	2 (1.2)	7 (4.8)		9 (2.6)
<i>Clopidogrel (B01AC04)</i>	1 (0.6)	3 (2.0)		4 (1.2)
<i>Fluindione (B01AA12)</i>	0 (0.0)	3 (2.0)		3 (0.9)
<i>Fondaparinux (B01AX05)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Nadroparin (B01AB06)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Vitamin k and other hemostatics (B02B)	0 (0.0)	2 (1.4)		2 (0.6)
<i>Phytomenadione (B02BA01)</i>	0 (0.0)	2 (1.4)		2 (0.6)
Blood and related products (B05A)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Albumin (B05AA01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Iron preparations (B03A)	1 (0.6)	0 (0.0)		1 (0.3)
<i>Ferrous sulfate (B03AA07)</i>	1 (0.6)	0 (0.0)		1 (0.3)
Vitamin b12 and folic acid (B03B)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Folic acid (B03BB01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<b>Genito urinary system and sex hormones (G)</b>	<b>6 (3.7)</b>	<b>13 (8.8)</b>		<b>19 (5.5)</b>
Hormonal contraceptives for systemic use (G03A)	4 (2.4)	6 (4.1)		10 (2.9)
<i>Levonorgestrel (G03AC03)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Levonorgestrel and estrogen (G03AA07)</i>	0 (0.0)	2 (1.4)		2 (0.6)
<i>Etonogestrel (G03AC08)</i>	1 (0.6)	0 (0.0)		1 (0.3)

	Acute drug overdose n = 164	Exposed to drugs n = 147	Not exposed to drugs n = 36	Total n = 347
<i>Gestodene and estrogen (G03AA10)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Progestogens (G03D)	1 (0.6)	4 (2.7)		5 (1.4)
<i>Nomegestrol (G03DB04)</i>	1 (0.6)	2 (1.4)		3 (0.9)
<i>Progesterone (G03DA04)</i>	0 (0.0)	2 (1.4)		2 (0.6)
Estrogens (G03C)	0 (0.0)	3 (2.0)		3 (0.9)
<i>Estradiol (G03CA03)</i>	0 (0.0)	3 (2.0)		3 (0.9)
Other urologicals, incl. antispasmodics (G04B)	1 (0.6)	1 (0.7)		2 (0.6)
<i>Solifenacin (G04BD08)</i>	1 (0.6)	1 (0.7)		2 (0.6)
Antiandrogens (G03H)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Cyproterone (G03HA01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Drugs used in benign prostatic hypertrophy (G04C)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Alfuzosin (G04CA01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Gonadotropins and other ovulation stimulants (G03G)	0 (0.0)	1 (0.7)		1 (0.3)
<b>Antineoplastic and immunomodulating agents (L)</b>	<b>1 (0.6)</b>	<b>7 (4.8)</b>		<b>8 (2.3)</b>
Immunosuppressants (L04A)	1 (0.6)	3 (2.0)		4 (1.2)
<i>Infliximab (L04AA12)</i>	1 (0.6)	1 (0.7)		2 (0.6)
<i>Etanercept (L04AB01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Leflunomide (L04AA13)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Methotrexate (L04AX03)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Tacrolimus (L04AD02)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Antimetabolites (L01B)	1 (0.6)	1 (0.7)		2 (0.6)
<i>Methotrexate (L01BA01)</i>	1 (0.6)	1 (0.7)		2 (0.6)
Alkylating agents (L01A)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Dacarbazine (L01AX04)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Cytotoxic antibiotics and related substances (L01D)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Doxorubicin (L01DB01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Immunostimulants (L03A)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Glatiramer acetate (L03AX13)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Other antineoplastic agents (L01X)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Imatinib (L01XE01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<b>Drugs</b>	<b>7 (4.3)</b>	<b>0 (0.0)</b>		<b>7 (2.0)</b>
Cannabis	6 (3.7)	0 (0.0)		6 (1.7)
Ecstasy	2 (1.2)	0 (0.0)		2 (0.6)
Cocaine	1 (0.6)	0 (0.0)		1 (0.3)
LSA	1 (0.6)	0 (0.0)		1 (0.3)
Mushrooms	1 (0.6)	0 (0.0)		1 (0.3)
<b>Antiparasitic products, insecticides and repellents (P)</b>	<b>1 (0.6)</b>	<b>3 (2.0)</b>		<b>4 (1.2)</b>

	Acute drug overdose n = 164	Exposed to drugs n = 147	Not exposed to drugs n = 36	Total n = 347
Antimalarials (P01B)	0 (0.0)	2 (1.4)		2 (0.6)
<i>Hydroxychloroquine (P01BA02)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Proguanil, combinations (P01BB51)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Antinematodal agents (P02C)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Albendazole (P02CA03)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<i>Antitrematodals (P02B)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<b>Dermatologicals (D)</b>	<b>1 (0.6)</b>	<b>3 (2.0)</b>		<b>4 (1.2)</b>
Antifungals for systemic use (D01B)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Terbinafine (D01BA02)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Corticosteroids, other combinations (D07X)	0 (0.0)	1 (0.7)		1 (0.3)
<i>Hydrocortisone (D07XA01)</i>	0 (0.0)	1 (0.7)		1 (0.3)
Corticosteroids, plain (D07A)	0 (0.0)	1 (0.7)		1 (0.3)
Other dermatological preparations (D11A)	1 (0.6)	0 (0.0)		1 (0.3)
<i>Minoxidil (D11AX01)</i>	1 (0.6)	0 (0.0)		1 (0.3)
<b>Homeopathy</b>	<b>1 (0.6)</b>	<b>2 (1.4)</b>		<b>3 (0.9)</b>
Homeopathy	0 (0.0)	1 (0.7)		1 (0.3)
Organic silicon	0 (0.0)	1 (1.2)		1 (0.4)
Sedatif PC	1 (0.8)	0 (0.0)		1 (0.4)
<b>Various (V)</b>	<b>0 (0.0)</b>	<b>3 (2.0)</b>		<b>3 (0.9)</b>
All other therapeutic products (V03A)	0 (0.0)	3 (2.0)		3 (0.9)
<i>Calcium folinate (V03AF03)</i>	0 (0.0)	1 (0.7)		1 (0.3)
<b>Food supplement</b>	<b>0 (0.0)</b>	<b>2 (1.4)</b>		<b>2 (0.6)</b>
Fortimel	0 (0.0)	1 (0.7)		1 (0.3)
Vitonic	0 (0.0)	1 (0.7)		1 (0.3)
<b>Herbal medicine</b>	<b>0 (0.0)</b>	<b>2 (1.4)</b>		<b>2 (0.6)</b>
Ginseng	0 (0.0)	1 (0.7)		1 (0.3)
Phytotherapy	0 (0.0)	1 (0.7)		1 (0.3)
<b>No ATC code</b>	<b>0 (0.0)</b>	<b>1 (0.7)</b>		<b>1 (0.3)</b>

**SALT-II - Table 20b: Paracetamol exposure of ALFT cases according to drug exposure in the 30 days prior to index date for the years 2005 to 2013**

	Acute drug overdose n = 164	Exposed to drugs n = 147	Not exposed to drugs n = 36	Total n = 347
<b>At least one exposure at paracetamol in the 30 days prior to index date, n (%)</b>				
<b>Paracetamol, plain and combinations</b>	<b>161 (98.2)</b>	<b>82 (55.8)</b>	<b>0 (0.0)</b>	<b>243 (70.0)</b>
Paracetamol (N02BE01)	138 (84.1)	73 (49.7)	0 (0.0)	211 (60.8)
Paracetamol, combinations excl. psycholeptics (N02BE51)	30 (18.3)	13 (8.8)	0 (0.0)	43 (12.4)
Paracetamol, combinations with psycholeptics (N02BE71)	2 (1.2)	2 (1.4)	0 (0.0)	4 (1.2)
Codeine, combinations excl. psycholeptics (N02AA59)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Tramadol, combinations (N02AX52)	6 (3.7)	0 (0.0)	0 (0.0)	6 (1.7)
<b>At least one overdose, n (%)</b>	<b>157 (95.7)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>157 (45.2)</b>
<b>At least one intentional overdose, n (%)</b>	<b>95 (57.9)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>95 (27.4)</b>
<b>At least one non-intentional overdose, n (%)</b>	<b>62 (37.8)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>62 (17.9)</b>

SALT-II - Table 21: Drug exposure of ALFT cases according to drug exposure in the 90 days prior to index date for the years 2005 to 2013

	Acute drug overdose n = 164	Exposed to drugs n = 157	Not exposed to drugs n = 26	Total n = 347
<b>At least one exposure at the following ATC codes in the 90 days prior to index date</b>	<b>164 (100.0)</b>	<b>157 (100.0)</b>	<b>0 (0.0)</b>	<b>321 (92.5)</b>
<b>Nervous system (N)</b>	<b>163 (99.4)</b>	<b>109 (69.4)</b>	<b>0 (0.0)</b>	<b>272 (78.4)</b>
Other analgesics and antipyretics (N02B)	158 (96.3)	90 (57.3)	0 (0.0)	248 (71.5)
<i>Paracetamol (N02BE01)</i>	138 (84.1)	77 (49.0)	0 (0.0)	215 (62.0)
<i>Paracetamol, combinations excl. psycholeptics (N02BE51)</i>	31 (18.9)	13 (8.3)	0 (0.0)	44 (12.7)
<i>Acetylsalicylic acid (N02BA01)</i>	2 (1.2)	11 (7.0)	0 (0.0)	13 (3.7)
<i>Paracetamol, combinations with psycholeptics (N02BE71)</i>	2 (1.2)	2 (1.3)	0 (0.0)	4 (1.2)
<i>Nefopam (N02BG06)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
Anxiolytics (N05B)	60 (36.6)	22 (14.0)	0 (0.0)	82 (23.6)
<i>Bromazepam (N05BA08)</i>	14 (8.5)	4 (2.5)	0 (0.0)	18 (5.2)
<i>Oxazepam (N05BA04)</i>	11 (6.7)	5 (3.2)	0 (0.0)	16 (4.6)
<i>Alprazolam (N05BA12)</i>	13 (7.9)	1 (0.6)	0 (0.0)	14 (4.0)
<i>Hydroxyzine (N05BB01)</i>	5 (3.0)	4 (2.5)	0 (0.0)	9 (2.6)
<i>Przepam (N05BA11)</i>	4 (2.4)	3 (1.9)	0 (0.0)	7 (2.0)
<i>Clobazam (N05BA09)</i>	3 (1.8)	2 (1.3)	0 (0.0)	5 (1.4)
<i>Diazepam (N05BA01)</i>	4 (2.4)	1 (0.6)	0 (0.0)	5 (1.4)
<i>Etifoxine (N05BX03)</i>	3 (1.8)	1 (0.6)	0 (0.0)	4 (1.2)
<i>Potassium clorazepate (N05BA05)</i>	2 (1.2)	2 (1.3)	0 (0.0)	4 (1.2)
<i>Lorazepam (N05BA06)</i>	1 (0.6)	2 (1.3)	0 (0.0)	3 (0.9)
<i>Meprobamate, combinations (N05BC51)</i>	2 (1.2)	1 (0.6)	0 (0.0)	3 (0.9)
<i>Meprobamate (N05BC01)</i>	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
Antidepressants (N06A)	43 (26.2)	17 (10.8)	0 (0.0)	60 (17.3)
<i>Escitalopram (N06AB10)</i>	11 (6.7)	1 (0.6)	0 (0.0)	12 (3.5)
<i>Paroxetine (N06AB05)</i>	8 (4.9)	2 (1.3)	0 (0.0)	10 (2.9)
<i>Venlafaxine (N06AX16)</i>	4 (2.4)	5 (3.2)	0 (0.0)	9 (2.6)
<i>Amitriptyline (N06AA09)</i>	4 (2.4)	3 (1.9)	0 (0.0)	7 (2.0)
<i>Fluoxetine (N06AB03)</i>	4 (2.4)	0 (0.0)	0 (0.0)	4 (1.2)
<i>Citalopram (N06AB04)</i>	2 (1.2)	1 (0.6)	0 (0.0)	3 (0.9)
<i>Mianserin (N06AX03)</i>	1 (0.6)	2 (1.3)	0 (0.0)	3 (0.9)
<i>Sertraline (N06AB06)</i>	3 (1.8)	0 (0.0)	0 (0.0)	3 (0.9)
<i>Iproniazide (N06AF05)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Mirtazapine (N06AX1)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Agomelatine (N06AX22)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Clomipramine (N06AA04)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Duloxetine (N06AX21)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Milnacipran (N06AX17)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Moclobemide (N06AG02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Tianeptine (N06AX14)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Trimipramine (N06AA06)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)

	Acute drug overdose n = 164	Exposed to drugs n = 157	Not exposed to drugs n = 26	Total n = 347
Antiepileptics (N03A)	19 (11.6)	19 (12.1)	0 (0.0)	38 (11.0)
<i>Valproic acid (N03AG01)</i>	7 (4.3)	5 (3.2)	0 (0.0)	12 (3.5)
<i>Clonazepam (N03AE01)</i>	5 (3.0)	4 (2.5)	0 (0.0)	9 (2.6)
<i>Carbamazepine (N03AF01)</i>	3 (1.8)	5 (3.2)	0 (0.0)	8 (2.3)
<i>Levetiracetam (N03AX14)</i>	3 (1.8)	3 (1.9)	0 (0.0)	6 (1.7)
<i>Pregabalin (N03AX16)</i>	2 (1.2)	3 (1.9)	0 (0.0)	5 (1.4)
<i>Lamotrigine (N03AX09)</i>	1 (0.6)	3 (1.9)	0 (0.0)	4 (1.2)
<i>Gabapentin (N03AX12)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Phenobarbital (N03AA02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Phenytoin (N03AB02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Topiramate (N03AX11)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Valpromide (N03AG02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Hypnotics and sedatives (N05C)	28 (17.1)	6 (3.8)	0 (0.0)	34 (9.8)
<i>Zolpidem (N05CF02)</i>	16 (9.8)	1 (0.6)	0 (0.0)	17 (4.9)
<i>Zopiclone (N05CF01)</i>	7 (4.3)	3 (1.9)	0 (0.0)	10 (2.9)
<i>Lormetazepam (N05CD06)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Nitrazepam (N05CD02)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Opioids (N02A)	18 (11.0)	5 (3.2)	0 (0.0)	23 (6.6)
<i>Tramadol, combinations (N02AX52)</i>	7 (4.3)	0 (0.0)	0 (0.0)	7 (2.0)
<i>Tramadol (N02AX02)</i>	4 (2.4)	2 (1.3)	0 (0.0)	6 (1.7)
<i>Morphine (N02AA01)</i>	3 (1.8)	1 (0.6)	0 (0.0)	4 (1.2)
<i>Dextropropoxyphene (N02AC04)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Dextropropoxyphene, comb. excl. psycholeptics (N02AC54)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Dihydrocodeine (N02AA08)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Fentanyl (N02AB03)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Oxycodone (N02AA05)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Antipsychotics (N05A)	10 (6.1)	5 (3.2)	0 (0.0)	15 (4.3)
<i>Cyamemazine (N05AA06)</i>	2 (1.2)	2 (1.3)	0 (0.0)	4 (1.2)
<i>Risperidone (N05AX08)</i>	3 (1.8)	1 (0.6)	0 (0.0)	4 (1.2)
<i>Olanzapine (N05AH03)</i>	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
<i>Tiapride (N05AL03)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Amisulpride (N05AL05)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Levomepromazine (N05AA02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Loxapine (N05AH01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Periciazine (N05AC01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Zuclopenthixol (N05AF05)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Drugs used in addictive disorders (N07B)	6 (3.7)	2 (1.3)	0 (0.0)	8 (2.3)
<i>Disulfiram (N07BB01)</i>	2 (1.2)	2 (1.3)	0 (0.0)	4 (1.2)
<i>Acamprosate (N07BB03)</i>	3 (1.8)	0 (0.0)	0 (0.0)	3 (0.9)
<i>Buprenorphine (N07BC01)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
Antimigraine preparations (N02C)	3 (1.8)	3 (1.9)	0 (0.0)	6 (1.7)
<i>Eletriptan (N02CC06)</i>	2 (1.2)	1 (0.6)	0 (0.0)	3 (0.9)

	Acute drug overdose n = 164	Exposed to drugs n = 157	Not exposed to drugs n = 26	Total n = 347
<i>Almotriptan (N02CC05)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Dihydroergotamine (N02CA01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Pizotifen (N02CX01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Zolmitriptan (N02CC03)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Anticholinergic agents (N04A)	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Biperiden (N04AA02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Tropatepine (N04AA12)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Anesthetics, general (N01A)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Desflurane (N01AB07)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Ketamine (N01AX03)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Sufentanil (N01AH03)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Thiopental (N01AF03)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Antivertigo preparations (N07C)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Acetylleucine (N07CA04)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Dopaminergic agents (N04B)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Levodopa (N04BA01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Piribedil (N04BC08)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Psychostimulants, agents used for adhd and nootropics (N06B)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Amphetamine (N06BA01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Alimentary tract and metabolism (A)</b>	<b>21 (12.8)</b>	<b>41 (26.1)</b>	<b>0 (0.0)</b>	<b>62 (17.9)</b>
Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) (A02B)	10 (6.1)	12 (7.6)	0 (0.0)	22 (6.3)
<i>Lansoprazole (A02BC03)</i>	4 (2.4)	2 (1.3)	0 (0.0)	6 (1.7)
<i>Omeprazole (A02BC01)</i>	3 (1.8)	3 (1.9)	0 (0.0)	6 (1.7)
<i>Esomeprazole (A02BC05)</i>	3 (1.8)	2 (1.3)	0 (0.0)	5 (1.4)
<i>Pantoprazole (A02BC02)</i>	0 (0.0)	3 (1.9)	0 (0.0)	3 (0.9)
<i>Rabeprazole (A02BC04)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Propulsives (A03F)	3 (1.8)	8 (5.1)	0 (0.0)	11 (3.2)
<i>Domperidone (A03FA03)</i>	1 (0.6)	6 (3.8)	0 (0.0)	7 (2.0)
<i>Metoclopramide (A03FA01)</i>	2 (1.2)	3 (1.9)	0 (0.0)	5 (1.4)
Blood glucose lowering drugs, excl. insulins (A10B)	2 (1.2)	8 (5.1)	0 (0.0)	10 (2.9)
<i>Metformin (A10BA02)</i>	1 (0.6)	5 (3.2)	0 (0.0)	6 (1.7)
<i>Acarbose (A10BF01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Glibenclamide (A10BB01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Gliclazide (A10BB09)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Glimepiride (A10BB12)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Metformin and sitagliptin (A10BD07)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Repaglinide (A10BX02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Sitagliptin (A10BH01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Drugs for functional bowel disorders (A03A)	4 (2.4)	6 (3.8)	0 (0.0)	10 (2.9)
<i>Phloroglucinol (A03AX12)</i>	3 (1.8)	4 (2.5)	0 (0.0)	7 (2.0)



	Acute drug overdose n = 164	Exposed to drugs n = 157	Not exposed to drugs n = 26	Total n = 347
<i>Trimebutine (A03AA05)</i>	1 (0.6)	2 (1.3)	0 (0.0)	3 (0.9)
<i>Alverine, combinations (A03AX58)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Antipropulsives (A07D)	4 (2.4)	4 (2.5)	0 (0.0)	8 (2.3)
<i>Loperamide (A07DA03)</i>	4 (2.4)	4 (2.5)	0 (0.0)	8 (2.3)
Antacids (A02A)	0 (0.0)	7 (4.5)	0 (0.0)	7 (2.0)
<i>Aluminium hydroxide (A02AB01)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Ordinary salt combinations and antifatulents (A02AF02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Laxatives (A06A)	1 (0.6)	4 (2.5)	0 (0.0)	5 (1.4)
<i>Bisacodyl (A06AB02)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Ispaghula, combinations (A06AC51)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Lactulose (A06AD11)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Liquid paraffin (A06AA01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Macrogol (A06AD15)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Senna glycosides, combinations (A06AB56)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Antiemetics and antinauseants (A04A)	2 (1.2)	2 (1.3)	0 (0.0)	4 (1.2)
<i>Metopimazine (A04AD05)</i>	2 (1.2)	1 (0.6)	0 (0.0)	3 (0.9)
Insulins and analogues (A10A)	1 (0.6)	2 (1.3)	0 (0.0)	3 (0.9)
<i>Insulin (human) (A10AB01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Insulin glargine (A10AE04)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Other drugs for acid related disorders (A02X)	1 (0.6)	2 (1.3)	0 (0.0)	3 (0.9)
Vitamin a and d, incl. combinations of the two (A11C)	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Calcifediol (A11CC06)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Colecalciferol (A11CC05)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Bile therapy (A05A)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Ursodeoxycholic acid (A05AA02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Calcium (A12A)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Intestinal antiinfectives (A07A)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Nifuroxazide (A07AX03)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Intestinal antiinflammatory agents (A07E)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Sulfasalazine (A07EC01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Multivitamins, combinations (A11A)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Multivitamins and other minerals, incl. combinations (A11AA03)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Other antidiarrheals (A07X)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Racecadotril (A07XA04)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Potassium (A12B)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Potassium chloride (A12BA01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Vitamin b1, plain and in combination with vitamin b6 and b12 (A11D)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Antiinfectives for systemic use (J)</b>	<b>7 (4.3)</b>	<b>48 (30.6)</b>	<b>0 (0.0)</b>	<b>55 (15.9)</b>
Drugs for treatment of tuberculosis (J04A)	0 (0.0)	19 (12.1)	0 (0.0)	19 (5.5)

	Acute drug overdose n = 164	Exposed to drugs n = 157	Not exposed to drugs n = 26	Total n = 347
<i>Rifampicin, pyrazinamide, ethambutol and isoniazid (J04AM06)</i>	0 (0.0)	11 (7.0)	0 (0.0)	11 (3.2)
<i>Rifampicin and isoniazid (J04AM02)</i>	0 (0.0)	6 (3.8)	0 (0.0)	6 (1.7)
<i>Ethambutol (J04AK02)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Isoniazid (J04AC01)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Pyrazinamide (J04AK01)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Rifampicin (J04AB02)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Rifampicin, pyrazinamide and isoniazid (J04AM05)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Rifabutin (J04AB04)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Beta-lactam antibacterials, penicillins (J01C)	4 (2.4)	13 (8.3)	0 (0.0)	17 (4.9)
<i>Amoxicillin (J01CA04)</i>	2 (1.2)	7 (4.5)	0 (0.0)	9 (2.6)
<i>Amoxicillin and enzyme inhibitor (J01CR02)</i>	1 (0.6)	4 (2.5)	0 (0.0)	5 (1.4)
<i>Piperacillin and enzyme inhibitor (J01CR05)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Cloxacillin (J01CF02)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Direct acting antivirals (J05A)	1 (0.6)	13 (8.3)	0 (0.0)	14 (4.0)
<i>Tenofovir disoproxil and emtricitabine (J05AR03)</i>	0 (0.0)	5 (3.2)	0 (0.0)	5 (1.4)
<i>Efavirenz (J05AG03)</i>	0 (0.0)	4 (2.5)	0 (0.0)	4 (1.2)
<i>Emtricitabine, tenofovir disoproxil and efavirenz (J05AR06)</i>	0 (0.0)	3 (1.9)	0 (0.0)	3 (0.9)
<i>Ritonavir (J05AE03)</i>	0 (0.0)	3 (1.9)	0 (0.0)	3 (0.9)
<i>Aciclovir (J05AB01)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Atazanavir (J05AE08)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Nucleoside and nucleotide reverse transcriptase inhibitors, combinations (J05AF30)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Tenofovir disoproxil (J05AF07)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Valaciclovir (J05AB11)</i>	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
<i>Didanosine (J05AF02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Emtricitabine (J05AF09)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Nevirapine (J05AG01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Raltegravir (J05AX08)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Ribavirin (J05AB04)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Valganciclovir (J05AB14)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Other beta-lactam antibacterials (J01D)	1 (0.6)	6 (3.8)	0 (0.0)	7 (2.0)
<i>Cefpodoxime (J01DD13)</i>	1 (0.6)	2 (1.3)	0 (0.0)	3 (0.9)
<i>Ceftazidime (J01DD02)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Cefixime (J01DD08)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Cefotaxime (J01DD01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Cefradine (J01DB09)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Ceftriaxone (J01DD04)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Macrolides, lincosamides and streptogramins (J01F)	0 (0.0)	4 (2.5)	0 (0.0)	4 (1.2)
<i>Azithromycin (J01FA10)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Erythromycin (J01FA01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Roxithromycin (J01FA06)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Telithromycin (J01FA15)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Aminoglycoside antibacterials (J01G)	0 (0.0)	3 (1.9)	0 (0.0)	3 (0.9)

	Acute drug overdose n = 164	Exposed to drugs n = 157	Not exposed to drugs n = 26	Total n = 347
<i>Amikacin (J01GB06)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Gentamicin (J01GB03)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Antimycotics for systemic use (J02A)	0 (0.0)	3 (1.9)	0 (0.0)	3 (0.9)
<i>Fluconazole (J02AC01)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Caspofungin (J02AX04)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Other antibacterials (J01X)	1 (0.6)	2 (1.3)	0 (0.0)	3 (0.9)
<i>Metronidazole (J01XD01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Nitrofurantoin (J01XE01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Vancomycin (J01XA01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Sulfonamides and trimethoprim (J01E)	0 (0.0)	3 (1.9)	0 (0.0)	3 (0.9)
<i>Sulfamethoxazole and trimethoprim (J01EE01)</i>	0 (0.0)	3 (1.9)	0 (0.0)	3 (0.9)
Quinolone antibacterials (J01M)	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Ciprofloxacin (J01MA02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Ofloxacin (J01MA01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Bacterial and viral vaccines, combined (J07C)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<b>Musculo-skeletal system (M)</b>	<b>25 (15.2)</b>	<b>26 (16.6)</b>	<b>0 (0.0)</b>	<b>51 (14.7)</b>
Antiinflammatory and antirheumatic products, non-steroids (M01A)	18 (11.0)	19 (12.1)	0 (0.0)	37 (10.7)
<i>Ibuprofen (M01AE01)</i>	7 (4.3)	8 (5.1)	0 (0.0)	15 (4.3)
<i>Ketoprofen (M01AE03)</i>	2 (1.2)	3 (1.9)	0 (0.0)	5 (1.4)
<i>Diclofenac (M01AB05)</i>	2 (1.2)	1 (0.6)	0 (0.0)	3 (0.9)
<i>Nimesulide (M01AX17)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Celecoxib (M01AH01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Diclofenac, combinations (M01AB55)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Meloxicam (M01AC06)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Naproxen (M01AE02)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Niflumic acid (M01AX02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Piascledine (M01AX26)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Piroxicam (M01AC01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Muscle relaxants, centrally acting agents (M03B)	7 (4.3)	3 (1.9)	0 (0.0)	10 (2.9)
<i>Tetrazepam (M03BX07)</i>	5 (3.0)	2 (1.3)	0 (0.0)	7 (2.0)
<i>Baclofen (M03BX01)</i>	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
<i>Thiocolchicoside (M03BX05)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Antigout preparations (M04A)</i>	2 (1.2)	1 (0.6)	0 (0.0)	3 (0.9)
<i>Allopurinol (M04AA01)</i>	2 (1.2)	1 (0.6)	0 (0.0)	3 (0.9)
Drugs affecting bone structure and mineralization (M05B)	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Risedronic acid (M05BA07)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Strontium ranelate (M05BX03)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Muscle relaxants, directly acting agents (M03C)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Dantrolene (M03CA01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Muscle relaxants, peripherally acting agents (M03A)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Rocuronium bromide (M03AC09)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)

	Acute drug overdose n = 164	Exposed to drugs n = 157	Not exposed to drugs n = 26	Total n = 347
Other drugs for disorders of the musculo-skeletal system (M09A)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Chondrocytes, autologous (M09AX02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Specific antirheumatic agents (M01C)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Penicillamine (M01CC01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<b>Cardiovascular system (C)</b>	<b>17 (10.4)</b>	<b>25 (15.9)</b>	<b>0 (0.0)</b>	<b>42 (12.1)</b>
Lipid modifying agents, plain (C10A)	7 (4.3)	11 (7.0)	0 (0.0)	18 (5.2)
<i>Atorvastatin (C10AA05)</i>	3 (1.8)	6 (3.8)	0 (0.0)	9 (2.6)
<i>Fenofibrate (C10AB05)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Rosuvastatin (C10AA07)</i>	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
<i>Simvastatin (C10AA01)</i>	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
<i>Colestyramine (C10AC01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Pravastatin (C10AA03)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Beta blocking agents (C07A)	4 (2.4)	6 (3.8)	0 (0.0)	10 (2.9)
<i>Atenolol (C07AB03)</i>	2 (1.2)	3 (1.9)	0 (0.0)	5 (1.4)
<i>Nebivolol (C07AB12)</i>	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
<i>Propranolol (C07AA05)</i>	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
<i>Sotalol (C07AA07)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Selective calcium channel blockers with mainly vascular effects (C08C)	3 (1.8)	7 (4.5)	0 (0.0)	10 (2.9)
<i>Lercanidipine (C08CA13)</i>	1 (0.6)	3 (1.9)	0 (0.0)	4 (1.2)
<i>Amlodipine (C08CA01)</i>	1 (0.6)	2 (1.3)	0 (0.0)	3 (0.9)
<i>Nicardipine (C08CA04)</i>	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
<i>Manidipine (C08CA11)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Angiotensin ii antagonists, plain (C09C)	3 (1.8)	6 (3.8)	0 (0.0)	9 (2.6)
<i>Losartan (C09CA01)</i>	0 (0.0)	4 (2.5)	0 (0.0)	4 (1.2)
<i>Irbesartan (C09CA04)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Candesartan (C09CA06)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Olmesartan medoxomil (C09CA08)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Valsartan (C09CA03)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Ace inhibitors, plain (C09A)	2 (1.2)	3 (1.9)	0 (0.0)	5 (1.4)
<i>Lisinopril (C09AA03)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Moexipril (C09AA13)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Perindopril (C09AA04)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Ramipril (C09AA05)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Ace inhibitors, combinations (C09B)	1 (0.6)	2 (1.3)	0 (0.0)	3 (0.9)
<i>Perindopril and diuretics (C09BA04)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Ramipril and diuretics (C09BA05)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Trandolapril and verapamil (C09BB10)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Angiotensin ii antagonists, combinations (C09D)	2 (1.2)	1 (0.6)	0 (0.0)	3 (0.9)
<i>Olmesartan medoxomil and amlodipine (C09DB02)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Olmesartan medoxomil and diuretics (C09DA08)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)

	Acute drug overdose n = 164	Exposed to drugs n = 157	Not exposed to drugs n = 26	Total n = 347
<i>Valsartan and diuretics (C09DA03)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Capillary stabilizing agents (C05C)	2 (1.2)	1 (0.6)	0 (0.0)	3 (0.9)
<i>Troxerutin, combinations (C05CA54)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Antiadrenergic agents, centrally acting (C02A)	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
<i>Moxonidine (C02AC05)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Rilmenidine (C02AC06)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Antiarrhythmics, class i and iii (C01B)	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
<i>Amiodarone (C01BD01)</i>	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
Vasodilators used in cardiac diseases (C01D)	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
<i>Glyceryl trinitrate (C01DA02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Heptaminol (C01DX08)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
High-ceiling diuretics (C03C)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Furosemide (C03CA01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Low-ceiling diuretics, excl. thiazides (C03B)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Indapamide (C03BA11)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Peripheral vasodilators (C04A)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Naftidrofuryl (C04AX21)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Potassium-sparing agents (C03D)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Spironolactone (C03DA01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<b>Respiratory system (R)</b>	<b>13 (7.9)</b>	<b>22 (14.0)</b>	<b>0 (0.0)</b>	<b>35 (10.1)</b>
Antihistamines for systemic use (R06A)	6 (3.7)	11 (7.0)	0 (0.0)	17 (4.9)
<i>Alimemazine (R06AD01)</i>	5 (3.0)	1 (0.6)	0 (0.0)	6 (1.7)
<i>Desloratadine (R06AX27)</i>	0 (0.0)	4 (2.5)	0 (0.0)	4 (1.2)
<i>Oxomemazine (R06AD08)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Cetirizine (R06AE07)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Dexchlorpheniramine (R06AB02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Levocetirizine (R06AE09)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Loratadine (R06AX13)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Adrenergics, inhalants (R03A)	6 (3.7)	6 (3.8)	0 (0.0)	12 (3.5)
<i>Salbutamol (R03AC02)</i>	5 (3.0)	3 (1.9)	0 (0.0)	8 (2.3)
<i>Formoterol and budesonide (R03AK07)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Terbutaline (R03AC03)</i>	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
<i>Formoterol (R03AC13)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Salmeterol and fluticasone (R03AK06)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Other drugs for obstructive airway diseases, inhalants (R03B)	1 (0.6)	3 (1.9)	0 (0.0)	4 (1.2)
<i>Budesonide (R03BA02)</i>	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
<i>Fluticasone (R03BA05)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Ipratropium bromide (R03BB01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Tiotropium bromide (R03BB04)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Other systemic drugs for obstructive airway diseases (R03D)	0 (0.0)	4 (2.5)	0 (0.0)	4 (1.2)
<i>Fenspiride (R03DX03)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)

	Acute drug overdose n = 164	Exposed to drugs n = 157	Not exposed to drugs n = 26	Total n = 347
<i>Montelukast (R03DC03)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Theophylline (R03DA04)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Cough suppressants, excl. combinations with expectorants (R05D)	2 (1.2)	1 (0.6)	0 (0.0)	3 (0.9)
<i>Combinations (R05DA20)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Pholcodine (R05DA08)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Expectorants, excl. combinations with cough suppressants (R05C)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Acetylcysteine (R05CB01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Other cold combination preparations (R05X)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<b>Blood and blood forming organs (B)</b>	<b>4 (2.4)</b>	<b>18 (11.5)</b>	<b>0 (0.0)</b>	<b>22 (6.3)</b>
Antithrombotic agents (B01A)	3 (1.8)	14 (8.9)	0 (0.0)	17 (4.9)
<i>Acetylsalicylic acid (B01AC06)</i>	2 (1.2)	8 (5.1)	0 (0.0)	10 (2.9)
<i>Clopidogrel (B01AC04)</i>	1 (0.6)	4 (2.5)	0 (0.0)	5 (1.4)
<i>Fluindione (B01AA12)</i>	0 (0.0)	3 (1.9)	0 (0.0)	3 (0.9)
<i>Fondaparinux (B01AX05)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Nadroparin (B01AB06)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Vitamin k and other hemostatics (B02B)	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Phytomenadione (B02BA01)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
Blood and related products (B05A)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Albumin (B05AA01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Iron preparations (B03A)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Ferrous sulfate (B03AA07)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Vitamin b12 and folic acid (B03B)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Folic acid (B03BB01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<b>Systemic hormonal preparations (excluded sex hormones and insulines) (H)</b>	<b>7 (4.3)</b>	<b>15 (9.6)</b>	<b>0 (0.0)</b>	<b>22 (6.3)</b>
Corticosteroids for systemic use, plain (H02A)	4 (2.4)	8 (5.1)	0 (0.0)	12 (3.5)
<i>Prednisolone (H02AB06)</i>	2 (1.2)	2 (1.3)	0 (0.0)	4 (1.2)
<i>Prednisone (H02AB07)</i>	2 (1.2)	2 (1.3)	0 (0.0)	4 (1.2)
<i>Methylprednisolone (H02AB04)</i>	0 (0.0)	3 (1.9)	0 (0.0)	3 (0.9)
<i>Betamethasone (H02AB01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Thyroid preparations (H03A)	3 (1.8)	6 (3.8)	0 (0.0)	9 (2.6)
<i>Levothyroxine sodium (H03AA01)</i>	3 (1.8)	6 (3.8)	0 (0.0)	9 (2.6)
Hypothalamic hormones (H01C)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<b>Genito urinary system and sex hormones (G)</b>	<b>7 (4.3)</b>	<b>13 (8.3)</b>	<b>0 (0.0)</b>	<b>20 (5.8)</b>
Hormonal contraceptives for systemic use (G03A)	4 (2.4)	6 (3.8)	0 (0.0)	10 (2.9)
<i>Levonorgestrel (G03AC03)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Levonorgestrel and estrogen (G03AA07)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
<i>Etonogestrel (G03AC08)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Gestodene and estrogen (G03AA10)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Progestogens (G03D)	1 (0.6)	4 (2.5)	0 (0.0)	5 (1.4)

	Acute drug overdose n = 164	Exposed to drugs n = 157	Not exposed to drugs n = 26	Total n = 347
<i>Nomegestrol (G03DB04)</i>	1 (0.6)	2 (1.3)	0 (0.0)	3 (0.9)
<i>Progesterone (G03DA04)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
Estrogens (G03C)	0 (0.0)	4 (2.5)	0 (0.0)	4 (1.2)
<i>Estradiol (G03CA03)</i>	0 (0.0)	4 (2.5)	0 (0.0)	4 (1.2)
Other urologicals, incl. antispasmodics (G04B)	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
<i>Solifenacin (G04BD08)</i>	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
Antiandrogens (G03H)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Cyproterone (G03HA01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Drugs used in benign prostatic hypertrophy (G04C)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Alfuzosin (G04CA01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Gonadotropins and other ovulation stimulants (G03G)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Other sex hormones and modulators of the genital system (G03X)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Antineoplastic and immunomodulating agents (L)</b>	<b>1 (0.6)</b>	<b>8 (5.1)</b>	<b>0 (0.0)</b>	<b>9 (2.6)</b>
Immunosuppressants (L04A)	1 (0.6)	4 (2.5)	0 (0.0)	5 (1.4)
<i>Infliximab (L04AA12)</i>	1 (0.6)	2 (1.3)	0 (0.0)	3 (0.9)
<i>Etanercept (L04AB01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Leflunomide (L04AA13)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Methotrexate (L04AX03)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Tacrolimus (L04AD02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Antimetabolites (L01B)	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
<i>Methotrexate (L01BA01)</i>	1 (0.6)	1 (0.6)	0 (0.0)	2 (0.6)
Alkylating agents (L01A)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Dacarbazine (L01AX04)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Cytotoxic antibiotics and related substances (L01D)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Doxorubicin (L01DB01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Immunostimulants (L03A)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Glatiramer acetate (L03AX13)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Other antineoplastic agents (L01X)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Imatinib (L01XE01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<b>Drugs</b>	<b>9 (5.5)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>9 (2.6)</b>
Cannabis	8 (4.9)	0 (0.0)	0 (0.0)	8 (2.3)
Ecstasy	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
Cocaine	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
LSA	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Mushrooms	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Antiparasitic products, insecticides and repellents (P)</b>	<b>1 (0.6)</b>	<b>4 (2.5)</b>	<b>0 (0.0)</b>	<b>5 (1.4)</b>
Antimalarials (P01B)	0 (0.0)	3 (1.9)	0 (0.0)	3 (0.9)
<i>Proguanil, combinations (P01BB51)</i>	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)

	Acute drug overdose n = 164	Exposed to drugs n = 157	Not exposed to drugs n = 26	Total n = 347
<i>Hydroxychloroquine (P01BA02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Antinematodal agents (P02C)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Albendazole (P02CA03)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Antitrematodals (P02B)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Dermatologicals (D)</b>	<b>1 (0.6)</b>	<b>3 (1.9)</b>	<b>0 (0.0)</b>	<b>4 (1.2)</b>
Antifungals for systemic use (D01B)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Terbinafine (D01BA02)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Corticosteroids, other combinations (D07X)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<i>Hydrocortisone (D07XA01)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Corticosteroids, plain (D07A)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Other dermatological preparations (D11A)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Minoxidil (D11AX01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Homeopathy</b>	<b>1 (0.6)</b>	<b>3 (1.9)</b>	<b>0 (0.0)</b>	<b>4 (1.2)</b>
Homeopathy	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.6)
Organic silicon	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Sedatif PC	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Various (V)</b>	<b>0 (0.0)</b>	<b>3 (1.9)</b>	<b>0 (0.0)</b>	<b>3 (0.9)</b>
All other therapeutic products (V03A)	0 (0.0)	3 (1.9)	0 (0.0)	3 (0.9)
<i>Calcium folinate (V03AF03)</i>	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<b>Food supplement</b>	<b>0 (0.0)</b>	<b>2 (1.3)</b>	<b>0 (0.0)</b>	<b>2 (0.6)</b>
Fortimel	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Vitonic	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<b>Herbal medicine</b>	<b>0 (0.0)</b>	<b>2 (1.3)</b>	<b>0 (0.0)</b>	<b>2 (0.6)</b>
Ginseng	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Phytotherapy	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
<b>No ATC code</b>	<b>0 (0.0)</b>	<b>1 (0.6)</b>	<b>0 (0.0)</b>	<b>1 (0.3)</b>



**SALT-II - Table 21b: Paracetamol exposure of ALFT cases according to drug exposure in the 90 days prior to index date for the years 2005 to 2013**

	Acute drug overdose n = 164	Exposed to drugs n = 157	Not exposed to drugs n = 26	Total n = 347
<b>At least one exposure at paracetamol in the 90 days prior to index date, n (%)</b>				
<b>Paracetamol, plain and combinations</b>	<b>161 (98.2)</b>	<b>86 (54.8)</b>	<b>0 (0.0)</b>	<b>247 (71.1)</b>
Paracetamol (N02BE01)	138 (84.1)	77 (49.0)	0 (0.0)	215 (62.0)
Paracetamol, combinations excl. psycholeptics (N02BE51)	31 (18.9)	13 (8.3)	0 (0.0)	44 (12.7)
Paracetamol, combinations with psycholeptics (N02BE71)	2 (1.2)	2 (1.3)	0 (0.0)	4 (1.2)
Codeine, combinations excl. psycholeptics (N02AA59)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Tramadol, combinations (N02AX52)	6 (3.7)	0 (0.0)	0 (0.0)	6 (1.7)
<b>At least one overdose, n (%)</b>	<b>157 (95.7)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>157 (45.2)</b>
<b>At least one intentional overdose, n (%)</b>	<b>95 (57.9)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>95 (27.4)</b>
<b>At least one non-intentional overdose, n (%)</b>	<b>62 (37.8)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>62 (17.9)</b>

**SALT-II - Table 22: Drug exposure of ALFT cases according to drug exposure in the 15 days prior to index date for the years 2005 to 2013**

	Acute drug overdose n = 164	Exposed to drugs n = 139	Not exposed to drugs n = 44	Total n = 347
<b>At least one exposure at the following ATC codes in the 15 days prior to index date</b>	<b>164 (100.0)</b>	<b>139 (100.0)</b>	<b>1 (2.3)</b>	<b>304 (87.6)</b>
<b>Nervous system (N)</b>	<b>163 (99.4)</b>	<b>101 (72.7)</b>	<b>1 (2.3)</b>	<b>265 (76.4)</b>
Other analgesics and antipyretics (N02B)	158 (96.3)	84 (60.4)	1 (2.3)	243 (70.0)
<i>Paracetamol (N02BE01)</i>	138 (84.1)	72 (51.8)	1 (2.3)	211 (60.8)
<i>Paracetamol, combinations excl. psycholeptics (N02BE51)</i>	30 (18.3)	13 (9.4)	0 (0.0)	43 (12.4)
<i>Acetylsalicylic acid (N02BA01)</i>	1 (0.6)	9 (6.5)	0 (0.0)	10 (2.9)
<i>Paracetamol, combinations with psycholeptics (N02BE71)</i>	2 (1.2)	2 (1.4)	0 (0.0)	4 (1.2)
<i>Nefopam (N02BG06)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
Anxiolytics (N05B)	55 (33.5)	19 (13.7)	0 (0.0)	74 (21.3)
<i>Oxazepam (N05BA04)</i>	11 (6.7)	5 (3.6)	0 (0.0)	16 (4.6)
<i>Bromazepam (N05BA08)</i>	12 (7.3)	3 (2.2)	0 (0.0)	15 (4.3)
<i>Alprazolam (N05BA12)</i>	13 (7.9)	1 (0.7)	0 (0.0)	14 (4.0)
<i>Hydroxyzine (N05BB01)</i>	4 (2.4)	3 (2.2)	0 (0.0)	7 (2.0)
<i>Prazepam (N05BA11)</i>	3 (1.8)	3 (2.2)	0 (0.0)	6 (1.7)
<i>Clobazam (N05BA09)</i>	3 (1.8)	2 (1.4)	0 (0.0)	5 (1.4)
<i>Diazepam (N05BA01)</i>	3 (1.8)	1 (0.7)	0 (0.0)	4 (1.2)
<i>Etifoxine (N05BX03)</i>	3 (1.8)	1 (0.7)	0 (0.0)	4 (1.2)
<i>Potassium clorazepate (N05BA05)</i>	2 (1.2)	2 (1.4)	0 (0.0)	4 (1.2)
<i>Meprobamate, combinations (N05BC51)</i>	2 (1.2)	1 (0.7)	0 (0.0)	3 (0.9)
<i>Lorazepam (N05BA06)</i>	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
<i>Meprobamate (N05BC01)</i>	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
Antidepressants (N06A)	42 (25.6)	16 (11.5)	0 (0.0)	58 (16.7)
<i>Escitalopram (N06AB10)</i>	11 (6.7)	1 (0.7)	0 (0.0)	12 (3.5)
<i>Paroxetine (N06AB05)</i>	7 (4.3)	2 (1.4)	0 (0.0)	9 (2.6)
<i>Venlafaxine (N06AX16)</i>	4 (2.4)	5 (3.6)	0 (0.0)	9 (2.6)
<i>Amitriptyline (N06AA09)</i>	4 (2.4)	2 (1.4)	0 (0.0)	6 (1.7)
<i>Fluoxetine (N06AB03)</i>	4 (2.4)	0 (0.0)	0 (0.0)	4 (1.2)
<i>Citalopram (N06AB04)</i>	2 (1.2)	1 (0.7)	0 (0.0)	3 (0.9)
<i>Mianserin (N06AX03)</i>	1 (0.6)	2 (1.4)	0 (0.0)	3 (0.9)
<i>Sertraline (N06AB06)</i>	3 (1.8)	0 (0.0)	0 (0.0)	3 (0.9)
<i>Iproniazide (N06AF05)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Mirtazapine (N06AX1)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Agomelatine (N06AX22)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Clomipramine (N06AA04)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Duloxetine (N06AX21)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Milnacipran (N06AX17)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Moclobemide (N06AG02)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Tianeptine (N06AX14)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Trimipramine (N06AA06)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)

	Acute drug overdose n = 164	Exposed to drugs n = 139	Not exposed to drugs n = 44	Total n = 347
Antiepileptics (N03A)	18 (11.0)	16 (11.5)	0 (0.0)	34 (9.8)
<i>Valproic acid (N03AG01)</i>	6 (3.7)	5 (3.6)	0 (0.0)	11 (3.2)
<i>Clonazepam (N03AE01)</i>	5 (3.0)	4 (2.9)	0 (0.0)	9 (2.6)
<i>Carbamazepine (N03AF01)</i>	3 (1.8)	4 (2.9)	0 (0.0)	7 (2.0)
<i>Levetiracetam (N03AX14)</i>	3 (1.8)	3 (2.2)	0 (0.0)	6 (1.7)
<i>Lamotrigine (N03AX09)</i>	1 (0.6)	3 (2.2)	0 (0.0)	4 (1.2)
<i>Pregabalin (N03AX16)</i>	2 (1.2)	1 (0.7)	0 (0.0)	3 (0.9)
<i>Gabapentin (N03AX12)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Phenytoin (N03AB02)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Topiramate (N03AX11)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Valpromide (N03AG02)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Hypnotics and sedatives (N05C)	25 (15.2)	5 (3.6)	0 (0.0)	30 (8.6)
<i>Zolpidem (N05CF02)</i>	13 (7.9)	1 (0.7)	0 (0.0)	14 (4.0)
<i>Zopiclone (N05CF01)</i>	6 (3.7)	3 (2.2)	0 (0.0)	9 (2.6)
<i>Lormetazepam (N05CD06)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Nitrazepam (N05CD02)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Opioids (N02A)	16 (9.8)	4 (2.9)	0 (0.0)	20 (5.8)
<i>Tramadol, combinations (N02AX52)</i>	6 (3.7)	0 (0.0)	0 (0.0)	6 (1.7)
<i>Tramadol (N02AX02)</i>	4 (2.4)	1 (0.7)	0 (0.0)	5 (1.4)
<i>Morphine (N02AA01)</i>	2 (1.2)	1 (0.7)	0 (0.0)	3 (0.9)
<i>Dextropropoxyphene (N02AC04)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Dextropropoxyphene, comb. excl. psycholeptics (N02AC54)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Dihydrocodeine (N02AA08)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Fentanyl (N02AB03)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Oxycodone (N02AA05)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Antipsychotics (N05A)	8 (4.9)	5 (3.6)	0 (0.0)	13 (3.7)
<i>Cyamemazine (N05AA06)</i>	2 (1.2)	2 (1.4)	0 (0.0)	4 (1.2)
<i>Risperidone (N05AX08)</i>	3 (1.8)	1 (0.7)	0 (0.0)	4 (1.2)
<i>Olanzapine (N05AH03)</i>	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
<i>Tiapride (N05AL03)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Levomepromazine (N05AA02)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Periciazine (N05AC01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Zuclopenthixol (N05AF05)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Drugs used in addictive disorders (N07B)	5 (3.0)	2 (1.4)	0 (0.0)	7 (2.0)
<i>Disulfiram (N07BB01)</i>	2 (1.2)	2 (1.4)	0 (0.0)	4 (1.2)
<i>Acamprosate (N07BB03)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Buprenorphine (N07BC01)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
Antimigraine preparations (N02C)	1 (0.6)	3 (2.2)	0 (0.0)	4 (1.2)
<i>Dihydroergotamine (N02CA01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Eletriptan (N02CC06)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Pizotifen (N02CX01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Zolmitriptan (N02CC03)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)

	Acute drug overdose n = 164	Exposed to drugs n = 139	Not exposed to drugs n = 44	Total n = 347
Anticholinergic agents (N04A)	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Biperiden (N04AA02)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Tropatepine (N04AA12)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Anesthetics, general (N01A)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Desflurane (N01AB07)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Ketamine (N01AX03)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Sufentanil (N01AH03)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Thiopental (N01AF03)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Antivertigo preparations (N07C)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Acetylleucine (N07CA04)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Dopaminergic agents (N04B)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Levodopa (N04BA01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Piribedil (N04BC08)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Psychostimulants, agents used for adhd and nootropics (N06B)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Amphetamine (N06BA01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Alimentary tract and metabolism (A)</b>	<b>18 (11.0)</b>	<b>36 (25.9)</b>	<b>0 (0.0)</b>	<b>54 (15.6)</b>
Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) (A02B)	7 (4.3)	8 (5.8)	0 (0.0)	15 (4.3)
<i>Lansoprazole (A02BC03)</i>	3 (1.8)	2 (1.4)	0 (0.0)	5 (1.4)
<i>Omeprazole (A02BC01)</i>	2 (1.2)	2 (1.4)	0 (0.0)	4 (1.2)
<i>Esomeprazole (A02BC05)</i>	2 (1.2)	1 (0.7)	0 (0.0)	3 (0.9)
<i>Pantoprazole (A02BC02)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Rabeprazole (A02BC04)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Blood glucose lowering drugs, excl. insulins (A10B)	2 (1.2)	8 (5.8)	0 (0.0)	10 (2.9)
<i>Metformin (A10BA02)</i>	1 (0.6)	5 (3.6)	0 (0.0)	6 (1.7)
<i>Acarbose (A10BF01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Glibenclamide (A10BB01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Gliclazide (A10BB09)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Glimepiride (A10BB12)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Metformin and sitagliptin (A10BD07)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Repaglinide (A10BX02)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Sitagliptin (A10BH01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Drugs for functional bowel disorders (A03A)	4 (2.4)	5 (3.6)	0 (0.0)	9 (2.6)
<i>Phloroglucinol (A03AX12)</i>	3 (1.8)	4 (2.9)	0 (0.0)	7 (2.0)
<i>Trimebutine (A03AA05)</i>	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
<i>Alverine, combinations (A03AX58)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Propulsives (A03F)	2 (1.2)	7 (5.0)	0 (0.0)	9 (2.6)
<i>Domperidone (A03FA03)</i>	1 (0.6)	5 (3.6)	0 (0.0)	6 (1.7)
<i>Metoclopramide (A03FA01)</i>	1 (0.6)	3 (2.2)	0 (0.0)	4 (1.2)
Antipropulsives (A07D)	4 (2.4)	4 (2.9)	0 (0.0)	8 (2.3)
<i>Loperamide (A07DA03)</i>	4 (2.4)	4 (2.9)	0 (0.0)	8 (2.3)
Antacids (A02A)	0 (0.0)	4 (2.9)	0 (0.0)	4 (1.2)

	Acute drug overdose n = 164		Exposed to drugs n = 139		Not exposed to drugs n = 44		Total n = 347	
<i>Aluminium hydroxide (A02AB01)</i>	0	(0.0)	2	(1.4)	0	(0.0)	2	(0.6)
<i>Ordinary salt combinations and antiflatulents (A02AF02)</i>	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
Antiemetics and antinauseants (A04A)	2	(1.2)	2	(1.4)	0	(0.0)	4	(1.2)
<i>Metopimazine (A04AD05)</i>	2	(1.2)	1	(0.7)	0	(0.0)	3	(0.9)
Insulins and analogues (A10A)	1	(0.6)	2	(1.4)	0	(0.0)	3	(0.9)
<i>Insulin (human) (A10AB01)</i>	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
<i>Insulin glargine (A10AE04)</i>	1	(0.6)	0	(0.0)	0	(0.0)	1	(0.3)
Other drugs for acid related disorders (A02X)	1	(0.6)	2	(1.4)	0	(0.0)	3	(0.9)
Vitamin a and d, incl. combinations of the two (A11C)	0	(0.0)	2	(1.4)	0	(0.0)	2	(0.6)
<i>Calcifediol (A11CC06)</i>	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
<i>Colecalciferol (A11CC05)</i>	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
Bile therapy (A05A)	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
<i>Ursodeoxycholic acid (A05AA02)</i>	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
Calcium (A12A)	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
Intestinal antiinfectives (A07A)	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
<i>Nifuroxazide (A07AX03)</i>	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
Intestinal antiinflammatory agents (A07E)	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
<i>Sulfasalazine (A07EC01)</i>	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
Laxatives (A06A)	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
<i>Liquid paraffin (A06AA01)</i>	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
Multivitamins, combinations (A11A)	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
<i>Multivitamins and other minerals, incl. combinations (A11AA03)</i>	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
Other antidiarrheals (A07X)	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
<i>Racecadotril (A07XA04)</i>	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
Potassium (A12B)	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
<i>Potassium chloride (A12BA01)</i>	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
Vitamin b1, plain and in combination with vitamin b6 and b12 (A11D)	1	(0.6)	0	(0.0)	0	(0.0)	1	(0.3)
<b>Antiinfectives for systemic use (J)</b>	<b>6</b>	<b>(3.7)</b>	<b>44</b>	<b>(31.7)</b>	<b>1</b>	<b>(2.3)</b>	<b>51</b>	<b>(14.7)</b>
Drugs for treatment of tuberculosis (J04A)	0	(0.0)	19	(13.7)	0	(0.0)	19	(5.5)
<i>Rifampicin, pyrazinamide, ethambutol and isoniazid (J04AM06)</i>	0	(0.0)	10	(7.2)	0	(0.0)	10	(2.9)
<i>Rifampicin and isoniazid (J04AM02)</i>	0	(0.0)	6	(4.3)	0	(0.0)	6	(1.7)
<i>Ethambutol (J04AK02)</i>	0	(0.0)	2	(1.4)	0	(0.0)	2	(0.6)
<i>Isoniazid (J04AC01)</i>	0	(0.0)	2	(1.4)	0	(0.0)	2	(0.6)
<i>Pyrazinamide (J04AK01)</i>	0	(0.0)	2	(1.4)	0	(0.0)	2	(0.6)
<i>Rifampicin (J04AB02)</i>	0	(0.0)	2	(1.4)	0	(0.0)	2	(0.6)
<i>Rifampicin, pyrazinamide and isoniazid (J04AM05)</i>	0	(0.0)	2	(1.4)	0	(0.0)	2	(0.6)
<i>Rifabutin (J04AB04)</i>	0	(0.0)	1	(0.7)	0	(0.0)	1	(0.3)
Beta-lactam antibacterials, penicillins (J01C)	4	(2.4)	10	(7.2)	0	(0.0)	14	(4.0)
<i>Amoxicillin (J01CA04)</i>	2	(1.2)	6	(4.3)	0	(0.0)	8	(2.3)
<i>Amoxicillin and enzyme inhibitor (J01CR02)</i>	1	(0.6)	3	(2.2)	0	(0.0)	4	(1.2)
<i>Cloxacillin (J01CF02)</i>	1	(0.6)	0	(0.0)	0	(0.0)	1	(0.3)

	Acute drug overdose n = 164	Exposed to drugs n = 139	Not exposed to drugs n = 44	Total n = 347
<i>Piperacillin and enzyme inhibitor (J01CR05)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Direct acting antivirals (J05A)	1 (0.6)	13 (9.4)	0 (0.0)	14 (4.0)
<i>Emtricitabine, tenofovir disoproxil and efavirenz (J05AR06)</i>	0 (0.0)	3 (2.2)	0 (0.0)	3 (0.9)
<i>Tenofovir disoproxil and emtricitabine (J05AR03)</i>	0 (0.0)	3 (2.2)	0 (0.0)	3 (0.9)
<i>Aciclovir (J05AB01)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Efavirenz (J05AG03)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Ritonavir (J05AE03)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Tenofovir disoproxil (J05AF07)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Valaciclovir (J05AB11)</i>	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
<i>Atazanavir (J05AE08)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Emtricitabine (J05AF09)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Nevirapine (J05AG01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Nucleoside and nucleotide reverse transcriptase inhibitors, combinations (J05AF30)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Raltegravir (J05AX08)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Ribavirin (J05AB04)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Valganciclovir (J05AB14)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Other beta-lactam antibacterials (J01D)	1 (0.6)	4 (2.9)	1 (2.3)	6 (1.7)
<i>Cefpodoxime (J01DD13)</i>	1 (0.6)	2 (1.4)	0 (0.0)	3 (0.9)
<i>Cefixime (J01DD08)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Cefradine (J01DB09)</i>	0 (0.0)	0 (0.0)	1 (2.3)	1 (0.3)
<i>Ceftazidime (J01DD02)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Ceftriaxone (J01DD04)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Macrolides, lincosamides and streptogramins (J01F)	0 (0.0)	4 (2.9)	0 (0.0)	4 (1.2)
<i>Azithromycin (J01FA10)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Erythromycin (J01FA01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Roxithromycin (J01FA06)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Telithromycin (J01FA15)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Aminoglycoside antibacterials (J01G)	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Amikacin (J01GB06)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
Antimycotics for systemic use (J02A)	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Fluconazole (J02AC01)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
Other antibacterials (J01X)	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
<i>Metronidazole (J01XD01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Nitrofurantoin (J01XE01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Quinolone antibacterials (J01M)	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Ciprofloxacin (J01MA02)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Ofloxacin (J01MA01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Sulfonamides and trimethoprim (J01E)	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Sulfamethoxazole and trimethoprim (J01EE01)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<b>Musculo-skeletal system (M)</b>	<b>25 (15.2)</b>	<b>21 (15.1)</b>	<b>1 (2.3)</b>	<b>47 (13.5)</b>
Antiinflammatory and antirheumatic products, non-steroids (M01A)	18 (11.0)	14 (10.1)	1 (2.3)	33 (9.5)

	Acute drug overdose n = 164	Exposed to drugs n = 139	Not exposed to drugs n = 44	Total n = 347
<i>Ibuprofen (M01AE01)</i>	7 (4.3)	6 (4.3)	1 (2.3)	14 (4.0)
<i>Ketoprofen (M01AE03)</i>	2 (1.2)	3 (2.2)	0 (0.0)	5 (1.4)
<i>Diclofenac (M01AB05)</i>	2 (1.2)	0 (0.0)	1 (2.3)	3 (0.9)
<i>Diclofenac, combinations (M01AB55)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Naproxen (M01AE02)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Niflumic acid (M01AX02)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Nimesulide (M01AX17)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Piascledine (M01AX26)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Piroxicam (M01AC01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Muscle relaxants, centrally acting agents (M03B)	7 (4.3)	2 (1.4)	1 (2.3)	10 (2.9)
<i>Tetrazepam (M03BX07)</i>	5 (3.0)	1 (0.7)	1 (2.3)	7 (2.0)
<i>Baclofen (M03BX01)</i>	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
<i>Thiocolchicoside (M03BX05)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Antigout preparations (M04A)	2 (1.2)	1 (0.7)	0 (0.0)	3 (0.9)
<i>Allopurinol (M04AA01)</i>	2 (1.2)	1 (0.7)	0 (0.0)	3 (0.9)
Drugs affecting bone structure and mineralization (M05B)	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Risedronic acid (M05BA07)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Strontium ranelate (M05BX03)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Muscle relaxants, directly acting agents (M03C)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Dantrolene (M03CA01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Muscle relaxants, peripherally acting agents (M03A)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Rocuronium bromide (M03AC09)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Other drugs for disorders of the musculo-skeletal system (M09A)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Chondrocytes, autologous (M09AX02)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Specific antirheumatic agents (M01C)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Penicillamine (M01CC01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<b>Cardiovascular system (C)</b>	<b>15 (9.1)</b>	<b>23 (16.5)</b>	<b>0 (0.0)</b>	<b>38 (11.0)</b>
Lipid modifying agents, plain (C10A)	6 (3.7)	11 (7.9)	0 (0.0)	17 (4.9)
<i>Atorvastatin (C10AA05)</i>	3 (1.8)	6 (4.3)	0 (0.0)	9 (2.6)
<i>Fenofibrate (C10AB05)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Simvastatin (C10AA01)</i>	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
<i>Colestyramine (C10AC01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Pravastatin (C10AA03)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Rosuvastatin (C10AA07)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Selective calcium channel blockers with mainly vascular effects (C08C)	3 (1.8)	7 (5.0)	0 (0.0)	10 (2.9)
<i>Lercanidipine (C08CA13)</i>	1 (0.6)	3 (2.2)	0 (0.0)	4 (1.2)
<i>Amlodipine (C08CA01)</i>	1 (0.6)	2 (1.4)	0 (0.0)	3 (0.9)
<i>Nicardipine (C08CA04)</i>	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
<i>Manidipine (C08CA11)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Angiotensin ii antagonists, plain (C09C)	3 (1.8)	6 (4.3)	0 (0.0)	9 (2.6)
<i>Losartan (C09CA01)</i>	0 (0.0)	4 (2.9)	0 (0.0)	4 (1.2)

	Acute drug overdose n = 164	Exposed to drugs n = 139	Not exposed to drugs n = 44	Total n = 347
Irbesartan (C09CA04)	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
Candesartan (C09CA06)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Olmesartan medoxomil (C09CA08)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Valsartan (C09CA03)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Beta blocking agents (C07A)	2 (1.2)	4 (2.9)	0 (0.0)	6 (1.7)
Atenolol (C07AB03)	1 (0.6)	3 (2.2)	0 (0.0)	4 (1.2)
Nebivolol (C07AB12)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Propranolol (C07AA05)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Ace inhibitors, plain (C09A)	2 (1.2)	2 (1.4)	0 (0.0)	4 (1.2)
Moexipril (C09AA13)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Perindopril (C09AA04)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Ramipril (C09AA05)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Ace inhibitors, combinations (C09B)	1 (0.6)	2 (1.4)	0 (0.0)	3 (0.9)
Perindopril and diuretics (C09BA04)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Ramipril and diuretics (C09BA05)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Trandolapril and verapamil (C09BB10)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Angiotensin ii antagonists, combinations (C09D)	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
Olmesartan medoxomil and amlodipine (C09DB02)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Olmesartan medoxomil and diuretics (C09DA08)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Antiadrenergic agents, centrally acting (C02A)	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
Moxonidine (C02AC05)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Rilmenidine (C02AC06)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Antiarrhythmics, class i and iii (C01B)	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
Amiodarone (C01BD01)	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
Capillary stabilizing agents (C05C)	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
Troxerutin, combinations (C05CA54)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
High-ceiling diuretics (C03C)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Furosemide (C03CA01)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Low-ceiling diuretics, excl. thiazides (C03B)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Indapamide (C03BA11)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Peripheral vasodilators (C04A)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Naftidrofuryl (C04AX21)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Potassium-sparing agents (C03D)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Spironolactone (C03DA01)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Vasodilators used in cardiac diseases (C01D)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Heptaminol (C01DX08)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Respiratory system (R)</b>	<b>13 (7.9)</b>	<b>19 (13.7)</b>	<b>0 (0.0)</b>	<b>32 (9.2)</b>
Antihistamines for systemic use (R06A)	6 (3.7)	8 (5.8)	0 (0.0)	14 (4.0)
Alimemazine (R06AD01)	5 (3.0)	1 (0.7)	0 (0.0)	6 (1.7)
Desloratadine (R06AX27)	0 (0.0)	3 (2.2)	0 (0.0)	3 (0.9)
Oxememazine (R06AD08)	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)



	Acute drug overdose n = 164	Exposed to drugs n = 139	Not exposed to drugs n = 44	Total n = 347
<i>Cetirizine (R06AE07)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Dexchlorpheniramine (R06AB02)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Loratadine (R06AX13)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Adrenergics, inhalants (R03A)	5 (3.0)	6 (4.3)	0 (0.0)	11 (3.2)
<i>Salbutamol (R03AC02)</i>	4 (2.4)	3 (2.2)	0 (0.0)	7 (2.0)
<i>Formoterol and budesonide (R03AK07)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Terbutaline (R03AC03)</i>	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
<i>Formoterol (R03AC13)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Salmeterol and fluticasone (R03AK06)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Other drugs for obstructive airway diseases, inhalants (R03B)	1 (0.6)	3 (2.2)	0 (0.0)	4 (1.2)
<i>Budesonide (R03BA02)</i>	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
<i>Fluticasone (R03BA05)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Ipratropium bromide (R03BB01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Tiotropium bromide (R03BB04)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Other systemic drugs for obstructive airway diseases (R03D)	0 (0.0)	4 (2.9)	0 (0.0)	4 (1.2)
<i>Fenspiride (R03DX03)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Montelukast (R03DC03)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Theophylline (R03DA04)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Cough suppressants, excl. combinations with expectorants (R05D)	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
<i>Combinations (R05DA20)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Pholcodine (R05DA08)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Expectorants, excl. combinations with cough suppressants (R05C)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Acetylcysteine (R05CB01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Other cold combination preparations (R05X)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<b>Blood and blood forming organs (B)</b>	<b>4 (2.4)</b>	<b>16 (11.5)</b>	<b>0 (0.0)</b>	<b>20 (5.8)</b>
Antithrombotic agents (B01A)	3 (1.8)	12 (8.6)	0 (0.0)	15 (4.3)
<i>Acetylsalicylic acid (B01AC06)</i>	2 (1.2)	7 (5.0)	0 (0.0)	9 (2.6)
<i>Clopidogrel (B01AC04)</i>	1 (0.6)	3 (2.2)	0 (0.0)	4 (1.2)
<i>Fluindione (B01AA12)</i>	0 (0.0)	3 (2.2)	0 (0.0)	3 (0.9)
<i>Fondaparinux (B01AX05)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Nadroparin (B01AB06)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Vitamin k and other hemostatics (B02B)	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Phytomenadione (B02BA01)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
Blood and related products (B05A)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Albumin (B05AA01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Iron preparations (B03A)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Ferrous sulfate (B03AA07)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Vitamin b12 and folic acid (B03B)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Folic acid (B03BB01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<b>Genito urinary system and sex hormones (G)</b>	<b>6 (3.7)</b>	<b>13 (9.4)</b>	<b>0 (0.0)</b>	<b>19 (5.5)</b>

	Acute drug overdose n = 164	Exposed to drugs n = 139	Not exposed to drugs n = 44	Total n = 347
Hormonal contraceptives for systemic use (G03A)	4 (2.4)	6 (4.3)	0 (0.0)	10 (2.9)
<i>Levonorgestrel (G03AC03)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Levonorgestrel and estrogen (G03AA07)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Etonogestrel (G03AC08)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Gestodene and estrogen (G03AA10)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Progestogens (G03D)	1 (0.6)	3 (2.2)	0 (0.0)	4 (1.2)
<i>Nomegestrol (G03DB04)</i>	1 (0.6)	2 (1.4)	0 (0.0)	3 (0.9)
<i>Progesterone (G03DA04)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Estrogens (G03C)	0 (0.0)	3 (2.2)	0 (0.0)	3 (0.9)
<i>Estradiol (G03CA03)</i>	0 (0.0)	3 (2.2)	0 (0.0)	3 (0.9)
Other urologicals, incl. antispasmodics (G04B)	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
<i>Solifenacin (G04BD08)</i>	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
Antiandrogens (G03H)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Cyproterone (G03HA01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Drugs used in benign prostatic hypertrophy (G04C)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Alfuzosin (G04CA01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Gonadotropins and other ovulation stimulants (G03G)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<b>Systemic hormonal preparations (excluded sex hormones and insulines) (H)</b>	<b>7 (4.3)</b>	<b>12 (8.6)</b>	<b>0 (0.0)</b>	<b>19 (5.5)</b>
Corticosteroids for systemic use, plain (H02A)	4 (2.4)	6 (4.3)	0 (0.0)	10 (2.9)
<i>Prednisone (H02AB07)</i>	2 (1.2)	2 (1.4)	0 (0.0)	4 (1.2)
<i>Prednisolone (H02AB06)</i>	2 (1.2)	1 (0.7)	0 (0.0)	3 (0.9)
<i>Methylprednisolone (H02AB04)</i>	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Betamethasone (H02AB01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Thyroid preparations (H03A)	3 (1.8)	6 (4.3)	0 (0.0)	9 (2.6)
<i>Levothyroxine sodium (H03AA01)</i>	3 (1.8)	6 (4.3)	0 (0.0)	9 (2.6)
<b>Antineoplastic and immunomodulating agents (L)</b>	<b>1 (0.6)</b>	<b>7 (5.0)</b>	<b>0 (0.0)</b>	<b>8 (2.3)</b>
Immunosuppressants (L04A)	0 (0.0)	3 (2.2)	0 (0.0)	3 (0.9)
<i>Etanercept (L04AB01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Infliximab (L04AA12)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Leflunomide (L04AA13)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Methotrexate (L04AX03)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Tacrolimus (L04AD02)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Antimetabolites (L01B)	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
<i>Methotrexate (L01BA01)</i>	1 (0.6)	1 (0.7)	0 (0.0)	2 (0.6)
Alkylating agents (L01A)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Dacarbazine (L01AX04)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Cytotoxic antibiotics and related substances (L01D)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Doxorubicin (L01DB01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Immunostimulants (L03A)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Glatiramer acetate (L03AX13)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)

	Acute drug overdose n = 164	Exposed to drugs n = 139	Not exposed to drugs n = 44	Total n = 347
Other antineoplastic agents (L01X)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Imatinib (L01XE01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<b>Drugs</b>	<b>7 (4.3)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>7 (2.0)</b>
Cannabis	6 (3.7)	0 (0.0)	0 (0.0)	6 (1.7)
Ecstasy	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
Cocaine	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
LSA	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Mushrooms	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Antiparasitic products, insecticides and repellents (P)</b>	<b>1 (0.6)</b>	<b>3 (2.2)</b>	<b>0 (0.0)</b>	<b>4 (1.2)</b>
Antimalarials (P01B)	0 (0.0)	2 (1.4)	0 (0.0)	2 (0.6)
<i>Hydroxychloroquine (P01BA02)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Proguanil, combinations (P01BB51)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Antinematodal agents (P02C)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Albendazole (P02CA03)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Antitrematodals (P02B)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Dermatologicals (D)</b>	<b>0 (0.0)</b>	<b>3 (2.2)</b>	<b>0 (0.0)</b>	<b>3 (0.9)</b>
Antifungals for systemic use (D01B)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Terbinafine (D01BA02)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Corticosteroids, other combinations (D07X)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<i>Hydrocortisone (D07XA01)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Corticosteroids, plain (D07A)	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<b>Homeopathy</b>	<b>1 (0.6)</b>	<b>2 (1.4)</b>	<b>0 (0.0)</b>	<b>3 (0.9)</b>
Homeopathy	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Organic silicon	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Sedatif PC	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Various (V)</b>	<b>0 (0.0)</b>	<b>3 (2.2)</b>	<b>0 (0.0)</b>	<b>3 (0.9)</b>
All other therapeutic products (V03A)	0 (0.0)	3 (2.2)	0 (0.0)	3 (0.9)
<i>Calcium folinate (V03AF03)</i>	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<b>Herbal medicine</b>	<b>0 (0.0)</b>	<b>2 (1.4)</b>	<b>0 (0.0)</b>	<b>2 (0.6)</b>
Ginseng	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
Phytotherapy	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<b>Food supplement</b>	<b>0 (0.0)</b>	<b>1 (0.7)</b>	<b>0 (0.0)</b>	<b>1 (0.3)</b>
Fortimel	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.3)
<b>No ATC code</b>	<b>0 (0.0)</b>	<b>1 (0.7)</b>	<b>0 (0.0)</b>	<b>1 (0.3)</b>

	Acute drug overdose n = 164	Exposed to drugs n = 139	Not exposed to drugs n = 44	Total n = 347

**SALT-II - Table 22b: Paracetamol exposure of ALFT cases according to drug exposure in the 15 days prior to index date for the years 2005 to 2013**

	Acute drug overdose n = 164	Exposed to drugs n = 139	Not exposed to drugs n = 44	Total n = 347
<b>At least one exposure at paracetamol in the 15 days prior to index date, n (%)</b>				
<b>Paracetamol, plain and combinations</b>	<b>161 (98.2)</b>	<b>81 (58.3)</b>	<b>1 (2.3)</b>	<b>243 (70.0)</b>
Paracetamol (N02BE01)	138 (84.1)	72 (51.8)	1 (2.3)	211 (60.8)
Paracetamol, combinations excl. psycholeptics (N02BE51)	30 (18.3)	13 (9.4)	0 (0.0)	43 (12.4)
Paracetamol, combinations with psycholeptics (N02BE71)	2 (1.2)	2 (1.4)	0 (0.0)	4 (1.2)
Codeine, combinations excl. psycholeptics (N02AA59)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Tramadol, combinations (N02AX52)	6 (3.7)	0 (0.0)	0 (0.0)	6 (1.7)
<b>At least one overdose, n (%)</b>	<b>157 (95.7)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>157 (45.2)</b>
<b>At least one intentional overdose, n (%)</b>	<b>95 (57.9)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>95 (27.4)</b>
<b>At least one non-intentional overdose, n (%)</b>	<b>62 (37.8)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>62 (17.9)</b>

**SALT-II - Table 23: Drug exposure of ALFT cases according to drug exposure in the 7 days prior to index date for the years 2005 to 2013**

	Acute drug overdose n = 164	Exposed to drugs n = 132	Not exposed to drugs n = 51	Total n = 347
<b>At least one exposure at the following ATC codes in the 7 days prior to index date</b>	164 (100.0)	132 (100.0)	0 (0.0)	296 (85.3)
<b>Nervous system (N)</b>	<b>162 (98.8)</b>	<b>96 (72.7)</b>	<b>0 (0.0)</b>	<b>258 (74.4)</b>
Other analgesics and antipyretics (N02B)	157 (95.7)	79 (59.8)	0 (0.0)	236 (68.0)
<i>Paracetamol (N02BE01)</i>	137 (83.5)	68 (51.5)	0 (0.0)	205 (59.1)
<i>Paracetamol, combinations excl. psycholeptics (N02BE51)</i>	30 (18.3)	12 (9.1)	0 (0.0)	42 (12.1)
<i>Acetylsalicylic acid (N02BA01)</i>	1 (0.6)	7 (5.3)	0 (0.0)	8 (2.3)
<i>Paracetamol, combinations with psycholeptics (N02BE71)</i>	2 (1.2)	2 (1.5)	0 (0.0)	4 (1.2)
<i>Nefopam (N02BG06)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
Anxiolytics (N05B)	55 (33.5)	19 (14.4)	0 (0.0)	74 (21.3)
<i>Oxazepam (N05BA04)</i>	11 (6.7)	5 (3.8)	0 (0.0)	16 (4.6)
<i>Bromazepam (N05BA08)</i>	12 (7.3)	3 (2.3)	0 (0.0)	15 (4.3)
<i>Alprazolam (N05BA12)</i>	13 (7.9)	1 (0.8)	0 (0.0)	14 (4.0)
<i>Hydroxyzine (N05BB01)</i>	4 (2.4)	3 (2.3)	0 (0.0)	7 (2.0)
<i>Prazepam (N05BA11)</i>	3 (1.8)	3 (2.3)	0 (0.0)	6 (1.7)
<i>Clobazam (N05BA09)</i>	3 (1.8)	2 (1.5)	0 (0.0)	5 (1.4)
<i>Diazepam (N05BA01)</i>	3 (1.8)	1 (0.8)	0 (0.0)	4 (1.2)
<i>Etifoxine (N05BX03)</i>	3 (1.8)	1 (0.8)	0 (0.0)	4 (1.2)
<i>Potassium clorazepate (N05BA05)</i>	2 (1.2)	2 (1.5)	0 (0.0)	4 (1.2)
<i>Meprobamate, combinations (N05BC51)</i>	2 (1.2)	1 (0.8)	0 (0.0)	3 (0.9)
<i>Lorazepam (N05BA06)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
<i>Meprobamate (N05BC01)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
Antidepressants (N06A)	42 (25.6)	16 (12.1)	0 (0.0)	58 (16.7)
<i>Escitalopram (N06AB10)</i>	11 (6.7)	1 (0.8)	0 (0.0)	12 (3.5)
<i>Paroxetine (N06AB05)</i>	7 (4.3)	2 (1.5)	0 (0.0)	9 (2.6)
<i>Venlafaxine (N06AX16)</i>	4 (2.4)	5 (3.8)	0 (0.0)	9 (2.6)
<i>Amitriptyline (N06AA09)</i>	4 (2.4)	2 (1.5)	0 (0.0)	6 (1.7)
<i>Fluoxetine (N06AB03)</i>	4 (2.4)	0 (0.0)	0 (0.0)	4 (1.2)
<i>Citalopram (N06AB04)</i>	2 (1.2)	1 (0.8)	0 (0.0)	3 (0.9)
<i>Mianserin (N06AX03)</i>	1 (0.6)	2 (1.5)	0 (0.0)	3 (0.9)
<i>Sertraline (N06AB06)</i>	3 (1.8)	0 (0.0)	0 (0.0)	3 (0.9)
<i>Iproniazide (N06AF05)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Mirtazapine (N06AX1)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Agomelatine (N06AX22)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Clomipramine (N06AA04)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Duloxetine (N06AX21)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Milnacipran (N06AX17)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Moclobemide (N06AG02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Tianeptine (N06AX14)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Trimipramine (N06AA06)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)

	Acute drug overdose n = 164	Exposed to drugs n = 132	Not exposed to drugs n = 51	Total n = 347
Antiepileptics (N03A)	18 (11.0)	14 (10.6)	0 (0.0)	32 (9.2)
<i>Valproic acid (N03AG01)</i>	6 (3.7)	5 (3.8)	0 (0.0)	11 (3.2)
<i>Clonazepam (N03AE01)</i>	5 (3.0)	3 (2.3)	0 (0.0)	8 (2.3)
<i>Carbamazepine (N03AF01)</i>	3 (1.8)	3 (2.3)	0 (0.0)	6 (1.7)
<i>Levetiracetam (N03AX14)</i>	3 (1.8)	3 (2.3)	0 (0.0)	6 (1.7)
<i>Lamotrigine (N03AX09)</i>	1 (0.6)	2 (1.5)	0 (0.0)	3 (0.9)
<i>Pregabalin (N03AX16)</i>	2 (1.2)	1 (0.8)	0 (0.0)	3 (0.9)
<i>Gabapentin (N03AX12)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Phenytoin (N03AB02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Topiramate (N03AX11)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Valpromide (N03AG02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Hypnotics and sedatives (N05C)	25 (15.2)	5 (3.8)	0 (0.0)	30 (8.6)
<i>Zolpidem (N05CF02)</i>	13 (7.9)	1 (0.8)	0 (0.0)	14 (4.0)
<i>Zopiclone (N05CF01)</i>	6 (3.7)	3 (2.3)	0 (0.0)	9 (2.6)
<i>Lormetazepam (N05CD06)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Nitrazepam (N05CD02)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Opioids (N02A)	16 (9.8)	4 (3.0)	0 (0.0)	20 (5.8)
<i>Tramadol, combinations (N02AX52)</i>	6 (3.7)	0 (0.0)	0 (0.0)	6 (1.7)
<i>Tramadol (N02AX02)</i>	4 (2.4)	1 (0.8)	0 (0.0)	5 (1.4)
<i>Morphine (N02AA01)</i>	2 (1.2)	1 (0.8)	0 (0.0)	3 (0.9)
<i>Dextropropoxyphene (N02AC04)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Dextropropoxyphene, comb. excl. psycholeptics (N02AC54)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Dihydrocodeine (N02AA08)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Fentanyl (N02AB03)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Antipsychotics (N05A)	8 (4.9)	5 (3.8)	0 (0.0)	13 (3.7)
<i>Cyamemazine (N05AA06)</i>	2 (1.2)	2 (1.5)	0 (0.0)	4 (1.2)
<i>Risperidone (N05AX08)</i>	3 (1.8)	1 (0.8)	0 (0.0)	4 (1.2)
<i>Olanzapine (N05AH03)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
<i>Tiapride (N05AL03)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Levomepromazine (N05AA02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Periciazine (N05AC01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Zuclopenthixol (N05AF05)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Drugs used in addictive disorders (N07B)	5 (3.0)	2 (1.5)	0 (0.0)	7 (2.0)
<i>Disulfiram (N07BB01)</i>	2 (1.2)	2 (1.5)	0 (0.0)	4 (1.2)
<i>Acamprosate (N07BB03)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Buprenorphine (N07BC01)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
Antimigraine preparations (N02C)	1 (0.6)	3 (2.3)	0 (0.0)	4 (1.2)
<i>Dihydroergotamine (N02CA01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Eletriptan (N02CC06)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Pizotifen (N02CX01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Zolmitriptan (N02CC03)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Anticholinergic agents (N04A)	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)

	Acute drug overdose n = 164	Exposed to drugs n = 132	Not exposed to drugs n = 51	Total n = 347
<i>Biperiden (N04AA02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Tropatepine (N04AA12)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Anesthetics, general (N01A)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Desflurane (N01AB07)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Ketamine (N01AX03)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Sufentanil (N01AH03)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Thiopental (N01AF03)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Antivertigo preparations (N07C)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Acetylcholine (N07CA04)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Dopaminergic agents (N04B)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Levodopa (N04BA01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Piribedil (N04BC08)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Psychostimulants, agents used for adhd and nootropics (N06B)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Amphetamine (N06BA01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Alimentary tract and metabolism (A)</b>	<b>18 (11.0)</b>	<b>35 (26.5)</b>	<b>0 (0.0)</b>	<b>53 (15.3)</b>
Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) (A02B)	7 (4.3)	8 (6.1)	0 (0.0)	15 (4.3)
<i>Lansoprazole (A02BC03)</i>	3 (1.8)	2 (1.5)	0 (0.0)	5 (1.4)
<i>Omeprazole (A02BC01)</i>	2 (1.2)	2 (1.5)	0 (0.0)	4 (1.2)
<i>Esomeprazole (A02BC05)</i>	2 (1.2)	1 (0.8)	0 (0.0)	3 (0.9)
<i>Pantoprazole (A02BC02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Rabeprazole (A02BC04)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Blood glucose lowering drugs, excl. insulins (A10B)	2 (1.2)	8 (6.1)	0 (0.0)	10 (2.9)
<i>Metformin (A10BA02)</i>	1 (0.6)	5 (3.8)	0 (0.0)	6 (1.7)
<i>Acarbose (A10BF01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Glibenclamide (A10BB01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Gliclazide (A10BB09)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Glimepiride (A10BB12)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Metformin and sitagliptin (A10BD07)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Repaglinide (A10BX02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Sitagliptin (A10BH01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Drugs for functional bowel disorders (A03A)	4 (2.4)	5 (3.8)	0 (0.0)	9 (2.6)
<i>Phloroglucinol (A03AX12)</i>	3 (1.8)	4 (3.0)	0 (0.0)	7 (2.0)
<i>Trimebutine (A03AA05)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
<i>Alverine, combinations (A03AX58)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Propulsives (A03F)	2 (1.2)	7 (5.3)	0 (0.0)	9 (2.6)
<i>Domperidone (A03FA03)</i>	1 (0.6)	5 (3.8)	0 (0.0)	6 (1.7)
<i>Metoclopramide (A03FA01)</i>	1 (0.6)	3 (2.3)	0 (0.0)	4 (1.2)
Antipropulsives (A07D)	4 (2.4)	3 (2.3)	0 (0.0)	7 (2.0)
<i>Loperamide (A07DA03)</i>	4 (2.4)	3 (2.3)	0 (0.0)	7 (2.0)
Antiemetics and antinauseants (A04A)	2 (1.2)	2 (1.5)	0 (0.0)	4 (1.2)



	Acute drug overdose n = 164	Exposed to drugs n = 132	Not exposed to drugs n = 51	Total n = 347
<i>Metopimazine (A04AD05)</i>	2 (1.2)	1 (0.8)	0 (0.0)	3 (0.9)
Antacids (A02A)	0 (0.0)	3 (2.3)	0 (0.0)	3 (0.9)
<i>Aluminium hydroxide (A02AB01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Ordinary salt combinations and antifatulents (A02AF02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Insulins and analogues (A10A)	1 (0.6)	2 (1.5)	0 (0.0)	3 (0.9)
<i>Insulin (human) (A10AB01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Insulin glargine (A10AE04)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Other drugs for acid related disorders (A02X)	1 (0.6)	2 (1.5)	0 (0.0)	3 (0.9)
Vitamin a and d, incl. combinations of the two (A11C)	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Calcifediol (A11CC06)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Colecalciferol (A11CC05)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Bile therapy (A05A)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Ursodeoxycholic acid (A05AA02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Calcium (A12A)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Intestinal antiinfectives (A07A)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Nifuroxazide (A07AX03)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Intestinal antiinflammatory agents (A07E)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Sulfasalazine (A07EC01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Laxatives (A06A)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Liquid paraffin (A06AA01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Multivitamins, combinations (A11A)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Multivitamins and other minerals, incl. combinations (A11AA03)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Other antidiarrheals (A07X)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Racecadotril (A07XA04)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Potassium (A12B)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Potassium chloride (A12BA01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Vitamin b1, plain and in combination with vitamin b6 and b12 (A11D)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Antiinfectives for systemic use (J)</b>	<b>6 (3.7)</b>	<b>40 (30.3)</b>	<b>0 (0.0)</b>	<b>46 (13.3)</b>
Drugs for treatment of tuberculosis (J04A)	0 (0.0)	17 (12.9)	0 (0.0)	17 (4.9)
<i>Rifampicin, pyrazinamide, ethambutol and isoniazid (J04AM06)</i>	0 (0.0)	8 (6.1)	0 (0.0)	8 (2.3)
<i>Rifampicin and isoniazid (J04AM02)</i>	0 (0.0)	5 (3.8)	0 (0.0)	5 (1.4)
<i>Isoniazid (J04AC01)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Pyrazinamide (J04AK01)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Rifampicin, pyrazinamide and isoniazid (J04AM05)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Ethambutol (J04AK02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Rifabutin (J04AB04)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Rifampicin (J04AB02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Direct acting antivirals (J05A)	1 (0.6)	13 (9.8)	0 (0.0)	14 (4.0)
<i>Emtricitabine, tenofovir disoproxil and efavirenz (J05AR06)</i>	0 (0.0)	3 (2.3)	0 (0.0)	3 (0.9)
<i>Tenofovir disoproxil and emtricitabine (J05AR03)</i>	0 (0.0)	3 (2.3)	0 (0.0)	3 (0.9)
<i>Aciclovir (J05AB01)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)

	Acute drug overdose n = 164	Exposed to drugs n = 132	Not exposed to drugs n = 51	Total n = 347
<i>Efavirenz (J05AG03)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Ritonavir (J05AE03)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Tenofovir disoproxil (J05AF07)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Valaciclovir (J05AB11)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
<i>Atazanavir (J05AE08)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Emtricitabine (J05AF09)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Nevirapine (J05AG01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Nucleoside and nucleotide reverse transcriptase inhibitors, combinations (J05AF30)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Raltegravir (J05AX08)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Ribavirin (J05AB04)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Valganciclovir (J05AB14)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Beta-lactam antibacterials, penicillins (J01C)	4 (2.4)	8 (6.1)	0 (0.0)	12 (3.5)
<i>Amoxicillin (J01CA04)</i>	2 (1.2)	4 (3.0)	0 (0.0)	6 (1.7)
<i>Amoxicillin and enzyme inhibitor (J01CR02)</i>	1 (0.6)	3 (2.3)	0 (0.0)	4 (1.2)
<i>Cloxacillin (J01CF02)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Piperacillin and enzyme inhibitor (J01CR05)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Other beta-lactam antibacterials (J01D)	1 (0.6)	3 (2.3)	0 (0.0)	4 (1.2)
<i>Cefpodoxime (J01DD13)</i>	1 (0.6)	2 (1.5)	0 (0.0)	3 (0.9)
<i>Cefixime (J01DD08)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Antimycotics for systemic use (J02A)	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Fluconazole (J02AC01)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
Macrolides, lincosamides and streptogramins (J01F)	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Erythromycin (J01FA01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Telithromycin (J01FA15)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Other antibacterials (J01X)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
<i>Metronidazole (J01XD01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Nitrofurantoin (J01XE01)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Quinolone antibacterials (J01M)	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Ciprofloxacin (J01MA02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Ofloxacin (J01MA01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Sulfonamides and trimethoprim (J01E)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Sulfamethoxazole and trimethoprim (J01EE01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<b>Musculo-skeletal system (M)</b>	<b>24 (14.6)</b>	<b>20 (15.2)</b>	<b>0 (0.0)</b>	<b>44 (12.7)</b>
Antiinflammatory and antirheumatic products, non-steroids (M01A)	17 (10.4)	13 (9.8)	0 (0.0)	30 (8.6)
<i>Ibuprofen (M01AE01)</i>	7 (4.3)	5 (3.8)	0 (0.0)	12 (3.5)
<i>Ketoprofen (M01AE03)</i>	2 (1.2)	3 (2.3)	0 (0.0)	5 (1.4)
<i>Diclofenac (M01AB05)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Diclofenac, combinations (M01AB55)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Naproxen (M01AE02)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Niflumic acid (M01AX02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Nimesulide (M01AX17)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)

	Acute drug overdose n = 164	Exposed to drugs n = 132	Not exposed to drugs n = 51	Total n = 347
<i>Piascledine (M01AX26)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Piroxicam (M01AC01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Muscle relaxants, centrally acting agents (M03B)	7 (4.3)	2 (1.5)	0 (0.0)	9 (2.6)
<i>Tetrazepam (M03BX07)</i>	5 (3.0)	1 (0.8)	0 (0.0)	6 (1.7)
<i>Baclofen (M03BX01)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
<i>Thiocolchicoside (M03BX05)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Antigout preparations (M04A)	2 (1.2)	1 (0.8)	0 (0.0)	3 (0.9)
<i>Allopurinol (M04AA01)</i>	2 (1.2)	1 (0.8)	0 (0.0)	3 (0.9)
Drugs affecting bone structure and mineralization (M05B)	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Risedronic acid (M05BA07)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Strontium ranelate (M05BX03)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Muscle relaxants, directly acting agents (M03C)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Dantrolene (M03CA01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Muscle relaxants, peripherally acting agents (M03A)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Rocuronium bromide (M03AC09)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Other drugs for disorders of the musculo-skeletal system (M09A)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Chondrocytes, autologous (M09AX02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Specific antirheumatic agents (M01C)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Penicillamine (M01CC01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<b>Cardiovascular system (C)</b>	<b>15 (9.1)</b>	<b>22 (16.7)</b>	<b>0 (0.0)</b>	<b>37 (10.7)</b>
Lipid modifying agents, plain (C10A)	6 (3.7)	10 (7.6)	0 (0.0)	16 (4.6)
<i>Atorvastatin (C10AA05)</i>	3 (1.8)	6 (4.5)	0 (0.0)	9 (2.6)
<i>Fenofibrate (C10AB05)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Simvastatin (C10AA01)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
<i>Colestyramine (C10AC01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Pravastatin (C10AA03)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Angiotensin ii antagonists, plain (C09C)	3 (1.8)	6 (4.5)	0 (0.0)	9 (2.6)
<i>Losartan (C09CA01)</i>	0 (0.0)	4 (3.0)	0 (0.0)	4 (1.2)
<i>Irbesartan (C09CA04)</i>	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Candesartan (C09CA06)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Olmesartan medoxomil (C09CA08)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Valsartan (C09CA03)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Selective calcium channel blockers with mainly vascular effects (C08C)	3 (1.8)	6 (4.5)	0 (0.0)	9 (2.6)
<i>Lercanidipine (C08CA13)</i>	1 (0.6)	3 (2.3)	0 (0.0)	4 (1.2)
<i>Amlodipine (C08CA01)</i>	1 (0.6)	2 (1.5)	0 (0.0)	3 (0.9)
<i>Nicardipine (C08CA04)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
Beta blocking agents (C07A)	2 (1.2)	4 (3.0)	0 (0.0)	6 (1.7)
<i>Atenolol (C07AB03)</i>	1 (0.6)	3 (2.3)	0 (0.0)	4 (1.2)
<i>Nebivolol (C07AB12)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Propranolol (C07AA05)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Ace inhibitors, plain (C09A)	2 (1.2)	2 (1.5)	0 (0.0)	4 (1.2)

	Acute drug overdose n = 164	Exposed to drugs n = 132	Not exposed to drugs n = 51	Total n = 347
<i>Moexipril (C09AA13)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Perindopril (C09AA04)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Ramipril (C09AA05)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Ace inhibitors, combinations (C09B)	1 (0.6)	2 (1.5)	0 (0.0)	3 (0.9)
<i>Perindopril and diuretics (C09BA04)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Ramipril and diuretics (C09BA05)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Trandolapril and verapamil (C09BB10)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Angiotensin ii antagonists, combinations (C09D)	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
<i>Olmesartan medoxomil and amlodipine (C09DB02)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Olmesartan medoxomil and diuretics (C09DA08)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Antiadrenergic agents, centrally acting (C02A)	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
<i>Moxonidine (C02AC05)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Rilmenidine (C02AC06)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Antiarrhythmics, class i and iii (C01B)	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
<i>Amiodarone (C01BD01)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
Capillary stabilizing agents (C05C)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Troxerutin, combinations (C05CA54)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
High-ceiling diuretics (C03C)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Furosemide (C03CA01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Low-ceiling diuretics, excl. thiazides (C03B)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Indapamide (C03BA11)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Peripheral vasodilators (C04A)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Naftidrofuryl (C04AX21)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Potassium-sparing agents (C03D)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Spironolactone (C03DA01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Vasodilators used in cardiac diseases (C01D)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Heptaminol (C01DX08)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Respiratory system (R)</b>	<b>13 (7.9)</b>	<b>17 (12.9)</b>	<b>0 (0.0)</b>	<b>30 (8.6)</b>
Antihistamines for systemic use (R06A)	6 (3.7)	7 (5.3)	0 (0.0)	13 (3.7)
<i>Alimemazine (R06AD01)</i>	5 (3.0)	1 (0.8)	0 (0.0)	6 (1.7)
<i>Desloratadine (R06AX27)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Oxememazine (R06AD08)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Cetirizine (R06AE07)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Dexchlorpheniramine (R06AB02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Loratadine (R06AX13)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Adrenergics, inhalants (R03A)	5 (3.0)	6 (4.5)	0 (0.0)	11 (3.2)
<i>Salbutamol (R03AC02)</i>	4 (2.4)	3 (2.3)	0 (0.0)	7 (2.0)
<i>Formoterol and budesonide (R03AK07)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Terbutaline (R03AC03)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
<i>Formoterol (R03AC13)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Salmeterol and fluticasone (R03AK06)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)

	Acute drug overdose n = 164	Exposed to drugs n = 132	Not exposed to drugs n = 51	Total n = 347
Other drugs for obstructive airway diseases, inhalants (R03B)	1 (0.6)	3 (2.3)	0 (0.0)	4 (1.2)
<i>Budesonide (R03BA02)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
<i>Fluticasone (R03BA05)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Ipratropium bromide (R03BB01)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Tiotropium bromide (R03BB04)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Other systemic drugs for obstructive airway diseases (R03D)	0 (0.0)	3 (2.3)	0 (0.0)	3 (0.9)
<i>Montelukast (R03DC03)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Fenspiride (R03DX03)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Theophylline (R03DA04)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Cough suppressants, excl. combinations with expectorants (R05D)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Combinations (R05DA20)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Expectorants, excl. combinations with cough suppressants (R05C)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Acetylcysteine (R05CB01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Other cold combination preparations (R05X)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<b>Blood and blood forming organs (B)</b>	<b>4 (2.4)</b>	<b>16 (12.1)</b>	<b>0 (0.0)</b>	<b>20 (5.8)</b>
Antithrombotic agents (B01A)	3 (1.8)	12 (9.1)	0 (0.0)	15 (4.3)
<i>Acetylsalicylic acid (B01AC06)</i>	2 (1.2)	7 (5.3)	0 (0.0)	9 (2.6)
<i>Clopidogrel (B01AC04)</i>	1 (0.6)	3 (2.3)	0 (0.0)	4 (1.2)
<i>Fluindione (B01AA12)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Fondaparinux (B01AX05)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Nadroparin (B01AB06)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Vitamin k and other hemostatics (B02B)	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Phytomenadione (B02BA01)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
Blood and related products (B05A)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Albumin (B05AA01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Iron preparations (B03A)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Ferrous sulfate (B03AA07)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Vitamin b12 and folic acid (B03B)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Folic acid (B03BB01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<b>Genito urinary system and sex hormones (G)</b>	<b>6 (3.7)</b>	<b>12 (9.1)</b>	<b>0 (0.0)</b>	<b>18 (5.2)</b>
Hormonal contraceptives for systemic use (G03A)	4 (2.4)	6 (4.5)	0 (0.0)	10 (2.9)
<i>Levonorgestrel (G03AC03)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Levonorgestrel and estrogen (G03AA07)</i>	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Etonogestrel (G03AC08)</i>	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<i>Gestodene and estrogen (G03AA10)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Progestogens (G03D)	1 (0.6)	3 (2.3)	0 (0.0)	4 (1.2)
<i>Nomegestrol (G03DB04)</i>	1 (0.6)	2 (1.5)	0 (0.0)	3 (0.9)
<i>Progesterone (G03DA04)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Estrogens (G03C)	0 (0.0)	3 (2.3)	0 (0.0)	3 (0.9)
<i>Estradiol (G03CA03)</i>	0 (0.0)	3 (2.3)	0 (0.0)	3 (0.9)

	Acute drug overdose n = 164	Exposed to drugs n = 132	Not exposed to drugs n = 51	Total n = 347
Other urologicals, incl. antispasmodics (G04B)	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
<i>Solifenacin (G04BD08)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
Antiandrogens (G03H)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Cyproterone (G03HA01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Drugs used in benign prostatic hypertrophy (G04C)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Alfuzosin (G04CA01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<b>Systemic hormonal preparations (excluded sex hormones and insulines) (H)</b>	<b>6 (3.7)</b>	<b>11 (8.3)</b>	<b>0 (0.0)</b>	<b>17 (4.9)</b>
Thyroid preparations (H03A)	3 (1.8)	6 (4.5)	0 (0.0)	9 (2.6)
<i>Levothyroxine sodium (H03AA01)</i>	3 (1.8)	6 (4.5)	0 (0.0)	9 (2.6)
Corticosteroids for systemic use, plain (H02A)	3 (1.8)	5 (3.8)	0 (0.0)	8 (2.3)
<i>Prednisone (H02AB07)</i>	2 (1.2)	2 (1.5)	0 (0.0)	4 (1.2)
<i>Prednisolone (H02AB06)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
<i>Betamethasone (H02AB01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Methylprednisolone (H02AB04)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<b>Antineoplastic and immunomodulating agents (L)</b>	<b>1 (0.6)</b>	<b>7 (5.3)</b>	<b>0 (0.0)</b>	<b>8 (2.3)</b>
Immunosuppressants (L04A)	0 (0.0)	3 (2.3)	0 (0.0)	3 (0.9)
<i>Etanercept (L04AB01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Infliximab (L04AA12)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Leflunomide (L04AA13)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Methotrexate (L04AX03)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Tacrolimus (L04AD02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Antimetabolites (L01B)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
<i>Methotrexate (L01BA01)</i>	1 (0.6)	1 (0.8)	0 (0.0)	2 (0.6)
Alkylating agents (L01A)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Dacarbazine (L01AX04)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Cytotoxic antibiotics and related substances (L01D)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Doxorubicin (L01DB01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Immunostimulants (L03A)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Glatiramer acetate (L03AX13)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Other antineoplastic agents (L01X)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Imatinib (L01XE01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<b>Drugs</b>	<b>7 (4.3)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>7 (2.0)</b>
Cannabis	6 (3.7)	0 (0.0)	0 (0.0)	6 (1.7)
Ecstasy	2 (1.2)	0 (0.0)	0 (0.0)	2 (0.6)
Cocaine	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
LSA	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
Mushrooms	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Antiparasitic products, insecticides and repellents (P)</b>	<b>1 (0.6)</b>	<b>3 (2.3)</b>	<b>0 (0.0)</b>	<b>4 (1.2)</b>

	Acute drug overdose n = 164	Exposed to drugs n = 132	Not exposed to drugs n = 51	Total n = 347
Antimalarials (P01B)	0 (0.0)	2 (1.5)	0 (0.0)	2 (0.6)
<i>Hydroxychloroquine (P01BA02)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Proguanil, combinations (P01BB51)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Antinematodal agents (P02C)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Albendazole (P02CA03)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Antitrematodals (P02B)	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Homeopathy</b>	<b>1 (0.6)</b>	<b>2 (1.5)</b>	<b>0 (0.0)</b>	<b>3 (0.9)</b>
Homeopathy	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Organic silicon	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Sedatif PC	1 (0.6)	0 (0.0)	0 (0.0)	1 (0.3)
<b>Various (V)</b>	<b>0 (0.0)</b>	<b>3 (2.3)</b>	<b>0 (0.0)</b>	<b>3 (0.9)</b>
All other therapeutic products (V03A)	0 (0.0)	3 (2.3)	0 (0.0)	3 (0.9)
<i>Calcium folinate (V03AF03)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<b>Dermatologicals (D)</b>	<b>0 (0.0)</b>	<b>2 (1.5)</b>	<b>0 (0.0)</b>	<b>2 (0.6)</b>
Corticosteroids, other combinations (D07X)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<i>Hydrocortisone (D07XA01)</i>	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Corticosteroids, plain (D07A)	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<b>Herbal medicine</b>	<b>0 (0.0)</b>	<b>2 (1.5)</b>	<b>0 (0.0)</b>	<b>2 (0.6)</b>
Ginseng	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
Phytotherapy	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<b>Food supplement</b>	<b>0 (0.0)</b>	<b>1 (0.8)</b>	<b>0 (0.0)</b>	<b>1 (0.3)</b>
Fortimel	0 (0.0)	1 (0.8)	0 (0.0)	1 (0.3)
<b>No ATC code</b>	<b>0 (0.0)</b>	<b>1 (0.8)</b>	<b>0 (0.0)</b>	<b>1 (0.3)</b>

**SALT-II - Table 23b: Paracetamol exposure of ALFT cases according to drug exposure in the 7 days prior to index date for the years 2008 to 2013**

	Acute drug overdose n = 164	Exposed to drugs n = 132	Not exposed to drugs n = 51	Total n = 347
<b>At least one exposure at paracetamol in the 7 days prior to index date, n (%)</b>				
<b>Paracetamol, plain and combinations</b>	<b>161 (98.2)</b>	<b>77 (58.3)</b>	<b>0 (0.0)</b>	<b>237 (68.3)</b>
Paracetamol (N02BE01)	137 (83.5)	68 (51.5)	0 (0.0)	205 (59.1)
Paracetamol, combinations excl. psycholeptics (N02BE51)	30 (18.3)	12 (9.1)	0 (0.0)	42 (12.1)
Paracetamol, combinations with psycholeptics (N02BE71)	2 (1.2)	2 (1.5)	0 (0.0)	4 (1.2)
Codeine, combinations excl. psycholeptics (N02AA59)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Tramadol, combinations (N02AX52)	6 (3.7)	0 (0.0)	0 (0.0)	6 (1.7)
<b>At least one overdose, n (%)</b>	<b>157 (95.7)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>157 (45.2)</b>
<b>At least one intentional overdose, n (%)</b>	<b>95 (57.9)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>95 (27.4)</b>
<b>At least one non-intentional overdose, n (%)</b>	<b>62 (37.8)</b>	<b>0 (0.0)</b>	<b>0 (0.0)</b>	<b>62 (17.9)</b>



Table 24: Drug exposure of ALFT cases according to time window for the years 2005 to 2013

Drug	n cases exposed to drugs in the 90 days prior to index date	n cases exposed to drugs in the 30 days prior to index date	n cases exposed to drugs in the 15 days prior to index date	n cases exposed to drugs in the 7 days prior to index date
Paracetamol *	86	82	81	77
Paracetamol * (with non-intentional overdoses)	148	144	143	139
Paracetamol * (with intentional or non-intentional overdoses)	243	239	238	234
Anxiolytics (N05B)	22	20	19	19
Antiepileptics (N03A)	19	18	16	14
NSAID (M01A)	19	18	14	13
Treatment for tuberculosis (J04A)	19	19	19	17
Antidepressants (N06A)	17	17	16	16
Antithrombotic agents (B01A)	14	12	12	12
Beta-lactam antibacterials, penicillins (J01C)	13	13	10	8
Direct acting antivirals (J05A)	13	13	13	13
Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) (A02B)	12	10	8	8
Acetylsalicylic acid (N02BA01)	11	11	9	7
Lipid modifying agents, plain (C10A)	11	11	11	10
Antihistamines (R06A)	11	8	8	7
Propulsives (A03F)	8	7	7	7
Blood glucose lowering drugs, excl. insulins (A10B)	8	8	8	8

<b>Acetylsalicylic acid (B01AC06)</b>	8	7	7	7
<b>Corticosteroids for systemic use, plain (H02A)</b>	8	7	6	5
<b>Antacids (A02A)</b>	7	6	4	3
<b>Selective calcium channel blockers (C08C)</b>	7	7	7	6
<b>Thyroid preparations (H03A)</b>	6	6	6	6
<b>Hypnotics and sedatives (N05C)</b>	6	5	5	5
<b>Drugs for functional bowel disorders (A03A)</b>	6	6	5	5
<b>Other beta-lactam antibacterials (J01D)</b>	6	6	4	3
<b>Beta blocking agents (C07A)</b>	6	5	4	4
<b>Angiotensin ii antagonists, plain (C09C)</b>	6	6	6	6
<b>Adrenergics, inhalants (R03A)</b>	6	6	6	6
<b>Hormonal contraceptives for systemic use (G03A)</b>	6	6	6	6
<b>Opioids (N02A)</b>	5	4	4	4
<b>Antipsychotics (N05A)</b>	5	5	5	5

---

\* Plain and combinations (N02BE01 + N02BE51 + N02BE71 + N02AA59 + N02AX52)

**SALT-II - Table 25: Selection of the reference population in the EGB for the years 2005 to 2013**

	2005 n = 471800	2006 n = 492827	2007 n = 482987	2008 n = 491925	2009 n = 500559	2010 n = 515611
<b>Gender, n (%)</b>						
Male	229153 (48.6)	239386 (48.6)	233749 (48.4)	237866 (48.4)	241979 (48.3)	249238 (48.3)
Female	242647 (51.4)	253441 (51.4)	249238 (51.6)	254059 (51.6)	258580 (51.7)	266373 (51.7)
<b>Age at the 1st January of the considered year (in years)</b>						
Size (missing)	471800 (0)	492827 (0)	482987 (0)	491925 (0)	500559 (0)	515611 (0)
Mean ( $\pm$ SD)	39.3 (22.8)	39.1 (22.9)	39.2 (23.1)	39.3 (23.1)	39.4 (23.2)	39.3 (23.3)
Median	39.0	38.0	39.0	39.0	39.0	39.0
[p25% - p75%]	[21.0;56.0]	[20.0;56.0]	[20.0;56.0]	[20.0;56.0]	[20.0;57.0]	[20.0;57.0]
[Min - Max]	[0.0;113.0]	[0.0;112.0]	[0.0;113.0]	[0.0;111.0]	[0.0;112.0]	[0.0;111.0]
<b>Patients with age &lt; 18 years at the 1st January of the considered year, n (%)</b>	<b>100217 (21.2)</b>	<b>106763 (21.7)</b>	<b>106417 (22.0)</b>	<b>108486 (22.1)</b>	<b>110691 (22.1)</b>	<b>113670 (22.0)</b>
<b>Patients with age &gt; 70 years at the 1st January of the considered year, n (%)</b>	<b>51202 (10.9)</b>	<b>53062 (10.8)</b>	<b>53294 (11.0)</b>	<b>54570 (11.1)</b>	<b>55733 (11.1)</b>	<b>56893 (11.0)</b>
<b>Patients with active cancer in the considered year, n (%)</b>	<b>15137 (3.2)</b>	<b>15905 (3.2)</b>	<b>16595 (3.4)</b>	<b>17288 (3.5)</b>	<b>18196 (3.6)</b>	<b>19106 (3.7)</b>
Patients with at least one ALD cancer in the considered year	12586 (2.7)	13353 (2.7)	14055 (2.9)	14765 (3.0)	15525 (3.1)	16451 (3.2)
Patients with at least one hospitalisation for cancer in the considered year	5322 (1.1)	5350 (1.1)	5514 (1.1)	5400 (1.1)	5888 (1.2)	5953 (1.2)
Patients with at least 3 dispensations of anti-androgens drug in the considered year	1435 (0.3)	1409 (0.3)	1485 (0.3)	1462 (0.3)	1424 (0.3)	1417 (0.3)
<b>Patients with age <math>\geq</math> 18 years and without active cancer (reference population), n (%)</b>	<b>356486 (75.6)</b>	<b>370189 (75.1)</b>	<b>360001 (74.5)</b>	<b>366190 (74.4)</b>	<b>371707 (74.3)</b>	<b>382852 (74.3)</b>
<b>Patients with age <math>\geq</math> 18 years and without active cancer (extrapolation), n</b>	<b>48 687 694</b>	<b>48 175 219</b>	<b>47 763 498</b>	<b>48 082 718</b>	<b>48 603 894</b>	<b>48 558 541</b>

\* affiliate to CNAM-TS (general regimen)

	2011 n = 514877	2012 n = 521210	2013 n = 527073	Total n = 619873
<b>Gender, n (%)</b>				
Male	248286 (48.2)	251252 (48.2)	254092 (48.2)	303135 (48.9)
Female	266591 (51.8)	269958 (51.8)	272981 (51.8)	316738 (51.1)
<b>Age at the 1st January of the considered year (in years)</b>				
Size (missing)	514877 (0)	521210 (0)	527073 (0)	619873 (0)
Mean ( $\pm$ SD)	39.6 (23.4)	39.7 (23.5)	39.9 (23.6)	34.4 (23.7)
Median	39.0	39.0	39.0	33.0
[p25% - p75%]	[20.0;57.0]	[20.0;57.0]	[21.0;58.0]	[15.0;52.0]
[Min - Max]	[0.0;112.0]	[0.0;113.0]	[0.0;112.0]	[0.0;113.0]
<b>Patients with age &lt; 18 years at the 1st January of the considered year, n (%)</b>	<b>113589 (22.1)</b>	<b>114678 (22.0)</b>	<b>115941 (22.0)</b>	<b>127911 (20.6)</b>
<b>Patients with age &gt; 70 years at the 1st January of the considered year, n (%)</b>	<b>57597 (11.2)</b>	<b>58415 (11.2)</b>	<b>59609 (11.3)</b>	<b>53433 (8.6)</b>
<b>Patients with active cancer in the considered year, n (%)</b>	<b>19741 (3.8)</b>	<b>19676 (3.8)</b>	<b>19500 (3.7)</b>	<b>12263 (2.0)</b>
Patients with at least one ALD cancer in the considered year	17109 (3.3)	17003 (3.3)	16967 (3.2)	11275 (1.8)
Patients with at least one hospitalisation for cancer in the considered year	6248 (1.2)	6211 (1.2)	6232 (1.2)	2210 (0.4)
Patients with at least 3 dispensations of anti-androgens drug in the considered year	1312 (0.3)	1296 (0.2)	1210 (0.2)	414 (0.1)
<b>Patients with age <math>\geq</math> 18 years and without active cancer (reference population), n (%)</b>	<b>381557 (74.1)</b>	<b>386856 (74.2)</b>	<b>391632 (74.3)</b>	<b>479658 (77.4)</b>
<b>Patients with age <math>\geq</math> 18 years and without active cancer (extrapolation), n</b>	<b>48 736 020</b>	<b>48 816 826</b>	<b>49 164 945</b>	<b>62 527 904</b>

\* affiliate to CNAM-TS (general regimen)

SALT-II - Table 26: Dispensation and number of DDD of the extrapolated population for the years 2005 to 2013

	2005 n = 48687694	2006 n = 48175219	2007 n = 47763498	2008 n = 48082718	2009 n = 48603894	2010 n = 48558541
<b>At least one dispensation of paracetamol *, n (%)</b>	<b>23405445 (48.1)</b>	<b>21814011 (45.3)</b>	<b>22962635 (48.1)</b>	<b>23717765 (49.3)</b>	<b>26224510 (54.0)</b>	<b>25880376 (53.3)</b>
<b>Number of DDD per patient of paracetamol **</b>						
Size (missing)	23405445 (0)	21814011 (0)	22962635 (0)	23717765 (0)	26224510 (0)	25880376 (0)
Mean ( $\pm$ SD)	27.4 (781.3)	29.8 (784.2)	31.4 (791.1)	31.0 (724.0)	32.5 (664.7)	35.5 (707.0)
Median	10.7	10.7	10.7	10.7	12.0	13.3
[p25% - p75%]	[5.3;24.0]	[5.3;26.7]	[5.3;27.3]	[5.3;26.7]	[5.3;29.3]	[5.3;32.0]
[Min - Max]	[0.3;17291.7]	[0.3;16055.0]	[0.3;15416.7]	[0.3;11266.0]	[0.3;2378.7]	[0.3;2548.0]
<b>Total number of DDD of paracetamol, n **</b>	<b>641216061</b>	<b>649766399</b>	<b>720027130</b>	<b>735037737</b>	<b>853113264</b>	<b>919911816</b>
<b>Patient-years exposed to paracetamol, n **</b>	<b>23277872</b>	<b>21688969</b>	<b>22833965</b>	<b>23650441</b>	<b>26083343</b>	<b>25734285</b>
<b>At least one dispensation of NSAID (M01A), n (%)</b>	<b>18322593 (37.6)</b>	<b>17529244 (36.4)</b>	<b>17980313 (37.6)</b>	<b>18355540 (38.2)</b>	<b>19102701 (39.3)</b>	<b>18707024 (38.5)</b>
<b>Number of DDD per patient of NSAID (M01A) **</b>						
Size (missing)	18322593 (0)	17529244 (0)	17980313 (0)	18355540 (0)	19102701 (0)	18707024 (0)
Mean ( $\pm$ SD)	44.3 (865.5)	45.0 (862.1)	45.5 (870.1)	44.8 (849.3)	44.8 (854.4)	45.1 (826.0)
Median	20.0	20.0	20.0	20.0	20.0	20.0
[p25% - p75%]	[11.7;41.7]	[13.3;42.5]	[13.3;43.0]	[11.7;42.5]	[11.7;42.5]	[13.3;43.3]
[Min - Max]	[2.5;1125.0]	[2.5;3550.0]	[2.5;1325.0]	[2.5;1755.0]	[2.5;2140.0]	[2.5;2625.8]
<b>Total number of DDD of NSAID (M01A), n **</b>	<b>811943574</b>	<b>789612404</b>	<b>818238952</b>	<b>822166724</b>	<b>856085661</b>	<b>843002002</b>
<b>Patient-years exposed to NSAID (M01A), n **</b>	<b>18246243</b>	<b>17457739</b>	<b>17906020</b>	<b>18331725</b>	<b>19026661</b>	<b>18631103</b>

\* Plain and combinations (N02BE01 + N02BE51 + N02BE71 + N02AA59 + N02AX52)

\*\* among those concerned

	2011 n = 48736020	2012 n = 48816826	2013 n = 49164945	Total n = 62527904
<b>At least one dispensation of paracetamol *, n (%)</b>	<b>27366226 (56.2)</b>	<b>27456622 (56.2)</b>	<b>27613634 (56.2)</b>	<b>51509379 (82.4)</b>
<b>Number of DDD per patient of paracetamol **</b>				
Size (missing)	27366226 (0)	27456622 (0)	27613634 (0)	51509379 (0)
Mean ( $\pm$ SD)	38.3 (772.8)	39.7 (772.6)	41.1 (785.4)	152.0 (3913.8)
Median	13.3	14.0	16.0	46.7
[p25% - p75%]	[6.0;35.3]	[6.7;37.3]	[8.0;40.0]	[18.7;126.7]
[Min - Max]	[0.3;7012.0]	[0.3;4033.0]	[0.3;4236.0]	[0.3;60576.0]
<b>Total number of DDD of paracetamol, n **</b>	<b>1048956945</b>	<b>1088965436</b>	<b>1136280730</b>	<b>7793275520</b>
<b>Patient-years exposed to paracetamol, n **</b>	<b>27215722</b>	<b>27370524</b>	<b>27450427</b>	<b>225305549</b>
<b>At least one dispensation of NSAID (M01A), n (%)</b>	<b>18796822 (38.6)</b>	<b>18681882 (38.3)</b>	<b>18337581 (37.3)</b>	<b>46273864 (74.0)</b>
<b>Number of DDD per patient of NSAID (M01A) **</b>				
Size (missing)	18796822 (0)	18681882 (0)	18337581 (0)	46273864 (0)
Mean ( $\pm$ SD)	42.8 (788.8)	43.5 (800.3)	43.0 (790.4)	158.8 (3912.4)
Median	20.0	20.0	20.0	61.7
[p25% - p75%]	[12.5;41.7]	[13.3;42.0]	[13.3;40.9]	[25.8;145.9]
[Min - Max]	[2.5;1316.7]	[2.5;1441.5]	[2.5;1433.0]	[2.5;8456.2]
<b>Total number of DDD of NSAID (M01A), n **</b>	<b>803653948</b>	<b>813230764</b>	<b>789188927</b>	<b>7347122957</b>
<b>Patient-years exposed to NSAID (M01A), n **</b>	<b>18722561</b>	<b>18658340</b>	<b>18264117</b>	<b>165244508</b>

\* Plain and combinations (N02BE01 + N02BE51 + N02BE71 + N02AA59 + N02AX52)

\*\* among those concerned

SALT-II - Table 27: ALFT incidence rates per billion in drug-exposed patients (cases exposed 30 days prior to index date) for the years 2005 to 2013

Drug	Number of cases exposed to drugs	Number of DDD of drug (extrapolation)	Number of patients exposed to drug (extrapolation)	Number of patient-years exposed to drugs (extrapolation)	Case per billion DDD (for 9 years) [95% CI] <sup>1</sup>	Case per billion patients (for 9 years) [95% CI] <sup>1</sup>	Case per billion patient-years [95% CI] <sup>1</sup>
<b>Paracetamol *</b>	82	7 793 275 520	51 509 379	225 305 549	10.52 [8.37 ; 13.06]	1591.94 [1266.18 ; 1975.95]	363.95 [289.47 ; 451.74]
<b>Paracetamol *</b> (with non-intentional overdoses)	144	7 793 275 520	51 509 379	225 305 549	18.48 [15.58 ; 21.76]	2795.61 [2357.64 ; 3291.87]	639.13 [539.00 ; 752.59]
<b>Paracetamol *</b> (with intentional or non-intentional overdoses)	239	7 793 275 520	51 509 379	225 305 549	30.67 [26.90 ; 34.82]	4639.93 [4070.32 ; 5267.48]	1060.78 [930.56 ; 1204.25]
<b>NSAID (M01A)</b>	18	7 347 122 957	46 273 864	165 244 508	2.45 [1.45 ; 3.87]	388.99 [230.58 ; 614.82]	108.93 [64.57 ; 172.17]

\* Plain and combinations (N02BE01 + N02BE51 + N02BE71 + N02AA59 + N02AX52)

<sup>1</sup> by the Poisson method

**SALT-II - Table 28: ALFT incidence rates per billion in drug-exposed patients (cases exposed 90 days prior to index date) for the years 2005 to 2013**

Drug	Number of cases exposed to drugs	Number of DDD of drug (extrapolation)	Number of patients exposed to drug (extrapolation)	Number of patient-years exposed to drugs (extrapolation)	Case per billion DDD (for 9 years) [95% CI] <sup>1</sup>	Case per billion patients (for 9 years) [95% CI] <sup>1</sup>	Case per billion patient-years [95% CI] <sup>1</sup>
<b>Paracetamol *</b>	86	7 793 275 520	51 509 379	225 305 549	11.04 [8.83 ; 13.63]	1669.60 [1335.48 ; 2061.95]	381.70 [305.32 ; 471.40]
<b>Paracetamol *</b> (with non-intentional overdoses)	148	7 793 275 520	51 509 379	225 305 549	18.99 [16.05 ; 22.31]	2873.26 [2428.99 ; 3375.80]	656.89 [555.32 ; 771.78]
<b>Paracetamol *</b> (with intentional or non-intentional overdoses)	243	7 793 275 520	51 509 379	225 305 549	31.18 [27.38 ; 35.36]	4717.59 [4143.07 ; 5350.03]	1078.54 [947.19 ; 1223.12]
<b>NSAID (M01A)</b>	19	7 347 122 957	46 273 864	165 244 508	2.59 [1.56 ; 4.04]	410.60 [247.22 ; 641.18]	114.98 [69.23 ; 179.55]

\* Plain and combinations (N02BE01 + N02BE51 + N02BE71 + N02AA59 + N02AX52)

<sup>1</sup> by the Poisson method



**SALT-II - Table 29: ALFT incidence rates per billion in drug-exposed patients (cases exposed 15 days prior to index date) for the years 2005 to 2013**

Drug	Number of cases exposed to drugs	Number of DDD of drug (extrapolation)	Number of patients exposed to drug (extrapolation)	Number of patient-years exposed to drugs (extrapolation)	Case per billion DDD (for 9 years) [95% CI] <sup>1</sup>	Case per billion patients (for 9 years) [95% CI] <sup>1</sup>	Case per billion patient-years [95% CI] <sup>1</sup>
<b>Paracetamol *</b>	81	7 793 275 520	51 509 379	225 305 549	10.39 [8.25 ; 12.92]	1572.53 [1248.90 ; 1954.60]	359.51 [285.52 ; 446.86]
<b>Paracetamol *</b> (with non-intentional overdoses)	143	7 793 275 520	51 509 379	225 305 549	18.35 [15.46 ; 21.62]	2776.19 [2339.81 ; 3270.87]	634.69 [534.93 ; 747.79]
<b>Paracetamol *</b> (with intentional or non-intentional overdoses)	238	7 793 275 520	51 509 379	225 305 549	30.54 [26.78 ; 34.68]	4620.52 [4052.14 ; 5246.84]	1056.34 [926.40 ; 1199.53]
<b>NSAID (M01A)</b>	14	7 347 122 957	46 273 864	165 244 508	2.84 [1.55 ; 4.77]	343.60 [187.75 ; 576.52]	125.41 [68.53 ; 210.42]

\* Plain and combinations (N02BE01 + N02BE51 + N02BE71 + N02AA59 + N02AX52)

<sup>1</sup> by the Poisson method

**SALT-II - Table 30: ALFT incidence rates per billion in drug-exposed patients (cases exposed 7 days prior to index date) for the years 2005 to 2013**

Drug	Number of cases exposed to drugs	Number of DDD of drug (extrapolation)	Number of patients exposed to drug (extrapolation)	Number of patient-years exposed to drugs (extrapolation)	Case per billion DDD (for 9 years) [95% CI] <sup>1</sup>	Case per billion patients (for 9 years) [95% CI] <sup>1</sup>	Case per billion patient-years [95% CI] <sup>1</sup>
<b>Paracetamol *</b>	77	7 793 275 520	51 509 379	225 305 549	9.88 [7.80 ; 12.35]	1494.87 [1179.79 ; 1868.40]	341.76 [269.72 ; 427.15]
<b>Paracetamol *</b> (with non-intentional overdoses)	139	7 793 275 520	51 509 379	225 305 549	17.84 [14.99 ; 21.06]	2698.54 [2268.56 ; 3186.83]	616.94 [518.64 ; 728.57]
<b>Paracetamol *</b> (with intentional or non-intentional overdoses)	234	7 793 275 520	51 509 379	225 305 549	30.03 [26.30 ; 34.13]	4542.86 [3979.43 ; 5164.24]	1038.59 [909.78 ; 1180.65]
<b>NSAID (M01A)</b>	13	7 347 122 957	46 273 864	165 244 508	2.64 [1.40 ; 4.51]	319.06 [169.84 ; 545.59]	116.45 [61.99 ; 199.13]

\* Plain and combinations (N02BE01 + N02BE51 + N02BE71 + N02AA59 + N02AX52)

<sup>1</sup> by the Poisson method